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Abstract
Neurodegenerative diseases share the unifying features of insoluble protein aggregates and irreversible
neuron loss. Parkinson’s disease (PD) is defined by proteinaceous Lewy bodies—which contain αsynuclein—and loss of dopamine neurons leading to motor dysfunction. Growing evidence implicates αsynuclein aggregation as a causal driver of neurodegeneration in certain forms of PD. However, the
precise mechanism(s) by which the process or products of α-synuclein aggregation drive neuron death
remains unknown. Better understanding of this key question might further development of
neuroprotective therapies for PD and related disorders. To address this gap, we reviewed how the native
conformation of α-synuclein relates to its physiological function and roles in pathology. We also
examined how the mouse brain proteome and phosphoproteome change in response to α-synuclein
aggregation using quantitative proteomics. This revealed that proteomic changes were not widespread,
but instead were enriched within certain functional areas. For the first time, we found that the
immunoproteasome is induced during aggregation, providing a new tunable target for studying αsynuclein aggregation and its connection to toxicity. We also employed nordihydroguaiaretic acid (NDGA)
and analogs to study the chemistry and products of phenolic inhibitors of α-synuclein aggregation. We
discovered that oxidation-dependent cyclization is required for NDGA analogs to inhibit α-synuclein
aggregation and that this inhibition is caused by modification of α-synuclein monomers that retain their
conformational dynamics and lipid interactions. Further, we found that these NDGA analog-modified
monomers exert a dominant negative effect on aggregation of untreated α-synuclein, exposing a novel
mechanism for inhibiting α-synuclein aggregation. Using transgenic Caenorhabditis elegans, we showed
that cyclized NDGA can prevent neurodegeneration driven by α-synuclein. These findings outline a novel
paradigm for small molecule inhibition of α-synuclein aggregation wherein they act by stabilizing dynamic
α-synuclein monomers, preventing aggregation. This in turn prevents aggregation of untreated αsynuclein and reduces neurodegeneration. Together this work underscores the importance of αsynuclein’s native structural dynamics and provides several novel tools for future use in untangling the
relationship between α-synuclein aggregation and neuron loss in PD and related disorders.
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ABSTRACT

STRUCTURAL REMODELING OF ALPHA-SYNUCLEIN BY SMALL MOLECULES:
A NOVEL PATH TO NEUROPROTECTIVE THERAPEUTICS
Malcolm James Daniels
Harry Ischiropoulos
Neurodegenerative diseases share the unifying features of insoluble protein aggregates and
irreversible neuron loss. Parkinson’s disease (PD) is defined by proteinaceous Lewy bodies—

which contain α-synuclein—and loss of dopamine neurons leading to motor dysfunction. Growing
evidence implicates α-synuclein aggregation as a causal driver of neurodegeneration in certain
forms of PD. However, the precise mechanism(s) by which the process or products of α-synuclein
aggregation drive neuron death remains unknown. Better understanding of this key question
might further development of neuroprotective therapies for PD and related disorders. To address
this gap, we reviewed how the native conformation of α-synuclein relates to its physiological
function and roles in pathology. We also examined how the mouse brain proteome and
phosphoproteome change in response to α-synuclein aggregation using quantitative proteomics.
This revealed that proteomic changes were not widespread, but instead were enriched within
certain functional areas. For the first time, we found that the immunoproteasome is induced
during aggregation, providing a new tunable target for studying α-synuclein aggregation and its
connection to toxicity. We also employed nordihydroguaiaretic acid (NDGA) and analogs to study
the chemistry and products of phenolic inhibitors of α-synuclein aggregation. We discovered that
oxidation-dependent cyclization is required for NDGA analogs to inhibit α-synuclein aggregation
and that this inhibition is caused by modification of α-synuclein monomers that retain their
conformational dynamics and lipid interactions. Further, we found that these NDGA analogmodified monomers exert a dominant negative effect on aggregation of untreated α-synuclein,
vi

exposing a novel mechanism for inhibiting α-synuclein aggregation. Using transgenic
Caenorhabditis elegans, we showed that cyclized NDGA can prevent neurodegeneration driven
by α-synuclein. These findings outline a novel paradigm for small molecule inhibition of αsynuclein aggregation wherein they act by stabilizing dynamic α-synuclein monomers, preventing
aggregation. This in turn prevents aggregation of untreated α-synuclein and reduces
neurodegeneration. Together this work underscores the importance of α-synuclein’s native
structural dynamics and provides several novel tools for future use in untangling the relationship
between α-synuclein aggregation and neuron loss in PD and related disorders.
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CHAPTER 1: INTRODUCTION
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1.1 Neurodegenerative diseases and protein aggregation
The most common neurodegenerative diseases are Alzheimer’s disease (AD),
Parkinson’s disease (PD), Huntington’s disease (HD), and Amyotrophic Lateral Sclerosis (ALS).
Each disease is characterized by degeneration in distinct regions of the brain, producing
neurologically correlated clinical symptoms. However, these diseases share remarkable
similarities: the progressive accumulation of proteinaceous inclusions, the progressive loss of
neurons, and a lack of curative therapies.
AD is characterized by accumulation of extracellular plaques containing the Aβ peptide
fragment (Glenner and Wong, 1984) and intracellular neurofibrillary tangles containing hyperphosphorylated tau (Lee et al., 1991). PD displays intracellular accumulation of α-synucleincontaining Lewy bodies (Spillantini et al., 1997). In HD, the protein huntingtin forms neuronal
intranuclear inclusions (DiFiglia et al., 1997). Most ALS patients develop motor neuron inclusions
containing ubiquitin and TDP-43 (Neumann et al., 2006). Increasing evidence suggests a causal
link between protein aggregation and neurodegeneration, but the mechanism of neurotoxicity has
not been identified. In this study, we examine how the physiological role and pathological
aggregation of α-synuclein are influenced by its dynamic structure, and how α-synuclein
aggregation changes the brain proteome. We also seek to better understand inhibitors of αsynuclein aggregation in hopes of providing a tool to address this deficit.
1.2 Parkinson’s disease
Parkinson’s disease (PD) is the most common age-related movement disorder, affecting
1.5-3% of people over the age of 75 (Van Den Eeden et al., 2003; Pringsheim et al., 2014).
Incidence is expected to rise as the age of the global population increases (Wirdefeldt et al.,
2011). The motor phenotype was first characterized in western medical literature by James
Parkinson in An Essay on the Shaking Palsy and is defined by resting tremor, rigidity, and
2

bradykinesia (Parkinson, 1817). More than a century later, a loss of neuromelanin pigmentation of
the substantia nigra pars compacta (SNpc) was described in PD (Trétiakoff, 1919). Ultimately,
parkinsonian motor symptoms can be attributed to a loss of dopamine in the SNpc (Ehringer and
Hornykiewicz, 1960). While dopamine neuron loss in the SNpc is normal in aging, the pattern of
degeneration in PD is distinct, involving greater loss in the ventrolateral and caudal portions
(Fearnley and Lees, 1991).
Many PD patients develop symptoms beyond the central motor phenotype. Nearly all PD
patients experience some form of sleep disturbance and many experience sensory dysfunction,
particularly olfactory (Koller, 1984; Lees et al., 1988). Older and more advanced PD patients often
experience dementia (Emre, 2003; Levy et al., 2002).
1.2.1 Genetics
Up to 10% of PD cases are familial, driven by both dominant and recessive genetic
inheritance (Hernandez et al., 2016). Autosomal dominant forms of familial PD are driven by
mutations in many genes (e.g. SNCA, LRRK2, VPS35, UCHL1) (Maraganore et al., 2004;
Paisán-Ruíz et al., 2004; Vilariño-Güell et al., 2011; Zimprich et al., 2004, 2011). LRRK2
mutations are the most common cause of familial PD cases, found in ~10% of patients (PaisánRuíz et al., 2008). Autosomal recessive forms of PD are caused by mutations in other genes,
such as PARK2, PINK1, and PARK7 (encoding Parkin, Pten-induced putative kinase 1, and DJ-1,
respectively) (Bonifati et al., 2003; Kitada et al., 1998; Valente et al., 2001, 2004). Many of the
autosomal recessive forms of PD caused by mutations in these three genes are juvenile onset.
While most PD cases are sporadic, with age as the greatest risk factor, genetic risk
factors can still contribute to disease. Genome-wide association studies have found PD risk
alleles across many genes previously identified in familial PD (SNCA, LRRK2, PARK16) as well
as others encoding proteins involved in pathology (MAPT, encoding microtubule-associated
protein tau) (Satake et al., 2009; Simón-Sánchez et al., 2009). More recent meta-analysis has
3

further expanded these findings both in terms of primary and conditional risk alleles (Nalls et al.,
2014).
1.2.2 Histopathology
The pathological hallmark of PD is the presence of Lewy bodies. These cellular
inclusions were first described by Friedrich Lewy in 1912 and later named Lewy bodies, after their
discoverer (Lewy, 1912; Trétiakoff, 1919). Lewy bodies are proteinaceous and were found in the
1980’s to contain both neurofilamin and ubiquitin (Goldman et al., 1983; Lennox et al., 1989).
Later examination revealed that aggregated α-synuclein is also a major component (Spillantini et
al., 1997). In addition to Lewy bodies, pathological neuronal projections termed Lewy neurites are
present in PD, and also contain aggregated α-synuclein (Braak et al., 1994; Spillantini et al.,
1998).
Sporadic PD cases can be scored based on a stereotypical pattern of the spread of Lewy
pathology which progresses to new regions while worsening in those previously affected (Braak
et al., 2003). As these stages progress, a rough correlation can be drawn between the
neurological functions of the regions affected and the additional symptoms experienced by
patients as PD worsens. This could be taken as evidence that Lewy bodies cause
neurodegeneration in PD. However, Lewy bodies have been found in tissue from normal patients
who lacked both PD symptoms and striatal neurodegeneration (Ding et al., 2006; Markesbery and
Jicha, 2009). Conversely, parkinsonian neurodegeneration can occur in the absence of Lewy
bodies. In fact, the most common LRRK2 mutation causes early onset PD that lacks any Lewy
pathology (Gaig et al., 2007).
1.3 α-Synuclein
Synuclein proteins were first discovered in cholinergic vesicles and nuclei purified from
the electric organ of Torpedo (Maroteaux et al., 1988). Syn1, later renamed α-synuclein, was first
4

characterized in rat brains probed with sera against electric organ samples (Maroteaux and
Scheller, 1991). A component of the α-synuclein sequence was detected as the non-amyloid
component of amyloid plaques in Alzheimer’s disease, but was not attributed to α-synuclein until
its discovery in humans (Jakes et al., 1994; Uéda et al., 1993). Interest in α-synuclein increased
greatly following its identification in Lewy bodies and the discovery of an α-synuclein point
mutation in a several kindreds with early-onset familial PD (Polymeropoulos et al., 1997;
Spillantini et al., 1997).
1.3.1 Sequence and structure
α-Synuclein is 140 amino acids in length with a calculated molecular mass of 14,460.16
kDa. Its primary sequence is divided into three functionally defined domains. The N-terminal
domain (composed of amino acids 1-60) is characterized primarily by lysine-rich imperfect
repeats projected to form amphipathic α-helices upon lipid interaction (George et al., 1995;
Maroteaux et al., 1988). These elements repeat seven times and contain amino acids 10-86. This
region has a greater affinity for acidic phospholipid membranes (Davidson et al., 1998). When
bound to lipid membranes, this region can form an extended conformation of two α-helices, or
double back to form a hairpin, depending on the curvature of the surface (Trexler and Rhoades,
2009; Ulmer and Bax, 2005). All α-synuclein point mutations (A30P, E46K, H50Q, G51D, A53E,
A53T) that cause autosomal dominant forms of PD occur in the N-terminal domain (AppelCresswell et al., 2013; Krüger et al., 1998; Lesage et al., 2013; Pasanen et al., 2014;
Polymeropoulos et al., 1997; Proukakis et al., 2013; Zarranz et al., 2004).
Amino acids 61-95 compose the NAC or non-amyloid component domain which was
named based on its fragmentary identification in amyloid plaques (Uéda et al., 1993). This
domain contains an amino acid sequence (71-82) that is both necessary and sufficient for αsynuclein aggregation into fibril aggregates with β-sheet secondary structure (Giasson et al.,
2001). The role of the NAC domain in α-synuclein aggregation has been reinforced by repeated
5

studies (Du et al., 2003). Recent crystallography has highlighted two regions, PreNAC (47-56)
and NACore (68-78), both of which can independently aggregate into fibrils, but may also directly
interface within the hydrophobic core of full length α-synuclein fibrils (Rodriguez et al., 2015).
The C-terminal domain (composed of amino acids 96-140) is hydrophobic and remains
unstructured both when α-synuclein is bound to lipids and aggregated into fibrils (Chen et al.,
2007; Ulmer and Bax, 2005). Although the C-terminal domain does not assume β-sheet
confirmation during aggregation, C-terminal truncation increases the rate of α-synuclein
aggregation (Hoyer et al., 2004; Li et al., 2005). This effect may be explained in part by transient,
temperature sensitive, long range interactions between the C-terminal domain and the N-terminal
domain (Dedmon et al., 2005). These interactions have been implicated in stabilizing monomeric
confirmation of α-synuclein, reducing its propensity to aggregate (Bertoncini et al., 2005a).
The C-terminal domain is the site of many post-translation modifications of α-synuclein,
particularly phosphorylation. This includes phosphorylation at serine 129, which was first detected
in Lewy body extracts and is used as a marker of pathologically aggregated α-synuclein (Fujiwara
et al., 2002). A more exhaustive discussion of α-synuclein post-translational modification can be
found in Section 2.4.
Many intramolecular interactions occur with the α-synuclein C-terminal domain.
Interactors include neurotransmitters, most notably dopamine, and other small molecules, which
are addressed at length in Section 1.4.3 (Conway et al., 2001). α-Synuclein has been shown to
interact with several metal ions, some of which are implicated in toxicity. Various metals have
been shown to alter α-synuclein conformation and aggregation kinetics (Uversky et al., 2001a).
The C-terminal domain is the site of interaction with a wide variety of divalent metal ions including
Fe(II), Mn(II), Co(II), and Ni(II) (Binolfi et al., 2006). Uniquely, interaction with Cu(II) is mediated
not only by the C-terminal, but also by H50 (Rasia et al., 2005). This interaction induces αsynuclein oligomerization (Paik et al., 1999). Subsequent experiments have shown that similar
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conformation changes are caused by interaction with Cu(II) and dopamine at the C-terminal (Ha
et al., 2014; Tavassoly et al., 2014).
The interaction between iron, α-synuclein, and PD has been an area of particular interest.
α-Synuclein has been found to bind with Fe(II) and Fe(III), the latter inducing α-synuclein
oligomerization (Binolfi et al., 2006; Hillmer et al., 2010; Tabner et al., 2002; Uversky et al.,
2001a). Environmental exposure to iron and other heavy metals (Gorell et al., 1999), as well as
their accumulation in the brain (Hirsch et al., 1991), have been linked to PD. The connection
between iron and α-synuclein in PD likely lies in oxidative stress and damage. Oxidative stress is
linked to both parkinsonianism and α-synuclein modification (Giasson et al., 2000; Javitch et al.,
1985; Krueger et al., 1990; Przedborski et al., 2001; Souza et al., 2000a). Interaction between αsynuclein and Fe(II) can be caused by redox cycling (Hillmer et al., 2010). The ratio of
Fe(II)/Fe(III) ions shifts toward Fe(III), while levels of glutathione, a key redox regulator, are
depleted in PD brains (Riederer et al., 1989). Recent evidence suggests that α-synuclein acts as
a ferrireductase (Davies et al., 2011). It is possible that aggregation of α-synuclein may prevent
its reductase activity causing a toxic loss of function during the progression of PD. While αsynuclein may act as a ferrireductase, there is abundant evidence suggesting its chief function is
to mediate vesicle fusion/fission in the synapse, further discussed in Section 1.3.2.
The native conformation of α-synuclein has been the subject of several studies and
intense debate, especially given the potential of native structural dynamics to alter its propensity
to aggregate. This topic is addressed at length in Section 2.4. Following the compilation of that
summary, further examination of the native state of α-synuclein has continued to reinforce the
importance of the N-terminal KTKEGV consensus repeats in α-synuclein multimer formation and
appropriate lipid interaction. KTKEGV repeat mutations designed to perturb multimerization also
induce inappropriate lipid interaction and may contribute to both increased α-synuclein
aggregation and defects in vesicular trafficking (Dettmer et al., 2017). The protein
glucocerebrosidase 1 (GBA1) is involved in lysosomal lipid quality control and loss of function
7

mutations are strong risk factors for PD (Sidransky et al., 2009). Deficiency in GBA1 has been
shown to inhibit α-synuclein multimerization and enhance pathology during α-synuclein
aggregation (Kim et al., 2018). Taken together, the growing body of work around the native state
of α-synuclein suggests that complex structural dynamics influence both its physiological function
and its propensity to aggregate. Therefore, any disturbances of native state—through mutations,
changes in lipid interaction, alteration of cellular redox state, etc.—may contribute to α-synuclein
dysfunction.
1.3.2 Physiological function
When identified, synucleins were found in the nucleus and presynapse of neurons
(Maroteaux et al., 1988). Subsequent studies have failed to reproduce detection of synucleins in
the nucleus, but have reinforced their presence in presynaptic terminals (George et al., 1995; Iwai
et al., 1995; Maroteaux and Scheller, 1991; Murphy et al., 2000; Withers et al., 1997). Synelfin,
later to be renamed α-synuclein, expression was found to increase during Zebra finch song
learning, suggesting a role in neurotransmission or long-term potentiation (George et al., 1995).
The identification of α-synuclein in the presynapse, and its implication in neuronal
plasticity, led to examination of neuronal function in α-synuclein knockout mice. These mice were
found to lack a gross developmental or functional phenotype (Abeliovich et al., 2000). Striatal
brain slices from knockout mice displayed higher levels of dopamine release in response to
repeated stimuli than those from wildtype mice, suggesting α-synuclein may play a role in
regulating neurotransmitter release. Subsequent studies on synuclein double (α and β) and triple
(α, β, and γ) knockout mice revealed a high degree of redundancy among the family (Burré et al.,
2010; Chandra et al., 2004). Only the triple knockout showed a profound phenotype, which
included age-related neurological deficits, premature mortality, and motor symptoms consistent
with models of dopamine neuron loss (Burré et al., 2010).
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α-Synuclein modulates vesicular trafficking during neurotransmission. While α-synuclein
knockout leads to increased vesicular reserve pool in presynaptic terminals (Murphy et al., 2000),
α-synuclein overexpression leads to deficits in vesicle fusion and increased vesicular pools in
some models (Larsen et al., 2006). α-Synuclein has been shown to regulate the function of
SNARE proteins involved in vesicular fission and fusion (Chandra et al., 2005). This work has
been further supported by direct evidence of physical interaction between α-synuclein and the vSNARE synaptobrevin 2 (Burré et al., 2010). α-Synuclein’s particular role may lie in facilitating
vesicle endocytosis following neurotransmitter release into the synapse (Vargas et al., 2014).
1.3.3 Aggregation and pathogenesis
The Lewy bodies found in sporadic and familial forms of PD contain aggregated αsynuclein (Baba et al., 1998; Spillantini et al., 1997). Rather than amorphous aggregates, the αsynuclein within Lewy bodies exists as unbranched fibrils roughly 10 nm in diameter and ranging
from 50 to 700 nm in length (Spillantini et al., 1998). Subsequently, these fibrils were shown to
contain α-synuclein with β-sheet secondary structure (Serpell et al., 2000). As such, α-synuclein
aggregates show strong structural similarity with Aβ amyloids in Alzheimer’s disease and many
other proteins that form amyloid-like fibril aggregates (Nelson et al., 2005; Sawaya et al., 2007).
Partially resolved structure based on a combination of nuclear magnetic resonance and electron
cryomicroscopy revealed an in-register, antiparallel conformation composed of five β-sheet
regions (Heise et al., 2005; Tuttle et al., 2016; Vilar et al., 2008). The rate limiting step in fibril
formation is the generation of a nucleus, while elongation of existing fibrils is much more rapid
(Uversky et al., 2001b; Wood et al., 1999).
All α-synuclein mutations associated with familial forms of the disease alter aggregation
kinetics, though not all enhance fibril formation (Appel-Cresswell et al., 2013; Giasson et al.,
1999; Krüger et al., 1998; Lesage et al., 2013; Li et al., 2001; Narhi et al., 1999; Pasanen et al.,
2014; Proukakis et al., 2013; Zarranz et al., 2004). Additionally, duplication and triplication of the
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SNCA gene encoding α-synuclein leads to α-synuclein aggregation and early onset, with age of
onset accelerated by greater gene dose (Chartier-Harlin et al., 2004; Singleton et al., 2003). This
suggests a causal link between α-synuclein aggregation and neurodegeneration.
Numerous animal models expressing excess α-synuclein or mutant α-synuclein prone to
aggregation exhibit neurodegeneration, though none perfectly recapitulates PD. Transgenic mice
expressing human wildtype and mutant α-synuclein exhibit inclusion formation and
neurodegeneration, though not within the SNpc (Emmer et al., 2011; Giasson et al., 2002;
Gomez-Isla et al., 2003; Lee et al., 2002; van der Putten et al., 2000). Lentiviral expression of
either wildtype or mutant α-synuclein leads to aggregation and progressive loss of dopaminergic
neurons in the SNpc (Lo Bianco et al., 2002; Kirik et al., 2002). Invertebrate models have also
been employed to examine α-synuclein toxicity. Caenorhabditis elegans and Drosophila
melanogaster models have been used extensively, showing particular utility for modeling
dopaminergic neurodegeneration and motor phenotypes, respectively (Cao et al., 2010; Feany
and Bender, 2000; Lakso et al., 2003).
A recent model of neurodegeneration driven by α-synuclein aggregation avoids the use
of transgenic models. Instead, a small amount of pre-formed α-synuclein fibrils (PFFs) is injected
into the brain of wildtype mice. This induces aggregation of endogenous α-synuclein that spreads
from the site of injection along the connectome as well as concomitant progressive
neurodegeneration and motor phenotype (Luk et al., 2012b, 2012a). These effects are not
observed in transgenic mice lacking the Snca gene encoding α-synuclein, demonstrating the role
of endogenous α-synuclein (Luk et al., 2012a). These results have been reproduced with
intramuscular injection in mice, enteric injection in rats and primates, and intracerebral injection in
mice, rats, and primates (Manfredsson et al., 2018; Paumier et al., 2015; Sacino et al., 2014a,
2014b; Shimozawa et al., 2017). Likewise, intracerebral and enteric injection of Lewy body
extracts results in spreading, progressive aggregation of endogenous α-synuclein and
neurodegeneration (Holmqvist et al., 2014; Recasens et al., 2014). These models provide
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compelling evidence that otherwise non-toxic α-synuclein leads to neurodegeneration when
undergoing aggregation.
Independent lines of evidence suggest that the propagation of α-synuclein aggregation
throughout the brain is caused by cell-to-cell transmission of aggregated α-synuclein seeds. This
connectome-based propagation is suggested by the progressive staging of Lewy body pathology
in sporadic PD (Braak et al., 2003), the accumulation of aggregates in fetal tissue grafted into the
striatum of PD patients (Kordower et al., 2008; Li et al., 2008), and the spread of aggregation
away from the site of injection in PFF animal models (Holmqvist et al., 2014; Luk et al., 2012a;
Manfredsson et al., 2018; Sacino et al., 2014b). How α-synuclein aggregates escape neurons is
unknown, but aggregates have been detected in exosomes and may escape during
neurotransmission due to the presynaptic localization of α-synuclein (Danzer et al., 2012). Uptake
of α-synuclein aggregates from the synapse may be neuronal endocytosis (Lee et al., 2008).
While mechanistic questions remain regarding the specifics of cell-to-cell transfer of α-synuclein
aggregates (Tyson et al., 2016), evidence still suggests that propagation is caused by aggregated
α-synuclein. In a model of propagation between primary neurons, treatment with antibodies
against pathologically aggregated α-synuclein reduces the spread of pathology (Tran et al.,
2014). Exogenous PFFs are taken up by neurons and localize to the lysosome. Transient
inhibition of lysosomal activity results in greater recruitment of endogenous α-synuclein into
aggregates (Karpowicz et al., 2017).
The mechanism by which α-synuclein aggregation leads to neurotoxicity remains an
important question in the field. Toxicity is most commonly attributed to a toxic gain of function,
rather than a toxic loss of α-synuclein function. This is supported by the fact that α-synuclein
knockout does not result in profound dysfunction (Abeliovich et al., 2000). Instead, the most
commonly accepted theory is that α-synuclein oligomers present during aggregation drive toxicity.
Enhanced oligomer—rather than fibril—formation can drive neurotoxicity caused by α-synuclein
mutants associated with familial PD (Conway et al., 2000). Toxicity may be a product of α11

synuclein oligomers causing membrane permeabilization, perhaps leading to metabolic stress as
neurons attempt to maintain physiological ion gradients. Certain types of α-synuclein oligomers
induce calcium influx through neuronal membranes and display pore-like structure when viewed
by atomic force microscopy (Danzer et al., 2007). In fact, many proteins that form amyloid-like
species aggregates can exist as oligomers that increase membrane ion-conductance (Kayed et
al., 2004). This permeabilization may also affect organellar membranes. α-Synuclein oligomers
can disturb mitochondrial ion gradients through this mechanism (Luth et al., 2014). Other
potential mechanisms of α-synuclein oligomer toxicity have been proposed including
perturbations of microtubule-kinesin transport (Prots et al., 2013) and alterations of vesicular
trafficking (Choi et al., 2013). Distinct populations of α-Synuclein oligomers are induced by
expression of A53T α-synuclein in mice. Oligomers extracted from regions with α-synuclein
inclusions cause in vitro neurotoxicity and act as seeds, while those from other regions do not.
Further, levels of inclusion formation and neurodegeneration within brain regions do not correlate
with the relative abundance of oligomers (Tsika et al., 2010). This suggests that α-synuclein
oligomers are not a single entity, but that multiple distinct populations may exist with markedly
different attributes and implications for disease. Whether or not oligomers are the sole cause of αsynuclein neurotoxicity, it is increasingly clear that the process of α-synuclein aggregation gives
rise to species or events that lead to neurodegeneration and eventual neuron death.
1.4 Therapies targeting α-synuclein
The body of evidence implicating α-synuclein in PD and related disorders has caused
substantial interest in PD therapies targeting α-synuclein. Many different methods have been
employed and an even greater number proposed.
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1.4.1 Expression and clearance
Altering the steady-state level of α-synuclein has long been an area of interest. The
promise of these attempts is underscored by the gene-dose dependent onset of familial PD
caused by SNCA gene duplication and triplication (Chartier-Harlin et al., 2004; Singleton et al.,
2003) as well as the resistance of α-synuclein knockout mice to MPTP, a toxin that leads to
parkinsonian neurodegeneration (Dauer et al., 2002; Thomas et al., 2011).
In vivo suppression of α-synuclein expression has been achieved in rodents through
delivery of AAV encoding shRNA and by both unprotected and exosome-protected siRNA.
(Alarcón-Arís et al., 2018; Benskey et al., 2018; Cooper et al., 2014; Lewis et al., 2008; Zharikov
et al., 2015a). These approaches reduce inclusion formation (Cooper et al., 2014). Knockdown
also preserves neurons and dopamine biosynthesis, as well as providing resistance to rotenone
toxicity (Zharikov et al., 2015a). Promisingly, one group found that α-synuclein expression in the
SNpc of mice can be reduced by intranasal delivery of siRNA, opening the door to non-surgical
intervention in adults (Alarcón-Arís et al., 2018).
Increasing α-synuclein clearance has shown promise in reducing pathology.
Overexpression of transcription factor EB, which regulates the autophagy-lysosomal degradation
pathway, reduces α-synuclein aggregation and cytosolic levels while protecting against
neurodegeneration. Conversely, inhibition of transcription factor EB expression exacerbates
aggregation and neuron loss (Decressac et al., 2013). Glucocerebrosidase (GCase), a lysosomal
glycoside hydrolase involved in Gaucher disease pathogenesis, has also been implicated in αsynuclein degradation. Loss of GCase leads to α-synuclein accumulation, while α-synuclein
inhibits lysosomal function, potentially creating a pathological feedback loop (Mazzulli et al.,
2011). AAV gene therapy increasing GCase expression reduces α-synuclein levels, aggregation,
and neurodegeneration in mouse models expressing A53T α-synuclein (Morabito et al., 2017;
Rocha et al., 2015; Sardi et al., 2013). Small molecule modulators of GCase activity have also
been identified and reduce α-synuclein levels in neurons induced from stem cells derived from
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Gaucher disease and parkinsonian patients (Aflaki et al., 2016). Several other lines of evidence
also suggest that enhancing autophagy could be therapeutic in PD (Moors et al., 2017).
1.4.2 Immunization and immunotherapy
Modulating immune responses to α-synuclein and α-synuclein aggregates has shown
promise in ameliorating pathology. Active immunization—induction of a host immune response
through antigen challenge—has been explored in mice. In the first such study, mice were actively
immunized with exposure to recombinant human α-synuclein. Mice in which immunization
produced a high antibody titer showed reduced levels of both total α-synuclein and inclusions, as
well as improved synaptic markers, while those with lower titers did not see a benefit (Masliah et
al., 2005). Subsequently, active immunization against α-synuclein has been shown to reduce
inclusion levels, neurodegeneration, and motor phenotype in mice, while inducing microglial
activation (Mandler et al., 2015).
Passive immunization with various antibodies against total α-synuclein and pathological
α-synuclein has also been examined. Transgenic mice expressing human wildtype or mutant
(A30P) α-synuclein showed reductions in inclusions and neurodegeneration following treatment
with antibodies against native and pathological α-synuclein (Bae et al., 2012; Games et al., 2014;
Lindström et al., 2014; Masliah et al., 2011). Passive immunization with Syn303, an antibody
against pathological α-synuclein aggregates, reduced α-synuclein inclusions, neurodegeneration,
and motor phenotype in wildtype mice treated with α-synuclein PFFs (Tran et al., 2014). The
considerable promise of immunotherapy against PD has led to several clinical trials, the most
advanced of which is recruiting for a phase 2 trial (NCT03100149, estimated primary completion
in 2020) examining the efficacy of the 9E4 antibody (Games et al., 2014; Masliah et al., 2011) to
delay motor phenotype in PD patients (Schenk et al., 2017).
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1.4.3 Altering aggregation
The strong evidence that α-synuclein aggregation plays a causal role in PD has led to
extensive examination of many approaches to modulating that aggregation pathway. Dopamine,
and related molecules containing catechol moieties (vicinal hydroxyls on an aromatic ring), were
the first small molecules shown to modulate α-synuclein aggregation. They inhibit α-synuclein
fibril formation, instead leading to formation of soluble oligomers (Conway et al., 2001). This
interaction has been shown to require oxidation of dopamine and can be inhibited by electron
donors (Mazzulli et al., 2006; Norris et al., 2005). Dopamine interacts with the α-synuclein Cterminal at residues Y125EMPS129 (Herrera et al., 2008; Mazzulli et al., 2007; Norris et al., 2005).
This interaction is stabilized by electrostatic interaction with E83 and can be impaired by E83A
mutation (Herrera et al., 2008).
The identification of dopamine as an aggregation inhibitor is notable given the selective
loss of dopaminergic neurons in PD. As discussed in Section 1.3.3, α-synuclein oligomers have
been shown to destabilize neuron membranes and may be responsible for α-synuclein
neurotoxicity. Recently, elevation of α-synuclein in mice expressing A53T α-synuclein was shown
to enhance neurodegeneration and oligomer formation. The same study found, in C. elegans, that
increased dopamine levels enhanced neurodegeneration in animals expressing A53T αsynuclein, but not in animals expressing A53T α-synuclein mutated in the Y125EMPS129 to abolish
dopamine interaction (Mor et al., 2017). These findings represent the most direct evidence to date
that direct interaction between dopamine and α-synuclein enhances α-synuclein neurotoxicity.
While dopamine may enhance α-synuclein toxicity through modulating aggregation,
studies have also identified potentially neuroprotective modulators. Many of these inhibitors
interact directly with α-synuclein and induce formation of oligomeric species. Some share little of
their structure or putative chemistry with dopamine, such as Anle138b (Deeg et al., 2015; Wagner
et al., 2013) and rifampicin (Li et al., 2004). However, the preponderance of oligomer-inducing
aggregation inhibitors are polyphenols, flavonoids, catechols, or lignans that bear vicinal hydroxyl
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substitutions on aromatic rings (Ehrnhoefer et al., 2008; Di Giovanni et al., 2010; Masuda et al.,
2009; Meng et al., 2010). An ongoing clinical trial is evaluating one such polyphenol,
epigallocatechin gallate (EGCG), in multiple system atrophy, a synucleinopathy characterized by
inclusion formation in glia (Levin et al., 2016; Wakabayashi et al., 1998). Previous studies
characterizing the effects EGCG on α-synuclein aggregation and neurodegeneration are further
discussed in Section 4.2.
Other attempts to alter α-synuclein aggregation have endeavored to alter protein-protein
interactions. Chaperone proteins such as heat shock proteins (Hsp) 70 and 104 have been
shown to reduce α-synuclein aggregation and toxicity. Hsp70 and Hsp40 are present in Lewy
bodies and expression of Hsp70 reduced α-synuclein aggregation and neurodegeneration in D.
melanogaster expressing A30P and A53T α-synuclein (Auluck et al., 2002). Hsp70 reduced αsynuclein aggregation in mice expressing A30P α-synuclein (Klucken et al., 2004). Hsp104 was
shown to reduce both α-synuclein aggregation and neurodegeneration in rats expressing A30P αsynuclein (Lo Bianco et al., 2008). Hsp expression can be altered pharmacologically and may
represent a druggable target in PD (Kilpatrick et al., 2013; McLean et al., 2004).
Altering α-synuclein-lipid interactions has also been explored as a method to alter
aggregation, though rationales and results have varied. The small molecules NPT100-18A and
squalamine displace α-synuclein from membranes, reducing α-synuclein oligomers and
neurodegeneration (Perni et al., 2017; Wrasidlo et al., 2016). Conversely, phtalocyanine
tetrasulfonate has been shown to stabilize lipid-bound α-synuclein and reduce aggregate
formation (Fonseca-Ornelas et al., 2014). Markedly altering the dynamics of α-synuclein-lipid
interactions may result in side-effects given their role in physiological function and
neurotransmission (covered in Section 1.3.2).
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1.5 Current study
Strong evidence implies that α-synuclein aggregation plays a causal role in PD
pathogenesis. As such, altering α-synuclein aggregation in PD represents a promising target for
therapeutics. While the interaction between α-synuclein and dopamine has been well
characterized, less is known about interactions between α-synuclein and putatively
neuroprotective molecules that alter aggregation. Additionally, many of these small molecules
may perturb the native interactions between α-synuclein membranes, either directly, or by
inducing membrane destabilizing oligomers.
Chapter 2 reviews α-synuclein’s remarkable structural flexibility, considering its role in
physiological function and pathological aggregation. We propose a model of the α-synuclein
aggregation energy landscape based on the existing literature.
Chapter 3 presents our examination of changes in the mouse brain proteome and
phosphoproteome during α-synuclein aggregation. We found that the proteome does not undergo
widespread changes. Instead, we identified specific changes in dopamine biosynthesis directly
related PD pathophysiology and the model’s motor phenotype. Importantly, we quantified
changes in levels of proteins not previously implicated in α-synuclein aggregation. We thoroughly
explored Lmp7, a subunit of the immunoproteasome, demonstrating that it also changes in PD
patient brains and that the immunoproteasome can degrade α-synuclein fibrils. The implication of
Lmp7 in PD, as well as the larger brain proteome we generated, provide novel insight into the
process of neurodegeneration driven by α-synuclein aggregation and open the door to new
therapies.
Chapter 4 contains our exploration the mechanism of action by which
nordihydroguaiaretic acid (NDGA), and novel related analogs (Asiamah et al., 2015), inhibit αsynuclein aggregation. We also analyzed the α-synuclein species formed, particularly considering
structural dynamics. We found that NDGA must undergo oxidation and cyclization before
interacting with α-synuclein in a manner distinct from EGCG and dopamine. We also found that
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NDGA renders monomeric α-synuclein resistant to aggregation without altering native lipid
interactions. Further, we observed that the presence of NDGA-modified monomers prevents
aggregation of untreated α-synuclein. Finally, we found that cyclized NDGA, but not NDGA,
reduces α-synuclein-driven dopamine neuron degeneration in Caenorhabditis elegans.
Chapter 5 includes a summary of our findings, seeks to contextualize them within the
field, and explores their implications for future research and therapeutic development.
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2.1 Abstract
α-Synuclein is a conserved, abundantly expressed protein that is partially localized in presynaptic terminals in the central nervous system. The precise biological function(s) and structure
of α-synuclein are under investigation. Recently, the native conformation and the presence of
naturally occurring multimeric assemblies have come under debate. These are important
deliberations because α-synuclein assembles into highly organized amyloid-like fibrils and nonamyloid amorphous aggregates that constitute the neuronal inclusions in Parkinson’s disease and
related disorders. Therefore understanding the nature of the native and pathological
conformations is pivotal from the standpoint of therapeutic interventions that could maintain αsynuclein in its physiological state. In this review, we will discuss the existing evidence that
define the physiological states of α-synuclein and highlight how the inherent structural flexibility of
this protein may be important in health and disease.
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2.2 Introduction
α-Synuclein is a soluble protein that is highly conserved in vertebrates and abundantly
expressed in nervous tissue (Jakes et al., 1994). It was first discovered in 1988 in association
with purified synaptic vesicles from the Torpedo electric ray (Maroteaux et al., 1988). Soon
afterward α-synuclein was found to be widely distributed across the mammalian brain and
localized to presynaptic nerve terminals, suggesting functions related to neurotransmission (Iwai
et al., 1995). Independent of these reports, α-synuclein was identified as the precursor to a
hydrophobic peptide found in Alzheimer’s disease senile plaques, termed the non-Aβ component
of Alzheimer’s disease amyloid (NAC) (Uéda et al., 1993). The α-synuclein gene was also
dynamically regulated during song learning in zebra finch, supporting a role in synaptic plasticity
(George et al., 1995).
The discovery of a mutation in the α-synuclein gene that was associated with autosomal
dominant inheritance of Parkinson’s disease (PD) provided the impetus for a major shift in αsynuclein research (Polymeropoulos et al., 1997). PD is a neurodegenerative disorder primarily
characterized by the loss of dopamine-producing neurons in the substantia nigra pars compacta
resulting in motor impairment. Since the original publication of the A53T mutation, several
mutations, as well as multiplications of the α-synuclein gene have been linked to PD (ChartierHarlin et al., 2004; Ferese et al., 2015; Krüger et al., 1998; Lesage et al., 2013; Pasanen et al.,
2014; Proukakis et al., 2013; Singleton et al., 2003; Zarranz et al., 2004). Furthermore, several
antibodies against α-synuclein robustly detect the well-known pathoanatomical features of PD,
Lewy bodies and Lewy neurites, in postmortem brain tissue from patients with sporadic PD as
well as other related neurodegenerative disorders (Baba et al., 1998; Spillantini et al., 1997;
Takeda et al., 1998). The finding that wildtype α-synuclein was detected in Lewy bodies and
Lewy neurites prompted the publication of numerous studies that investigated the biochemistry
and biology of α-synuclein. Despite the rather impressive body of work several fundamental
21

questions remain: What is the physiological function of α-synuclein? What is the structure of
native α-synuclein? What factors contribute to the induction of aggregation-competent
conformational states of α-synuclein? In this review, we will briefly review the evidence for the
different biological functions and discuss ongoing efforts to precisely define physiological
structures of α-synuclein.
2.3 The physiological function(s) of α-synuclein
The initial studies indicated that α-synuclein is not required for neuronal development or
synapse formation, but instead may modulate synaptic activity. In rodents, α-synuclein is
detected close to the time of birth and continues to increase until one month of age, when it
reaches a steady-state level that is maintained throughout adulthood (Shibayama-Imazu et al.,
1993). Similarly, in cultured rat neurons the development of synapses precedes α-synuclein
expression and translocation to axonal terminals (Murphy et al., 2000; Withers et al., 1997). The
hypothesis that α-synuclein regulates synaptic activity was directly tested in mice lacking αsynuclein. α-Synuclein null mice develop normal brain architecture and synaptic contacts, and do
not exhibit gross behavioral phenotypes (Abeliovich et al., 2000). However, subtle abnormalities
in activity-dependent neurotransmitter release have been observed. Upon repeated stimulation,
dopaminergic synapses from α-synuclein null mice sustain highly elevated dopamine release
(Abeliovich et al., 2000; Yavich, 2004). Functional redundancy among α-synuclein and the other
synuclein family members, β- and γ-synuclein, may account for the mild phenotypes observed in
the single knockout. In α/β-synuclein double knockout mice, synaptic plasticity appears unaltered
relative to α-synuclein single knockouts, although dopamine levels in the striatum are reduced
(Chandra et al., 2004). The importance of synucleins is particularly highlighted by α/β/γ-synuclein
triple knockouts, which have decreased life span and late-onset synaptic dysfunction compared
with wildtype mice (Burré et al., 2010; Greten-Harrison et al., 2010). Triple knockouts in another
study had motor deficits and decreased striatal dopamine, along with abnormal dopamine
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neurotransmission (Anwar et al., 2011). Collectively, these reports emphasize the important role
of the synucleins in long-term synaptic maintenance and plasticity.
Synaptic vesicle trafficking. Examination of the role of α-synuclein in the synaptic vesicle
cycle has yielded conflicting results. Depletion of α-synuclein from rodent hippocampal neurons
both in vivo and in vitro induces a significant loss of undocked synaptic vesicles, suggesting that
α-synuclein acts to replenish or maintain the resting and/or reserve vesicle pools (Cabin et al.,
2002; Murphy et al., 2000). In contrast, another study found that increasing α-synuclein in rodent
hippocampal neurons reduces the recycling pool of vesicles (Nemani et al., 2010). The effect of
α-synuclein on vesicles docked at the plasma membrane prior to exocytosis is similarly unclear.
Knockout or knockdown of α-synuclein in rodent hippocampal neurons results in either a
decrease or no change in the number of docked vesicles (Cabin et al., 2002; Murphy et al.,
2000). Conversely α-synuclein expression in PC12 cells causes an accumulation of vesicles at
the plasma membrane and impairment of exocytosis (Larsen et al., 2006). However, in mice
modestly overexpressing α-synuclein (levels are not associated with neurotoxicity), hippocampal
synapses display a redistribution of vesicles away from the active zone. The density of vesicles
in synaptic boutons is also reduced, consistent with α-synuclein-mediated inhibition of vesicle
clustering. This is supported by α-synuclein-induced defects in vesicle re-clustering following
endocytosis in rat hippocampal neurons (Nemani et al., 2010). Still, opposing results have been
obtained from yeast, in which α-synuclein expression results in massive accumulations of
vesicles that co-localize with Rab GTPases (Gitler et al., 2008; Soper et al., 2008). Likewise, αsynuclein has been shown to restrict vesicle diffusion away from synapses in mouse hippocampal
neurons (Wang et al., 2014). Several lines of evidence, therefore, support the participation of αsynuclein in synaptic vesicle trafficking, though the specific steps for which it may be most
important, i.e. vesicle docking, recycling and/or re-clustering, remain unclear.
Chaperone-like activity and neurotransmitter release. α-Synuclein and the other
synuclein family members may act as molecular chaperones, facilitating neurotransmitter release.
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Cysteine-string protein α (CSPα) is a chaperone that is essential for synaptic health; its deletion
in mice leads to a decrease in SNARE protein complexes, nerve terminal degeneration, motor
impairment and death. When expressed in CSPα-deficient mice, α-synuclein is able to rescue
this degenerative phenotype and restore levels of SNARE complexes in synaptic terminals.
Moreover, mice lacking both α-synuclein and CSPα exhibit an exacerbated phenotypic decline
(Chandra et al., 2005). These findings suggest that α-synuclein is able to complement the activity
of CSPα in promoting synapse integrity. Direct evidence for the interaction of α-synuclein with
SNARE complexes was documented by co-immunoprecipitation of α-synuclein with SNARE
proteins and specific binding to the vesicle-associated SNARE protein synaptobrevin-2. In
mammalian cells and purified in vitro systems, α-synuclein dose-dependently facilitates SNARE
complex assembly (Burré et al., 2010). Additional support for chaperone-like activity includes
sequence homology between α-synuclein and 14-3-3 protein chaperones as well as the
association of α-synuclein with 14-3-3 and its binding partners in rat brain (Ostrerova et al.,
1999). α-, β-, and γ-synucleins are also able to prevent the aggregation of denatured proteins in
vitro (Souza et al., 2000b), further supporting a conserved chaperone-like function of synucleins
and the existence of several protein-protein interactions that facilitate synaptic function.
Putative role in neurotransmitter synthesis and reuptake. Published evidence indicates
that α-synuclein-mediated protein-protein interactions may modulate dopamine synthesis and
recycling. α-Synuclein may inhibit the activity of tyrosine hydroxylase (TH), the rate-limiting
enzyme in dopamine synthesis. α-Synuclein and TH co-immunoprecipitate from rat striatal tissue
and MN9D dopaminergic cells and α-synuclein was shown to inhibit TH activity in MN9D and
PC12 cells, potentially through PP2A phosphatase-mediated reduction of serine 40
phosphorylation of TH (Peng, 2005; Perez et al., 2002). α-Synuclein may also interact with and
inhibit the activity of aromatic amino acid decarboxylase, which catalyzes the conversion of LDOPA to dopamine (Tehranian et al., 2006). Thus, α-synuclein may serve as a negative
regulator of dopamine synthesis, though further validation of these findings is necessary. Several
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reports have also implicated α-synuclein in the regulation of the dopamine transporter (DAT),
though the evidence is conflicting with regards to the functional consequences. Direct binding of
α-synuclein to DAT has been demonstrated in multiple studies. However, α-synuclein does not
appear to alter DAT function, but rather in various cellular contexts can promote or inhibit DAT
trafficking to the plasma membrane (Oaks and Sidhu, 2011). Elucidating the relationship
between α-synuclein and DAT requires further investigation.
2.4 α-Synuclein structural flexibility
Primary sequence. The primary sequence of α-synuclein consists of 140 amino acids
with a predicted molecular mass of 14,460.16 Da and an isoelectric point of 4.67 (Figure 2.1).
The sequence of α-synuclein is composed of three functionally defined domains. The N-terminal
region (amino acids 1-60) is characterized by the presence of unique and highly conserved
sequence of imperfect tandem repeats with a central consensus motif of K(A)-T(A,V)-K(V)E(Q,T)-G(Q)-V(A). These motifs spanning residues 10-86 are projected to form two amphipathic
α-helices and are characteristic of several proteins such as apolipoproteins that bind reversibly to
membranes (George et al., 1995; Maroteaux et al., 1988). Indeed the structure of membrane
bound α-synuclein contains two α-helices (amino acids 3-37 and 45-92) in a roughly antiparallel
arrangement with a short linking region (Ulmer and Bax, 2005). These helices are stabilized by
interaction with a variety of phospholipid bilayers, though α-synuclein interacts preferentially with
membranes of high curvature and an abundance of acidic phospholipids, properties consistent
with those of synaptic vesicles (Davidson et al., 1998; Zhu et al., 2003b). Upon interaction with
membranes of low curvature α-synuclein adopts a distinct secondary structure characterized by a
single extended helix that includes both previously described helical domains and the linker
region (amino acids 38-44) (Ferreon et al., 2009; Georgieva et al., 2010; Trexler and Rhoades,
2009). All known mutations associated with familial PD (A30P, E46K, H50Q, G51D, A53E, and
A53T) are found in the N-terminal domain (Krüger et al., 2008; Lesage et al., 2013; Pasanen et
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al., 2014; Polymeropoulos et al., 1997; Proukakis et al., 2013; Zarranz et al., 2004). These
mutations, with the exception of G51D, A53E, and A30P, increase the propensity of α-synuclein
to form insoluble aggregates and produce morphologically distinct aggregate species (Ghosh et
al., 2014; Giasson et al., 1999; Greenbaum et al., 2005; Lesage et al., 2013; Mahul-Mellier et al.,
2015; Narhi et al., 1999). Though the precise mechanism by which these mutations promote
aggregation has not been conclusively shown, evidence implicate an accelerated formation of
oligomers (Conway et al., 2000) likely due to the destabilization of the native N-terminal
conformation (Bertoncini et al., 2005b; Burré et al., 2015; Coskuner and Wise-Scira, 2013;
Dettmer et al., 2015a).
Amino acids 61-95 compose the hydrophobic NAC domain (Uéda et al., 1993). This
region contains a sequence of amino acids (71-82) necessary and sufficient for α-synuclein selfassembly into amyloid fibrils (Giasson et al., 2001). Recently the crystal structures of residues
68-78 (termed NACore), and residues 47-56 (PreNAC) were resolved by the use of microelectron diffraction, revealing that strands in this region stack in-register into β-sheets that are
typical of amyloid assemblies (Rodriguez et al., 2015).
The C-terminal domain (96-140) is rich in negatively charged amino acids (contains 10
glutamate and 5 aspartate residues) and was originally proposed to be essential for maintaining
the solubility of the protein. The presence of 5 proline residues, which are known to induce turns

Figure 2.1: Primary sequence of human α-synuclein. Green color indicates the imperfect
tandem repeats. Known mutations are indicated in red. The hydrophobic NAC domain is
underlined. The major sites of posttranslational modifications identified in vivo are highlighted
in blue (Ac, acetylation; Ub, ubiquitination; NO2, nitration; and PO3- phosphorylation).
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and disrupt secondary protein structure, suggested that this region is devoid of secondary
structure (George et al., 1995; Ulmer and Bax, 2005). However, the C-terminus was shown to
form transient, long-range interactions with the N-terminus resulting in the formation of multiple
compact monomeric structures (Bertoncini et al., 2005b; Dedmon et al., 2005). These compacted
structures of α-synuclein are temperature sensitive and are resistant to aggregation. The data
also indicated that at elevated temperatures the C-terminus assumes an extended conformation
that liberates N-terminal associations and enables aggregation (Bertoncini et al., 2005b; Dedmon
et al., 2005). Moreover, C-terminally truncated forms of α-synuclein aggregate faster than full
length protein (Hoyer et al., 2004; Li et al., 2005). Truncated α-synuclein has been detected in
the brains of both control (non-disease) and PD patients. Cleavage of full-length protein at
residues D115, D119, N122, D125 and Y133 was documented in α-synuclein extracted from LBs
(Anderson et al., 2006).
The C-terminus appears to be important for the interaction of α-synuclein with other
proteins and for the interaction with small molecules (Burré et al., 2010, 2012; Conway et al.,
2001; Mazzulli et al., 2006; Souza et al., 2000a; Woods et al., 2007). Additionally, it contains the
major sites of metal binding and post-translational modifications. Binding of iron, copper, and
other metals has been shown to influence α-synuclein function and aggregation (Uversky et al.,
2001a). Addition of Fe(III), but not Fe(II) to preformed oligomers of α-synuclein accelerates
aggregation, raising the question of metal binding at different points during the aggregation
process (Kostka et al., 2008). Cu(II) is unique among metals at accelerating aggregation of αsynuclein at physiologically relevant concentrations. The sole histidine residue H50 in αsynuclein was found to be critical for Cu(II) binding (Rasia et al., 2005) whereas other divalent
metal ions, including Mn(II), Co(II), Ni(II) and Fe(II), preferentially bind to the C-terminus of αsynuclein at residues D121, N122, and E123 (Binolfi et al., 2006).
Post-translational modifications. α-Synuclein undergoes a number of post-translational
modifications, including N-terminal acetylation, serine and tyrosine phosphorylation, lysine
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ubiquitination and tyrosine nitration (Barrett and Greenamyre, 2015; Oueslati et al., 2010). αSynuclein purified under mild conditions is acetylated in the N-terminus. The N-terminal
acetylation may account for the formation of an oligomeric form of the protein with partial α-helical
structure (Trexler and Rhoades, 2012). However, semisynthetic production of N-terminally
acetylated α-synuclein demonstrated that modified and unmodified versions of the protein share
similar secondary structure, aggregation propensities, and membrane binding (Fauvet et al.,
2012). NMR studies indicated that the first 12 residues undergo a chemical shift due to Nterminal acetylation. This modification also appears to stabilize the helicity of the N-terminus
within the context of the full-length protein, and increases the affinity of α-synuclein for lipids
(Dikiy and Eliezer, 2014).
Mass spectrometry-based methodologies revealed that α-synuclein extracted from
human Lewy bodies was phosphorylated at S129 (Fujiwara et al., 2002). An antibody raised
against phosphorylated S129 was then used to show that α-synuclein was phosphorylated at this
site only in subjects with disease and that S129 phosphorylated α-synuclein was present only in
the Triton-X- and Sarkosyl-insoluble, urea soluble fraction. These data indicated that some
form(s) of aggregated α-synuclein and not the soluble protein is targeted for phosphorylation at
S129. Indeed in vitro data showed that purified fibrils of α-synuclein are substrates for casein
kinase 1 or 2 (Waxman and Giasson, 2010). Other data indicated that polo-like kinase (PLK) 2mediated phosphorylation of S129 increased autophagy-mediated degradation of α-synuclein,
suggesting that phosphorylation may be a neuroprotective mechanism to accelerate clearance of
aggregated protein (Oueslati et al., 2013). In addition to the monomeric α-synuclein, S129
phosphorylated bands with apparent molecular weight of 22 kDa and 29 kDa were observed in
the detergent insoluble extract (Hasegawa et al., 2002). These bands were also immunoreactive
with anti-ubiquitin antibodies suggesting that S129 phosphorylated α-synuclein is also targeted
for mono- and di-ubiquitination. It has long been established that the core of Lewy bodies stains
positive for both α-synuclein and ubiquitin whereas the surrounding halo is immunoreactive for α28

synuclein (Hasegawa et al., 2002). Of the 15 lysine residues in α-synuclein, the major sites of
LB-derived α-synuclein undergoing ubiquitination were residues K12, K21, and K23 (Anderson et
al., 2006; Hasegawa et al., 2002; Sampathu et al., 2003).
A number of spectroscopic methodologies (CD and NMR) were employed to explore the
effect of S129 phosphorylation on the structure of α-synuclein. CD data revealed that
phosphorylation of S129 did not affect secondary structure, such that both non-phosphorylated
and phosphorylated S129 exhibited random coil structure (Paleologou et al., 2008). NMR data
revealed a number of chemical shifts that occur due to phosphorylation. While the residues
surrounding S129 exhibited the greatest perturbation, residues 1-90 also exhibited detectable
chemical shifts (Paleologou et al., 2008) This likely reflects the previously documented longrange interactions of the C- and N-termini. The potential effects of phosphorylation of S129 on
the structure of the protein were not faithfully reproduced by mutation of S129 to either E or D,
two common phosphomimics used to study the structural consequences of phosphorylation. For
example, phosphorylation at S129 increased the hydrodynamic radius of the protein, whereas
S129 E/D mutants did not (Paleologou et al., 2008).
Subsequent studies found additional sites of phosphorylation. Elevated levels of
phosphorylated α-synuclein at residue S87 were detected in human brains with Alzheimer’s
disease, Lewy Body disorders, and multiple system atrophy (Paleologou et al., 2010). S87
phosphorylation alters the biophysical properties of α-synuclein, including inhibition of fibril
formation and reduction in membrane binding (Paleologou et al., 2010). Additionally,
phosphorylated α-synuclein at residue Y125 was detected in Drosophila expressing human
wildtype α-synuclein as well as in human brains, though levels were decreased in disease
compared with aged-matched healthy controls (Chen et al., 2009).
The proximity of the α-synuclein phosphorylation sites to the metal binding sites raised
the question of how phosphorylation may affect metal ion interactions. This was investigated by
the use of C-terminal peptides containing residues 119-132 that were either unmodified,
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phosphorylated at Y125 or at S129 (Liu and Franz, 2005). By exploiting the luminescence
properties of Tb3+, it was found that phosphorylated Y125 showed enhanced Tb3+ binding relative
to wildtype or phosphorylated S129. Additionally, phosphorylated Y125 preferentially bound to
trivalent rather than divalent metal ions. To investigate this further, longer C-terminal fragments
comprised of residues 107-140 that were either unmodified of monophosphorylated at Y125 or
S129 were tested for their affinity to various metal ions. By using a fluorescence quenching
assay, the dissociation constants of the metal ion complexes and the α-synuclein peptides were
determined. These data indicate that either phosphorylation at Y125 or S129 increases the
binding affinity for Cu (II) and Fe(II), but not Fe(III). Furthermore, phosphorylated Y125 has a
greater affinity for Pb(II) than wildtype, but phosphorylated S129 has an even greater affinity than
phosphorylated Y125. Additionally, tandem MS indicated that phosphorylation causes the metal
ion binding sites to shift towards the C-terminal end of α-synuclein (Lu et al., 2011).
α-Synuclein within Lewy bodies is nitrated on all four tyrosine residues (Giasson et al.,
2000). Chemical nitration of α-synuclein results in the formation of both tyrosine nitrated
monomers and nitrated dimers (Souza et al. 2000b). Immunoelectron microscopy confirmed that
nitrated monomers and dimers are incorporated into amyloid fibrils. Purified nitrated α-synuclein
monomer by itself was unable to form fibrils, whereas the nitrated dimer accelerated aggregation
of unmodified α-synuclein (Hodara et al., 2004). Additionally, nitration at residue Y39 in the Nterminus decreased binding to synthetic vesicles and prevented the protein from adopting αhelical conformation (Hodara et al., 2004). These observations were recently confirmed and
elegantly expanded by the generation of site-specifically nitrated α-synuclein using protein
semisynthetic chemistries (Burai et al. 2015). Using the synthetic nitrated α-synuclein the data
showed that nitration did not interfere with phosphorylation of S129 by PLK3 and reaffirmed that
intermolecular interactions between the N- and C-terminal regions of α-synuclein are critical in
directing nitration-induced oligomerization of α-synuclein (Burai et al. 2015).

30

Native conformation(s) of α-synuclein. Figure 2.2 depicts the rapid growth in the number
of publications identified in PubMed using the term synuclein and highlights key studies that
explored the native structure and conformation of the protein. Early biochemical studies of αsynuclein isolated from bacterial expression systems or α-synuclein expressed in rodent tissues
indicated that it is monomeric with limited secondary structure. Electrophoretic separation of αsynuclein purified without heating on 6, 10, or 14% acrylamide gels estimated an apparent
molecular weight of 20±3 kDa. However, the values of sedimentation coefficient (S20,w = 1.7S),
stokes radius (34 Å), analysis on native gels and derivation of the frictional coefficient (f/fo=2.09)
indicated an apparent molecular weight in the range 57-58 kDa (Weinreb et al., 1996). To
reconcile this apparently anomalous behavior it was proposed that monomeric α-synuclein
achieves minimal structure in simple solutions and this rather extended unstructured
conformation resembles a globular protein with a larger apparent molecular weight. This
assumption was further corroborated by examination of purified monomeric α-synuclein by CD,
FTIR and small angle X-ray scattering, which failed to identify significant secondary structural
features. Furthermore, minimal shifts in the spectroscopic features of α-synuclein were observed
when the protein was placed in solutions that would increase hydrophobicity and neutralize
negative charges indicating that the protein is natively unstructured, joining a growing group of

Figure 2.2. The graph depicts the number of publications retrieved from PubMed using
the search term “alpha synuclein” from a single publication in 1998 to 862 in 2015. Significant
milestones that examined the native structure and conformations of α-synuclein are displayed.
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proteins sharing similar biochemical and biophysical characteristics (Uversky et al., 2001b). NMR
and CD data, however, indicated that α-synuclein assumes increasingly folded secondary
structure when exposed to conditions that promote aggregation (low pH and high temperature) or
upon interaction with phospholipids. Collectively these data indicated that native α-synuclein is
primarily an unstructured monomer, which can assume different compact conformations that
resist aggregation, adopts α-helical conformation upon binding to lipids and undergoes
conformational changes prior to oligomerization and formation of amyloid fibrils (Uversky et al.,
2001b). However, the methodologies employed to quantify the molecular weight of α-synuclein in
these elegant studies were not based on first principles and therefore a lingering uncertainty
remains regarding the native size of the protein. Moreover, crosslinking experiments in both
intact cells expressing α-synuclein and lipid-free lysates revealed the stabilization of high
molecular weight α-synuclein multimers (consistent with dimers, trimers, and larger multimers).
These multimers were not reduced by dilution of lysates before crosslinking, nor by reducing the
concentration of crosslinker from 1 mM to 8 µM, suggesting that they represented endogenous
protein complexes (Cole et al., 2002).
Examination of the α-synuclein native state was reignited in 2011 with the publication of
results indicating that α-synuclein exists natively as a tetramer, rather than a monomer.
Methodologies that are based on first principles were employed to examine the molecular weight
and size of α-synuclein extracted under non-denaturing conditions from human red blood cells.
Analytical ultracentrifugation produced a sedimentation equilibrium value of 4.78 S, indicating a
molecular weight of 57.8 kDa. Analysis of particle geometry by scanning transmission electron
microscopy revealed the presence of roughly spherical molecules with a diameter of
approximately 3.0-3.5 nm. Automated sampling of 1000 α-synuclein particles showed a
distribution of molecular weights between 10 and 175 kDa with a peak distribution at 55 kDa.
These findings constitute the most direct measurements of the native molecular weight of α-
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synuclein. The tetrameric species were shown to have α-helical conformation and were resistant
to aggregation (Bartels et al., 2011).
Complimentary observations were made using recombinant GST-tagged α-synuclein
purified from bacterial expression systems under non-denaturing conditions. Single-particle
electron microscopy of purified α-synuclein revealed complexes of sizes and internal geometries
consistent with trimers and dimers, which were corroborated by measurements of the
hydrodynamic radii and elution on native state PAGE. As observed previously, these species
were more resistant to aggregation than denatured monomer. CD also showed that several αsynuclein mutations associated with early onset PD (A30P, E46K, A53T) exist in less ordered
conformations than wildtype α-synuclein. These mutants were also more prone to aggregation
(Wang et al., 2011). However, using the same α-synuclein construct that contains a 10-residue
N-terminal extension, which forms multimers when isolated from E. coli, NMR studies indicated
that only a small fraction of α-synuclein assembles into α-helical trimers and tetramers and the
majority remains as a disordered monomer (Gurry et al., 2013). These data indicated that
several potential conformers of α-synuclein may exist in equilibrium. The observation that αhelical trimers and tetramers constitute only a small fraction of the total α-synuclein may explain
other studies in which in-cell NMR was used to probe for the structure of α-synuclein and
reported primarily the presence of unstructured monomer. NMR data of α-synuclein in intact cells
failed to detect stable or highly populated α-synuclein multimers and confirmed the intrinsically
disordered nature of the protein in E. coli regardless of its purification method (Binolfi et al.,
2012). Collectively these studies generated an apparent controversy and stimulated several
additional studies that explored the native size and structure of α-synuclein.
A re-examination of the native state of α-synuclein reasserted that the behavior of αsynuclein from various sources was consistent with a disordered monomer. This behavior was
observed with protein extracted and isolated under both denaturing and non-denaturing
conditions. CD spectra previously attributed to tetrameric assemblies were not reproduced using
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isolated monomer, but were replicated with the addition of small unilamellar vesicles. Natively
isolated α-synuclein before or after boiling that disrupts secondary structure migrated as high
molecular weight α-synuclein bands in native PAGE, which was attributed to the rather expanded
size of the unstructured monomer in solution. These findings reaffirmed that the majority of
native α-synuclein is a monomer with minimal secondary structure (Fauvet et al., 2012). Further
support was provided by similar explorations in the mouse brain, which indicated that the
predominant native form of α-synuclein is an unstructured monomer. α-Synuclein exhibited
random coil structure in solution, readily aggregated over time, and adopted α-helical structure
only upon membrane binding (Burré et al., 2013).
α-Synuclein multimers were detected in postmortem non-diseased human brain using
mild protein extraction methods, but no further purification. These α-synuclein multimers had
Stokes radii ranging from 33.2-37.5 Å, sedimentation coefficients ranging from 1.4S to 3.8S and
apparent molecular weights ranging from 53-70 kDa in native gradient gels. The multimers were
detected by anti-α-synuclein antibodies that recognize different epitopes and the multimer identity
was confirmed by mass spectrometry. Consistent with previous observations, melting point
thermostability analysis showed progressive loss of the α-synuclein multimers and heating of the
brain extracts above 55 oC collapsed the higher molecular weight α-synuclein conformers into the
53 kDa species, which corresponds to the unstructured monomer. These data indicated the
presence of α-synuclein conformers, defined as conformationally diverse α-synuclein multimers,
in the human brain. Therefore it appears that both monomer and metastable multimers coexist
and that interactions with lipids, other proteins, or small molecules may transiently stabilize these
species (Gould et al., 2014). This was further supported by controlled bimolecular fluorescence
complementation methodologies in different cell types that found α-synuclein metastable
conformers assembled in synapses. It was suggested that the function of these multimeric αsynuclein conformers is to restrict recycling of synaptic vesicles and thus reduce neurotransmitter
release (Wang et al., 2014).
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Additional support for native multimeric species comes from recent studies in which serial
purification of α-synuclein from non-pathological human cortical tissue was performed. Removal
of lysate components other than protein followed by sequential removal of proteins though size
exclusion, anion chromatography, and thiopropyl sepharose 6b separation, resulted in the
isolation of >90% pure α-synuclein. Each step of serial purification resulted in a progressive loss
of α-synuclein immunoreactive high molecular weight bands observed after disuccinimidyl
glutarate crosslinking and SDS-PAGE separation. Analysis of α-synuclein secondary structure by
CD found that the sequentially purified protein had greater α-helical content than the recombinant
α-synuclein. However, a high degree of variability in secondary structure was observed between
purified samples raising questions about the stability of these helical conformations (Luth et al.,
2015). Furthermore, crosslinking experiments conducted in brain tissue from mice expressing
wildtype or A53T human α-synuclein in the absence of mouse α-synuclein showed that the A53T
mutation reduced the presence of soluble multimeric α-synuclein (Dettmer et al., 2015a).
2.5 Concluding remarks and perspectives
Collectively the studies on the native structure indicate a remarkable conformational
plasticity and structural flexibility of α-synuclein. The ability of the protein to adopt N-terminal αhelical conformation through its association with lipids has been well documented. The
association with lipids has been shown to prevent fibril formation (Martinez et al., 2007; Zhu and
Fink, 2003) and may also stabilize physiological multimeric species that together with the
monomer regulate SNARE complex assembly and recycling of synaptic vesicles (Burré et al.,
2014; Wang et al., 2014). However, other groups have demonstrated a role for phospholipid
membranes in promoting pathological α-synuclein aggregation, potentially by acting as a scaffold
for amyloid nucleation. This event may preferentially occur at low lipid to protein ratios, when
monomeric α-synuclein is free in solution and can participate in nucleation (Galvagnion et al.,
2015; Ysselstein et al., 2015).
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In figure 2.3 we propose a model which incorporates and summarizes the existing
knowledge regarding α-synuclein biology and structure. The steady state levels of α-synuclein
are carefully regulated by protein synthesis and removal by several pathways such as the
ubiquitin-proteasome pathways and autophagy (Webb et al., 2003). Controlling the steady state
levels of this protein by regulating synthesis and degradation may be the first critical defense in
preventing aggregation. Conformational change to α-helical rich structures, and stabilization of
metastable multimers is achieved by specific interactions with vesicular phospholipids and
proteins. The sequestration of α-synuclein in association with membrane vesicles and with other
proteins may be of critical importance for preventing aggregation. Therefore these dynamic
equilibria maintain functionality and promote assemblies that are resistant to aggregation.
Catastrophic events that may include inappropriate post-translational modifications will
disassemble the multimers as well as transform aggregation-incompetent monomers to

Figure 2.3. Free energy landscape of possible α-synuclein conformers and multimeric
assemblies. The conversion of native α-synuclein to aggregation-competent monomers
may depend on dissociation from stabilizing interactions with lipids and/or proteins as well as
dissociation of the metastable tetrameric species. α-Synuclein aggregation-competent
monomers can then assemble into dimers and larger oligomeric conformers. The generation
of α-synuclein oligomers can rapidly lead to formation of stable amyloid fibrils, or ‘offpathway’ amorphous aggregates, both of which have been observed in postmortem brain
tissue from patients with PD and related disorders.
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aggregation-competent species. The first step in the pathway to amyloid fibril formation is the
generation of a dimer that is either held together by hydrophobic interactions induced by
increased conformational transition to β-sheet structure or upon covalent cross-linking. Following
this nucleation event (Wood et al., 1999) the hydrophobic patch of amino acids between residues
71-82 appears to be primarily responsible for allowing additional α-synuclein monomers to
assemble to form oligomeric structures. This transition is the committed rate limiting step for
aggregation and must overcome a relatively large thermodynamic requirement that permits the
conversion from an unstructured coil to organized β-sheet conformation. Oligomers are soluble
in aqueous buffers and can appear spherical or ring-like by atomic force and electron microscopy
(Conway et al., 2000; Lashuel et al., 2002). Soluble, high molecular weight oligomers have been
extracted from human brain tissue and their levels appear to be increased in PD brain (Sharon et
al., 2003) as well as mouse models of α-synuclein aggregation (Tsika et al., 2010). As oligomers
grow, they reach an undefined critical length and are able to assume additional quaternary
structure. At this stage, these structures may continue to grow in linear β-sheets, forming
polarized protofibrils and eventually fibrils. Fibrils may further arrange into protein inclusions
although it remains unclear if other proteins within these inclusions anchor these fibrils.
Alternatively, oligomers may remain soluble by interacting with small molecules (Conway et al.,
2001) or by incorporating post-translationally modified α-synuclein molecules. These structures
remain “off the amyloid fibril pathway” and may constitute what has been described in human
postmortem tissue as “dots” or “dust-like” amorphous aggregates (Braak et al., 2001; Duda et al.,
2002). At this juncture, it remains unclear which of these assemblies are toxic to neurons.
Recent data indicate that several conformationally distinct assemblies (possibly different strains)
of α-synuclein generated in vitro will induce the aggregation of endogenous α-synuclein resulting
in neurodegeneration (Guo et al., 2013; Luk et al., 2012a; Peelaerts et al., 2015; Sacino et al.,
2014b). The appreciation of different α-synuclein conformers and assemblies as well as their
roles in disease may guide potential therapeutic approaches. For example, therapeutic strategies
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can be centered on preserving and stabilizing the physiological multimeric conformers as well as
preventing monomers from aggregating. Alternatively, sequestration and removal of aggregationcompetent monomers and oligomers can be considered.
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3.1 Abstract
Accumulation of aggregated α-synuclein into Lewy bodies is thought to contribute to the onset
and progression of dopaminergic neuron degeneration in Parkinson’s disease (PD) and related
disorders. Although protein aggregation is associated with perturbation of proteostasis, how αsynuclein aggregation affects the brain proteome and signaling remains uncertain. In a mouse
model of α-synuclein aggregation, 6% of 6,215 proteins and 1.6% of 8,183 phosphopeptides
changed in abundance, indicating conservation of proteostasis and phosphorylation signaling.
The proteomic analysis confirmed changes in abundance of proteins that regulate dopamine
synthesis and transport, synaptic activity and integrity, and unearthed changes in mRNA binding,
processing and protein translation. Phosphorylation signaling changes centered on axonal and
synaptic cytoskeletal organization and structural integrity. Proteostatic responses included a
significant increase in the levels of Lmp7, a component of the immunoproteasome. Increased
Lmp7 levels and activity were also quantified in postmortem human brains with PD and dementia
with Lewy bodies. Functionally, the immunoproteasome degrades α-synuclein aggregates and
generates potentially antigenic peptides. Expression and activity of the immunoproteasome may
represent testable targets to induce adaptive responses that maintain proteome integrity and
modulate immune responses in protein aggregation disorders.
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3.2 Introduction
Cells have developed protein homeostasis networks to maintain proper cellular function
and combat potentially toxic protein aggregation. Failure to sustain proteostasis upon protein
aggregation may contribute to the pathogenesis of several neurodegenerative diseases of aging
such as Parkinson’s disease, Alzheimer’s disease and Amyotrophic lateral sclerosis (Balch et al.,
2008; Douglas and Dillin, 2010; Powers et al., 2009). These diseases are characterized by
progressive misfolding and aggregation of proteins and ultimately neuron death.
However, it remains unclear how intracellular aggregation of proteins leads to neuron
dysfunction and death. Studies in cellular model systems have shed some light on the
pathological mechanisms of endogenous protein aggregation. Dynamic changes in the proteome
of cultured cells following intracellular aggregation of artificial synthetic proteins indicated that the
formation of amyloid-like aggregates attracted several interacting proteins, which were
functionally linked to protein synthesis and quality control (Olzscha et al., 2011). These findings
were recently expanded to show that not only artificial synthetic proteins enriched in β-sheet
structure but also fragments of mutant huntingtin and TAR DNA-binding protein 43 (TDP-43)
peptides, which aggregate in human diseases, cause disturbances in the proteome by interfering
with nuclear-cytoplasmic protein and RNA transport (Woerner et al., 2016). Collectively, these
studies highlight the impact of protein aggregation on the proteome and proteostasis, and provide
the intriguing hypothesis that the re-allocation of cellular resources to combat changes in the
proteome upon endogenous protein aggregation leads to dysfunction and ultimately neuron
death.
To explore, for the first time, protein aggregation induced changes in the proteome and
signaling through phosphorylation in vivo we capitalized on the development of a mouse model of
α-synuclein aggregation and the use of quantitative mass spectrometry (MS)-based proteomic
technologies. α-Synuclein is a 140 amino acid protein that is predominantly localized to vesicles
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in pre-synaptic terminals (Davidson et al., 1998; George et al., 1995; Maroteaux et al., 1988)
participating in the regulation of neurotransmitter release and synaptic plasticity (Abeliovich et al.,
2000; Chandra et al., 2004; Nemani et al., 2010). Several point mutations, as well as
multiplications, of the α-synuclein gene are associated with familial Parkinson’s disease (PD)
(Farrer et al., 2004; Polymeropoulos et al., 1997; Singleton et al., 2003). Moreover, highly
organized amyloid-like fibrils and non-amyloid amorphous aggregates of non-mutant α-synuclein
are deposited into Lewy bodies, cytoplasmic inclusions that serve as histopathological hallmarks
of sporadic PD and other related neurodegenerative disorders (Duda et al., 2002; Giasson et al.,
2000; Spillantini et al., 1997).
To investigate the pathological mechanisms of α-synuclein aggregation, Luk et al.
developed a mouse model of α-synuclein aggregation (Luk et al., 2012a). In this model,
unilateral injection of preformed fibrils (PFFs) of recombinant wild type mouse α-synuclein into the
striatum of non-transgenic mice induces progressive aggregation of endogenous α-synuclein, first
in regions proximal to the injection site 30 days post injection (dpi) with further involvement of
distally interconnected regions by 90 and 180 dpi. Injected mice developed significant
dopaminergic neuron degeneration and impaired balance and motor coordination at 180 dpi (Luk
et al., 2012a, 2016). Importantly, degeneration and α-synuclein inclusions within the nigrostriatal
dopaminergic system are confined to the injected side and absent in the non-injected
contralateral side of the brain at 180 dpi. Additionally, injection of PFFs into α-synuclein null
(Snca-/-) mice fails to induce these effects, indicating that endogenous α-synuclein is required for
aggregation and dopamine neuron degeneration (Luk et al., 2012a). This PFF injection model
has been reproduced in mice, rats and non-human primates (Osterberg et al., 2015; Paumier et
al., 2015; Peelaerts et al., 2015; Sacino et al., 2014b; Shimozawa et al., 2017). Therefore, this
model (both wild type and Snca -/- injected mice) provides an opportunity for in vivo study of
quantitative changes in the proteome upon aggregation of α-synuclein using MS-based
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proteomics and phosphoproteomics when used in combination with Stable Isotope Labeling in
Mammals (SILAM) (Wu et al., 2004).
3.3 Methods
Animals. Wild type female, 2-3 month old, C57BL6/C3H mice were obtained from the Jackson
Laboratories (Bar Harbor, ME). Snca-/- mice were maintained on a C57BL6 background.

13C-

Stable Isotope Labeling in Mammals (SILAM) mouse brain tissue (C57BL6 female, L-Lysine-13C6,
97%) was purchased from Cambridge Isotope Laboratories, Inc. All housing, breeding, and
procedures were performed according to the NIH Guide for the Care and Use of Experimental
Animals and approved by the University of Pennsylvania Institutional Animal Care and Use
Committee (IACUC).
Stereotaxic injection of PFFs. For stereotaxic injections, the PFFs were diluted in sterile PBS
and fragmented using a Bioruptor bath sonicator (Diagenode, Denville, NJ). Sonication was
performed at high power for 10 cycles (30s on, 30s off, at 10°C). Mice were anesthetized with
ketamine hydrochloride (100 mg/kg, i.p.) and xylazine (10 mg/kg, i.p.). For each animal, PFFs
were stereotaxically targeted into the ventral striatum (AP: +0.2 mm Bregma, lateral: 2.0 mm from
midline, depth: 3.6 mm beneath the dura), dorsal striatum (AP: +0.2 mm, lateral: 2.0 mm, depth:
2.6 mm), and overlaying cortex (AP: +0.2 mm, lateral: 2.0 mm, depth: 0.8 mm). Injections were
made through a single needle tract using 10 µL syringes (Hamilton, NV) at a rate of 0.1 µL per
min (2.5 µL total per site) with the needle in place for ≥ 5 min at each target. Animals were
monitored regularly following recovery from surgery. Mice were sacrificed at 90 days post
injection by overdose with ketamine/xylazine. For biochemical studies, dorsal striatum and
ventral midbrain from ipsilateral and contralateral sides were dissected and stored at -80 °C until
used. For histological studies, the brain and spinal cord were removed after transcardial
perfusion with PBS and underwent overnight post-fixation in either neutral buffered formalin
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(Fisher Scientific) or 70% ethanol (in 150 mM NaCl, pH 7.4), before being processed and
embedded in paraffin.
Immunohistochemistry and neuron counting for mouse brain. Immunohistochemistry for αsynuclein phosphorylated at Ser-129 and tyrosine hydroxylase (TH) were performed on 6 µm
thick coronal sections as previously described (Luk et al., 2012a). Digitized images of stained
sections were acquired using a Perkin Elmer Lamina scanner at 20x magnification. Midbrain
dopaminergic neurons belonging to the substantia nigra pars compacta and the ventral tegmental
area were quantified from TH-immunostained coronal sections spanning the entire extent of the
midbrain (every 9th section). Only intact neurons with visible nuclei and TH positive staining were
included in the counting based on established criteria (Fu et al., 2012). Statistical analysis
between groups was compared using unpaired t-test.
Sample preparation and LC-MS/MS analysis. For each mouse injected, the midbrain and
striatum of the injected and non-injected sides were individual dissected and kept separate. Two
midbrain and striatum regions of the injected hemisphere were combined to generate one
biological sample for the proteomic analysis. The same approach was employed for the noninjected side. Four biological samples for wild type and three for Snca-/- for each injected and
non-injected side were analyzed through the proteomic workflow. Homogenates were prepared
as described previously (Mertins et al., 2013). Briefly, brains were homogenized with a tissue
grinder in cold urea buffer: 8 M urea, 75 mM NaCl, 50 mM Tris HCl pH 8.0, 1 mM EDTA, 2 µg/mL
aprotinin (Sigma, A6103), 10 µg/mL leupeptin (Roche, 11017101001), 1 mM PMSF (Sigma,
78830), 10 mM NaF, 5 mM sodium butyrate, 5 mM iodoacetamide (Sigma, A3221), Phosphatase
Inhibitor Cocktail 2 (1:100, Sigma, P5726), and Phosphatase Inhibitor Cocktail 3 (1:100, Sigma,
P0044). Following 10 min centrifugation at 20,000g, protein concentration was determined by a
BCA assay (Thermo, 23235). The supernatant was then combined with 13C-labeled brain lysates
in a 1:1 ratio (5µg). Samples were reduced for 45 min with 5 mM dithiothreitol followed by
alkylation with 20 mM iodoacetamide for 45 min. Samples were then diluted 1:4 with 50 mM Tris
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HCl pH 8.0 (to reduce urea concentration to 2 M), then digested overnight with trypsin (Promega,
V5111) at 37°C overnight. 1% formic acid was added to the digests to remove urea by pelleting.
The tryptic peptides were desalted by ultraMicro-Spin Vydac C18 column (Nestgroup, Inc,
SUMSS18V). After peptide separation by high-pH reverse phase chromatography, 95% of
peptides were combined in a concatenated pattern into 12 fractions for phosphoproteomic
analysis. Lyophilized phosphopeptides fractions were re-suspended in 50% acetonitrile/0.1%
trifluoroacetic acid (TFA) and then diluted 1:1 with 100% acetonitrile/0.1% TFA. These samples
were then enriched for phosphorylation by incubation with 10 µL immobilized metal affinity
chromatography (IMAC) for 30 min. Enriched IMAC beads were the loaded onto C18 silicapacked stage tips washed twice with 50 µL of 80% acetonitrile/0.1% TFA and 100 µL of 1%
formic acid. Phosphopeptides were then eluted from IMAC beads with three washes of 70 µL
500 mM dibasic sodium phosphate, pH 7.0, (Sigma, S9763) and 2 washes of 100 µL of 1%
formic acid. Elution from stage tips was then performed with 60µL of 50% acetonitrile/0.1% formic
acid. Washes were performed on a tabletop centrifuge at a maximum speed of 3,500 g. The
peptides were analyzed by mass spectrometry (MS) and the data was analyzed with MaxQuant
(described below). The SILAM ratio of light/heavy generated from the MaxQuant was converted
to log2 scale and the median of the SILAM ratios therefore was calculated. If the SILAM ratio was
close to 1:1, a larger scale sample prep was performed similarly as described above. Protein (2
mg heavy: 2 mg light) was digested with trypsin/Lys-C mix (Promega, V5073) at 1:25 enzyme:
protein ratio. This protease mix has been reported to enhance mass spectrometry-based
proteomics analysis by reducing the missed cleavages at lysine residue of a given peptide
(Mertins et al., 2013). The peptide fragments were desalted on tC18 SepPak cartridge (Waters,
WAT036815) and the peptides were lyophilized and stored in -80 °C. For reverse phase-HPLC,
the peptides were reconstituted in 20 mM ammonium formate, pH 10.0. Peptide concentration
was determined by UV280 before they were separated by high-pH reverse phage
chromatography (Acquity UPLC H-Class instrument, Waters) to 72 fractions. Solvent A (2%
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acetonitrile, 5mM ammonium formate, pH10) and solvent B (90% acetonitrile, 5mM ammonium
formate, pH 10) were used to separate peptides with a ZPRBAX 300Extend-C18 column
(4.6mmx250mm, 5 Micron, Agilent). The gradient for separation was 1 mL/min flow rate as at 9
min, 100% A; 13 min, 94% A; 63 min, 71.5%; 68.5 min, 66% A; 81.5 min, 40% A; 83 min; 0% A;
at 88-120 min with 1.2 mL/min with 100%A. Five percent of the samples were removed and
recombined in a concatenated pattern into 24 fractions for proteomics analysis.
Peptide digests were analyzed on a hybrid LTQ Orbitrap Elite mass spectrometer (Thermofisher
Scientific, San Jose, CA) coupled with a NanoLC Ultra (Eksigent Technologies). Mobile phase A
consisted of 1% methanol/0.1% formic acid and mobile phase B consisted of 1% methanol/0.1%
formic acid/79% acetonitrile. Peptides were eluted into the MS at 200 nl/min with each RP-LC
run comprising a 15 min sample load at 3% B and a 90 min linear gradient from 5 to 45% B. The
mass spectrometer repetitively scanned m/z from 300 to 1800 (R = 240,000 for LTQ-Orbitrap).
FTMS full scan maximum fill time was set to 500 ms, while ion trap MSn fill time was 50 ms;
microscans were set at one. FT preview mode, charge state screening, and monoisotopic
precursor selection were all enabled with rejection of unassigned and 1+ charge states.
Database searching, construction of the mouse brain reference proteome and proteomic
data analysis. Protein identification was performed with MaxQuant (1.5.1.2) using a mouse
UniProt database. Carbamidomethyl was defined as a fixed modification. The False Discovery
Rate for peptides was set at 1%. Fragment ion tolerance was set to 0.5 Da. The MS/MS
tolerance was set at 20 ppm. The minimum peptide length was set at 7 amino acids. The requantification option was left unchecked and the match-between-runs was turned on. For a
protein to be quantified, the peptide must be identified at least once in light and once in heavy.
To construct a unified set of literature and experimental proteins, UniProt accessions were crossreferenced by gene or protein name. For literature proteins, we selected several studies that
used MS-based proteomics to identify proteins in the unperturbed mouse brain (Price et al., 2010;
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Walther and Mann, 2011; Wang et al., 2006). A reference proteome was generated combining
the literature proteome with proteins identified in our experimental runs (Data file S4).
The Light-to-Heavy (L/H) ratio in the non-injected side was divided by the L/H ratio in the injected
side to compute the injected/non-injected ratio of ratios. Resulting lists of proteins were analyzed
using the Perseus software (http://www.coxdocs.org/doku.php) (Tyanova et al., 2016). The H/L
ratios reported by MaxQuant were inverted and log2 transformed. The mean, standard deviation,
coefficient of variation, and principle component analysis (PCA) were calculated to examine the
precision and repeatability of experiments. We used Z-score to scale the data by subtracting the
mean of each column from the values and dividing by the standard deviation of the column.
Student’s t-test and group averages were calculated and visualized in volcano plots within
Perseus. Lists of statistically significant proteins with p-value < 0.05 were selected and DAVID
Bioinformatics Resources V6.8 was employed for Gene Ontology (GO) analysis. GO data was
visualized using GO plot package in R (Walter et al., 2015). The gene network analysis was
performed using GeneMANIA (http://genemania.org/) prediction server (Montojo et al., 2014).
Motif-x software tool was used for motif analysis of phosphoproteome using IPI Mouse Proteome
as background.
The mass spectrometry proteomics data have been deposited to the ProteomeXchance
Consortium via the PRIDE partner repository with the dataset identifier PXD0009647.
Western blot analysis of mouse tissue. Mouse brain samples were extracted using the same
method described above for the MS analysis. For each analysis, 5-20 μg of sample was added
per lane, separated on 12% Bis-Tris Pre-Cast gels (ThermoFisher) and transferred to PVDF
membranes using 7.5% BSA in TBS for blocking. All primary antibodies were used overnight at
1:1000. Antibodies were used against TH (tyrosine hydroxylase; EMD Millipore, 657012
RRID:AB_696697), DAT (dopamine transporter; EMD Millipore, MAB369 RRID:AB_2190413),
Ddc (aromatic-L-amino-acid decarboxylase; Abcam, ab3905 RRID:AB_304145), NSE (neuron
specific enolase; Abcam, ab53025 RRID:AB_881756), PKC-β2 (protein kinase C beta-2; Abcam,
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ab32026 RRID:AB_779042), Akt (protein kinase B; Cell Signaling, 9272 RRID:AB_329827),
Lmp7 (proteasome subunit beta type-8; Abcam, ab3329 RRID:AB_303708), and α-synuclein
clone D37A6 (Cell Signaling Technology, #4179 RRID:AB_1904156) or clone Syn211 (SigmaAldrich Cat# S5566, RRID:AB_261518). Antigen-antibody complexes were detected using an
Odyssey LC scanner (LiCor) after incubation with appropriate secondary antibodies.
Densitometry was used to quantify intensity of protein bands.
Western blot analysis and proteasome activity of human tissue. Brain samples (amygdala,
cortex) from dementia with Lewy bodies and non-disease brains that have been described
previously (Rutherford et al., 2013; Waxman et al., 2008) were extracted using high salt buffer
containing 1% Triton-X100 (150 mM NaCl, 50 mM Tris, pH 7.6). Protease inhibitors were added
to buffer prior to use. To collect triton-soluble fractions, samples were homogenized, sonicated
and centrifuged at 15,000 rpm for 30 min. 500 μL of buffer was added to each sample. Protein
concentrations were determined by BCA assay (Thermo Fisher). Samples were separated in a
12% Bis-Tris Pre-Cast gel (ThermoFisher) and transferred to a PVDF membrane and blocked
using 7.5% BSA in TBS. For each analysis 40 μg of sample was added per lane. All primary
antibodies were used overnight at 1:1000. Antibodies were used against Lmp7 (proteasome
subunit beta type-8; Abcam, ab3329 RRID:AB_303708), β5 (proteasome subunit beta type-5;
Invitrogen, PA1-977 RRID:AB_2172052) and NSE (neuron specific enolase; Abcam, ab53025
RRID:AB_881756). Antigen-antibody complexes were detected using an Odyssey LC scanner
(LiCor) after incubation with appropriate secondary antibodies. Densitometry was used to
quantify intensity of protein bands. For proteasome activity, the brain samples were
homogenized as described above in the absence of protease inhibitors and freshly prepared
samples were analyzed using the proteasome activity fluorometric assay (BioVision K245).
Assays were performed in a 96-well plate at 37°C using 5 μg of brain lysate per experimental
condition. Each condition was analyzed with or without the proteasome inhibitor lactacystin
(Enzo Life Science PI104). After 60 min, the fluorescence with inhibitor was subtracted from the
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fluorescence without inhibitor in each sample. Three biological replicates were quantified for
each experimental condition. Statistical analysis between groups was compared using unpaired
t-test.
Immunohistochemistry for human brain. Human brain sections were obtained from the Brain
Bank of the Honolulu Asian Aging Study (White and al, 1996). The study is approved by the
Kuakini Medical Center Institutional Review Board and participants signed informed consents.
Five cases of PD and five healthy controls were examined. DAB and fluorescent
Immunohistochemistry for Lmp7, IBA1, and GFAP was performed on 10 µm thick tissue sections.
For colorimetric DAB staining, formalin fixed paraffin embedded sections were rehydrated in
ethanol and diH2O and submerged in H2O2 for 30 minutes to quench endogenous peroxidase
activity. Antigen retrieval was accomplished by microwaving the slides in a pressure cooker with
R Buffer U (Electron Microscopy Sciences, 62706-13). The tissue sections were then blocked at
room temperature in 2% normal horse serum and incubated with Lmp7 antibody (Abcam,
Ab3329, 1:5000) at 4° C for 18 hours. Slides were rinsed in 0.1M Tris and incubated with a
biotinylated secondary antibody, ABC, and DAB solution according to Vectastain instructions
(Vector Labs, PK-6200 and SK-4100). Images were acquired using a Nikon Eclipse E800
microscope. For fluorescent triple labeling, tissue sections were also rehydrated in ethanol and
diH2O and subjected to the same antigen retrieval and blocking steps as described previously.
Slides were then incubated with the same Lmp7 antibody at 1:2500 concentration, along with
antibodies against IBA1 (ionized calcium binding adaptor molecule 1; Abcam, ab5076
RRID:AB_2224402, 1:1000) and GFAP (glial fibrillary acidic protein; Millipore, NE1015
RRID:AB_2043416, 1:2000) antibodies at 4° C for 18 hours. Slides were then rinsed in 0.1M Tris
and incubated with corresponding Alexa Fluor-conjugated secondary antibodies (Invitrogen,
A10042 RRID:AB_2534017; A21202 RRID:AB_141607; A21447 RRID:AB_2535864) for 1 hour
at room temperature. Slides were rinsed again in 0.1M Tris and incubated with Hoechst 33342
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(Life Technologies, H3570), mounted with Fluormount G (Southern Biotech, 0100-01) and coverslipped. I mages were acquired using a Nikon A1RSI laser scanning confocal microscope.
In Vitro Degradation Assay. Purified human WT α-synuclein was aggregated at 5 mg/mL for 7
days at 1,400 rpm at 37°C. The fibrils generated from the aggregation of α-synuclein were used
as substrate for the in vitro degradation assays. Myelin Basic Protein (Sigma M1891) was used
at 25 μM and α-synuclein was used at 1 mg/mL. Human Immunoproteasome 20S (Enzo BMLPW8720) and Human Proteasome 20S (Enzo BML-PW9645) were used at a ratio of 0.11:1
proteasome:α-synuclein. Human Proteasome Activator 11S complex (BML-PW9420) was added
at a final concentration of 500 nM. Reactions were incubated at 37°C agitating at 600 rpm, and
samples were removed at indicated time points. Samples were separated in a 12% Bis-Tris PreCast gel (ThermoFisher) and stained with colloidal blue. Densitometry was used to quantify
protein degradation of monomer bands of α-synuclein. Initial time point was considered 100% for
each experimental condition. Three biological replicates were quantified for each experimental
condition. For mass spectrometry analysis of the immunoproteasome peptides, the samples were
removed following the indicated incubation time and frozen prior to processing. For the
processing, a modified enhanced filter aided sample preparation (eFASP) was used. Briefly, 10
kDa cutoff microcon filters (Millipore) were first passivated in a solution of 5% Tween 20 overnight
to reduce peptide binding, followed by extensive washes with dH2O. The samples were then
transferred to the filters and centrifuged at 14,000 xg for 10 min, retaining the flow through
containing the peptides. Sample volume was then reduced to roughly 50 µL by SpeedVac.
Contaminants in the sample were removed using C18 Stage Tips (Thermo Electron) and the
samples were transferred to autosampler vials. LC-MS/MS conditions and instrument settings
proceeded as above with the exception that the samples were not fractionated prior to analysis.
The raw data was searched against a database constructed with the human sequence of αsynuclein, proteasome and immunoproteasome subunits using MaxQuant (1.5.1.2) with peptide
cleavage set to nonspecific and a FDR of 1%.
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Cell treatments. U-251 cells were grown in high glucose DMEM supplemented with 10% FBS,
1% penicillin and streptomycin, 1% glutamine and 1% HEPES. Cells were plated at low density
and allowed to adhere for 24h, after which cells were pretreated with 0.1 µg/mL human interferon
gamma (Pepro Tech Inc.) alone or in conjunction with the Lmp7 inhibitor ONX 0914 (Cayman
Chemicals) at a final concentration of 0.2 µM. Following incubation overnight, 5 µg/mL αsynuclein fibrils were added to the media and incubated for 4d. The cells were washed 3x with
PBS and lysed in PBS + 1% Trition-X100. 12 µg of protein was loaded into each lane and the
western proceeded as described above. Primary antibodies to α-synuclein (clone Syn211,
SigmaAldrich, S5566 RRID:AB_261518), Lmp7 (proteasome subunit beta type-8; Abcam,
ab3329), and Actin (Sigma Aldrich, A2066 RRID:AB_476693) were incubated with the membrane
at a concentration of 1:1000 overnight at 4°C (Syn211) or for 1 h at room temp (Lmp7, Actin). IR
Dye conjugated anti-mouse or anti-rabbit secondary was incubated at 1:5000 for 1 h and the blots
were visualized using an Odyssey LC scanner (LiCor).
3.4 Results
Mouse Model of α-Synuclein Aggregation.
To identify proteomic and signaling perturbations induced by the aggregation of αsynuclein, a modified version of the recently developed and independently verified mouse model
was employed (Luk et al., 2012a; Osterberg et al., 2015; Sacino et al., 2014b). α-Synuclein
aggregation in non-transgenic mice was induced by unilateral injection of PFFs into three
locations, the motor cortex, dorsal and ventral-striatum. PFFs were generated by aggregating
purified recombinant mouse monomers of α-synuclein to insoluble amyloid-like fibrils exhibiting
typical β-sheet secondary structure, then sonicating them to produce smaller, β-sheet PFFs (Fig.
3.S1). The changes in the proteome and phosphoproteome were quantified 90 dpi, a time point
that is characterized by aggregation of α-synuclein, but prior to significant dopaminergic neuron
loss (Luk et al., 2012a).
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Although this model has been extensively validated, dopaminergic neurons belonging to
the substantia nigra pars compacta were stereologically quantified from tyrosine hydroxylase (TH)
stained coronal sections spanning the entire extent of the midbrain at 90 dpi (Luk et al., 2012a).
A non-significant 19 ± 6% loss of substantia nigra dopaminergic neurons was quantified in the
injected side of wild type mice, (n=3, t-test, p-value = 0.0507) as compared to the non-injected
side (Fig. 3.S2c). In contrast, no changes in TH staining was observed in the injected side of
Snca-/- mice (Fig. 3.S2c), consistent with the previous results (Luk et al., 2012a). An antibody that
recognizes phosphorylated α-synuclein at Ser-129 (pS129), a marker for α-synuclein inclusions in
human disorders was used to stain brain tissue obtained at 90 dpi (Anderson et al., 2006; ColomCadena et al., 2017; Fujiwara et al., 2002). Consistent with the previous report (Luk et al.,
2012a), Lewy body-like inclusions immunoreactive for pS129 were abundant in the substantia
nigra (Fig. 3.S2a) and striatum (Fig. 3.S2b) ipsilateral to the injection site by 90 dpi. In contrast,
no staining was detected in the same areas on the non-injected side at this time point. Total
levels of mouse α-synuclein are unchanged in the injected and non-injected side (Fig. 3.S2e).
Moreover, there were no detectable pS129 α-synuclein inclusions in the brains of Snca-/- mice
injected with PFFs in the same manner (Fig. 3.S2). Collectively, these data confirmed the
presence of PFF-triggered α-synuclein aggregation in the ipsilateral injected side of wild type
mice, which is associated with mild TH-positive neuron loss, consistent with previous findings in
this model (Luk et al., 2012a).
Acquisition and overview of the proteome and phosphoproteome.
A quantitative proteomic workflow depicted in figure 3.1a was implemented to quantify
changes in the relative abundance of proteins in both wild type and Snca-/- mice. The method
incorporated the use of [13C6-lysine]-SILAM mouse brain as an internal “heavy” standard.
Detailed examination of the [13C6-lysine]-containing internal reference peptides showed excellent
reproducibility (average Pearson correlation coefficient = 0.87, 80% overlap) (Fig. 3.S3).
Although the [13C6-lysine] internal standard was derived from the entire brain, whereas the “light”
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samples were derived from combining the midbrain and striatum regions only, we report high
correlations and tighter spreads of the corresponding heavy-to-light peptide pairs (average
Pearson correlation = 0.96) than the heavy-to-heavy peptide pairs (Fig. 3.S3). This improvement
likely arises from the coincident sample processing workflow of the SILAM experiment as
opposed to the parallel sample processing shown by the heavy-to-heavy comparisons. This
analysis validated the use of [13C6-lysine]-SILAM mouse brain as an appropriate standard for
accurate proteome quantification.
The quantitative proteomic analysis was restricted to brain regions of pathological
interest, which include the midbrain and the striatum. These two regions, dissected from two
mice, were combined to generate sufficient protein for the proteomic analysis. Using this
approach the proteomic analysis included four replicates derived from the injected and noninjected sides of wild type and three replicates obtained from each side of the similarly injected
Snca-/- mice. Combined analysis of the replicates in wild type mice applying a false discovery
rate of 1% and removal of contaminants and reversed sequences resulted in the identification of
6,508 proteins with a light-to-heavy (L/H) ratio in the injected side, 6,496 in the non-injected side,
with 6,215 proteins identified in both sides (Fig. 3.1b). Analysis in the Snca-/- mice resulted in the
identification of 4,661 proteins with L/H ratio in the injected side, 4,994 in the non-injected side,
with 4,460 proteins identified in both sides (Fig. 3.S4a). Immobilized metal affinity
chromatography (IMAC) enrichment for phosphopeptides resulted in the identification of 10,058
phosphopeptides in the injected and 10,134 in the non-injected side of the wild type mice; 8,183
phosphopeptides were common between the two sides. Similarly, 10,285 and 9,775
phosphopeptides were identified in the Snca-/- mice; 8,031 were shared between the two sides
(Data file S1 and Fig. 3.S4b).
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Figure 3.1. Workflow for the acquisition and overall description of proteomes. (a)
Overview of proteomic workflow. The midbrain and striatum from the brains of two mice were
dissected and combined to generate one sample replicate. The ipsilateral injected and the
contralateral non-injected sides were kept separate and processed throughout the workflow
independently. Immobilized metal affinity chromatography (IMAC) was used to enrich for
phosphorylated peptides.
(b) Venn diagrams depicting the number of proteins and
phosphopeptides quantified in 4 independent sample replicates in the injected side and noninjected side in wild type mice. The acquired proteomes in wild type and Snca-/- showed typical
distribution in terms of molecular weight, cellular location and major biological processes when
compared to a whole mouse brain proteome: (c) Distribution of the proteins quantified in wild
type and Snca-/- mice based on protein molecular weight. (d) Gene ontology enrichment
analysis using cellular components (e) Gene enrichment using biological process and KEGG
pathways.
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In order to determine the extent by which the proteins quantified in this study are
reflective of the proteins expressed in the mouse brain, and to protect against potential biases
during the acquisition of the proteomic data, we constructed a global mouse brain proteome. For
the mouse brain proteome we combined our non-injected wild type proteome with proteins
identified by mass spectrometry in unperturbed mouse brain from several existing studies (Price
et al., 2010; Sharma et al., 2015; Walther and Mann, 2011; Wang et al., 2006). The resulting
proteome comprised of 11,055 unique proteins was curated through UniProt
(http://www.uniprot.org). The distribution of the proteins quantified in our study was evaluated
based on their molecular weight, cellular localization and biological function against the reference
proteome. The proteins quantified were representative of the whole mouse brain proteome
covering the entire range of molecular weights >10 kDa to >400 kDa (Fig. 3.1c) all major cellular
compartments (Fig. 3.1d) and major biological processes (Fig. 3.1e). Together, these analyses
indicated that the number of proteins quantified through this workflow in the midbrain and striatum
are compatible with recent studies (Jung et al., 2017; Sharma et al., 2015) and are representative
of the proteins expressed in the mouse brain.
Analysis of the proteome and phosphoproteome reveals selective disease-related
changes.
Changes in the relative abundance of proteins were quantified by a ratiometric method,
dividing the L/H ratio of the non-injected side by the L/H ratio in the injected side. The data was
Log2 transformed, the coefficient of variance for each experiment determined, and the data
scaled using the standard z-score. Statistically significant changes in proteins (t-test, p <0.05)
between the injected and non-injected sides were identified (Data file S2) and typical volcano
plots integrating the p-value and the magnitude change were generated. The relative abundance
of 377 of 6,215 in wild type and 112 of 4,460 proteins in the Snca-/- mice changed significantly in
the injected side (Fig. 3.2a; Fig. 3.S5). Similarly, 132 of 8,183 phosphopeptides in wild type and
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109 of 8,031 in the Snca-/- mice showed significant change (Fig. 3.3a; Fig. 3.S5). There was a
minimal overlap between the proteins that showed changes in the injected side of the wild type
and Snca-/- mice (7 proteins), indicating that the changes in the wild type were driven primarily by
the aggregation of α-synuclein. This analysis indicated that aggregation of α-synuclein does not
induce large remodeling of the proteome or phosphorylation-dependent signaling. Ontological
and functional analysis of the 377 proteins is depicted in the circular plot (Fig. 3.2b) in which the
outer circle is a scatter plot for each biological term of the logFC (fold change) of the enriched
proteins and the size of the inner trapezoids correspond to the adjusted p-value and the color
indicates the z-score. Some of these functional protein clusters (extracellular exosome, synaptic
vesicle) have been previously linked to α-synuclein and may represent adaptive response to
maintain proteostasis and synaptic function.
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Figure 3.2. Analysis of Quantified Proteins. (a) Volcano plot showing the 377 proteins (black
circles) that changed significantly (p < 0.05) in relative abundance in the injected side as
compared to the contralateral non-injected side of wild type mice. The red dots indicate the
proteins with >2-fold increase and the blue dots the proteins with >2-fold decrease in relative
abundance. (b) Ontological analysis of the 377 proteins, which showed significant changes in
relative abundance between the ipsilateral injected side and the contralateral non-injected side
in the wild type mice. The circular plot depicts the enriched functional networks of proteins. The
outer circle is a scatter plot for each biological term of the logFC of the enriched proteins. Within
each network, a protein is depicted as a dot, red for upregulated and blue for downregulated.
The size of the inner trapezoids correspond to the adjusted p-value and the color indicates the zscore as calculated by GOplot algorithm. (c) Representative immunoblots from two independent
biological replicates for the significantly changed proteins TH, DAT, and Ddc paired with NSE,
PKC-β2 and Akt as unchanged protein controls. The graphs indicate the mean ± sem for protein
levels quantified by the SILAM-MS based method and the average of two independent western
blot analysis. The relative abundance of NSE, PKC-β2 and Akt did not change in the injected
wild type or Snca-/- mice.
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The proteomic analysis identified five proteins selectively expressed in dopaminergic
neurons among the proteins that decreased in abundance in the injected side of wild type mice.
The analysis showed a significant decline in the levels of TH 50 ± 3%, aromatic-L-amino-acid
decarboxylase (Ddc) 26 ± 4%, dopamine transporter (DAT; Slc6a3) 31 ± 9%, synaptic vesicular
monoamine transporter-2 (VMAT2; Slc18a2) 42 ± 8% and Slc10a4 (specific function is unclear
but is specifically expressed in dopaminergic neurons) (Larhammar et al., 2015; Patra et al.,
2015) 44 ± 3%. In contrast, the relative abundance of monoamine oxidase A (MAO-A) and
catechol-O-methyl transferase (COMT) that metabolize dopamine and are expressed in both glia
cells and dopaminergic neurons, did not change significantly (increased by 3 ± 4% and 8 ± 4%,
respectively). This finding indicates that, despite possible dilution of the proteome by multiple cell
types, our quantitative proteomic approach was capable of identifying specific changes in
dopaminergic neurons. Moreover, the decline in the abundance of proteins critical for dopamine
synthesis, transport, and recycling exceeded the loss of dopamine neurons (Fig. 3.S2) suggesting
ongoing dopamine neuron dysfunction consistent with the progressive injury in the setting of αsynuclein aggregation. As a reference, the abundance of TH, Ddc and DAT did not change in the
injected side of Snca-/- mice when compared to the contralateral, non-injected side.
Finally, the changes in the levels of TH, DAT and Ddc quantified by SILAM-MS-based
methodology were further confirmed by western blot analysis. The western blot analysis matched
closely the MS-based quantification showing similar decline in the levels of TH, DAT and Ddc in
the injected versus the non-injected side (Fig. 3.2c). The levels of TH, DAT and Ddc were
unchanged in the injected side of Snca-/- mice when quantified by western blot (Fig. 3.2c). As
controls for the western blots, we probed for unchanged proteins as determined by the MS
analysis. NSE, PKC-β2 and Akt, showed no change in the levels between injected and noninjected side in wild type and Snca-/- mice (Fig. 3.2c) by both MS-based quantification and
western.
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Although a relatively small number of phosphopeptides showed significant change in the
injected side of the wild type mice (132 phosphopeptides identified in 125 proteins, Fig. 3.3a), the
data was mined for kinases and functional pathways impacted by α-synuclein aggregation. First,
we performed a motif analysis to identify possible sequences targeted by kinase families. This
analysis revealed the enrichment for two motifs (Fig. 3.3b). The first motif, X(any amino acid)-XSerine-Proline is a known minimal sequence motif for phosphorylation by mitogen-activated
protein kinases (MAPK), which have been implicated in α-synuclein aggregation related disorders
(Ferrer et al., 2001; Iwata et al., 2001; Wilms et al., 2009; Zhu et al., 2003a). The second motif,
Arginine-X-X-Serine-X indicates the minimal motif for phosphorylation by Ca2+/calmodulindependent protein kinase II (CaMK-II), a serine/threonine kinase enriched at synaptic sites (Miller
and Kennedy, 1986; Moriguchi et al., 2012; Picconi et al., 2004). To further explore
phosphorylation signal networks, bubble plots of the enriched cellular components and molecular
functions were constructed using the z-score and the negative logarithm of the adjusted p-value
(Fig. 3.3c). The changes in phosphorylation signaling localize primarily in synapses and axons,
and functionally relate to proteins that regulate axonal and synaptic cytoskeletal organization and
structural integrity (Fig. 3.3c; Data file S3). Moreover, when the changes in synapse associated
phosphopeptides were combined with changes in synaptic vesicle proteins (Fig. 3.2b), the
integrated network highlighted numerous physical interactions indicative of functional changes to
synaptic architecture and secretory processes in response to α-synuclein aggregation occurring
before significant neuron loss (Fig. 3.3d).
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Figure 3.3. Analysis of Quantified Phosphopeptides. (a) Volcano plot showing the 132
phosphorylated proteins (black circles) that changed significantly (p < 0.05) in relative
abundance in the injected side as compared to the contralateral non-injected side of wild type
mice. The red dots indicate the phosphoproteins with >2-fold increase and the blue dots the
phosphoproteins with >2-fold decrease in relative abundance. (b) Motif analysis of the 132
phosphopeptides, which showed a significant change in relative abundance. Enrichment for two
motifs was discovered; the XXSP motif, a known target for phosphorylation by MAP kinase and
RXXS indicating substrates for CaMK-II kinase. (c) Bubble-plot indicating the cellular
components (red) and molecular functions (blue) that were significantly enriched among the 132
phosphopeptides. The area of the displayed circles is proportional to the number of proteins.
(d) Construction of a synaptic network from the 377 proteins and 132 phosphopeptides. Black
circles indicate proteins that are functionally assigned to synaptic vesicles and showed
significant changes in relative abundance. The yellow circles indicate phosphoproteins assigned
to synapse and showed significant changes in relative abundance. The gray circles are proteins
imported based on known interactions. Physical interactions are depicted as pink edges;
associations based on co-localization (blue) and shared protein domains (gold).
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Upregulation of the Immunoproteasome in α-synuclein aggregation disorders.
Among the significantly changed proteins a prominent increase in the relative levels of
the proteasome subunit beta type-8 (Psmb8; common name, low molecular mass protein 7;
Lmp7), was quantified in the injected side of wild type mice (Fig. 3.2a). The increase in relative
abundance of Lmp7 by MS in the injected side of wild type mice was validated by western blot
analysis (Fig. 3.S6 and 3.S7). Lmp7 is one of the three subunits of the catalytic core of the
immunoproteasome (Cascio et al., 2001; Driscoll et al., 1993; Gaczynska et al., 1994; Huber et
al., 2012), an inducible form of the proteasome assembled in response to inflammatory stimuli,
primarily IFNγ (Ebstein et al., 2013; Nathan et al., 2013; Seifert et al., 2010; Yun et al., 2016).
The immunoproteasome is defined by the replacement of catalytic subunits β1, β2 and β5 of the
proteasome with proteasome subunit beta type-9 (low molecular mass protein 2; Lmp2),
proteasome subunit beta type-10 (multicatalytic endopeptidase complex subunit-1; MECL-1) and
Lmp7, respectively (Cascio et al., 2001; Driscoll et al., 1993; Gaczynska et al., 1994; Huber et al.,
2012).
Since there are no previous studies linking α-synuclein aggregation to
immunoproteasome induction and its potential role in proteostasis, we examined whether a
similar increase of the immunoproteasome levels and activity occurs in human disease. We
compared the levels of Lmp7 in the brains of dementia with Lewy bodies (DLB), which contain
aggregated α-synuclein (Duda et al., 2002; Giasson et al., 2000; Waxman et al., 2008), and nondisease control subjects. The analysis revealed a 3-fold increase in the levels of Lmp7 in DLB as
compared to controls but no change in the levels of constitutive proteasome catalytic subunit β5
(Fig. 3.4a and 3.4b). Chymotrypsin-like activity, which is selectively elevated in the
immunoproteasome (Gaczynska et al., 1994; Huber et al., 2012), was quantified to evaluate if the
increase in protein levels correlates with activity. An 80% increase in the lactacystin-sensitive,
chymotrypsin-like activity was quantified in the DLB brain homogenates as compared to controls
(Fig. 3.4c).
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Figure 3.4. The Immunoproteasome in Human Disease Driven by α-Synuclein
Aggregation. (a) Representative western blot analysis in human DLB and non-disease control
brains for Lmp7 and the proteasome protein β5. (b) Densitometric analysis of western blots
normalized to the levels of NSE protein indicate a significant increase (**p<0.01, t test) in Lmp7
levels in DLB brains (n=5) compared with controls, (n = 3). (c) Concomitant with the increase in
Lmp7 protein levels the chymotrypsin-like activity, a proxy for immunoproteasome activity, is
increased by 189% in DLB brain compared with control brain (**p<0.01, n = 3, t test). (d)
Immunohistochemical staining revealed increased immunoreactivity for Lmp7 in PD substantia
nigra and VTA. (d1) Representative staining for Lmp7b in control substantia nigra and (d2) VTA.
Increased Lmp7 staining in both neurons (asterisks) and glia (arrows) in PD substantia nigra (d3)
and VTA (d4). Nuclei were counterstained with hematoxylin (blue). Scale bar = 50 µm. (e) Colocalization of Lmp7 with glial markers. Representative fluorescent staining for the astrocyte
marker, GFAP; microglial marker, IBA1; and Lmp7. Overlay of GFAP, IBA1, LMP7 and Hoechst
nuclear stain is displayed in the right column. Staining in non-disease control substantia nigra
(e1-4) and in VTA (e5-8). Increased staining for Lmp7 in the PD substantia nigra (e9-12) and in the
VTA (e12-16). Lmp7 co-localized with both astrocytes and microglia. Staining increased in glial
processes and soma (arrows) and neurons (asterisks) in PD substantia nigra relative to normal
controls. Lmp7 staining increased in astrocytes and microglia (arrows) of PD VTA relative to
non-disease controls. Scale bar = 20 µm.
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Immunohistochemical analysis of PD (n = 5) and non-disease control tissue (n = 5)
showed increased staining for Lmp7 in both the substantia nigra and ventral tegmental area
(VTA) in PD tissue (Fig. 3.4d). Increased staining for Lmp7 was observed in both neurons and
glia in the substantia nigra of PD cases but not in control cases (Fig. 3.4d and 3.4e). Neuronal
staining occurred in pigmented and non-pigmented neurons in PD substantia nigra. In PD ventral
tegmental area, Lmp7 staining occurred primarily in glia, while neuronal Lmp7 was not detected
in PD or control VTA. In glia and neurons, Lmp7 staining was detected throughout both cell
bodies and processes. Lmp7 localization was further characterized by fluorescent triple labeling
of astrocytes, microglia and Lmp7 (Fig. 3.4e). In the VTA of PD cases, 47 ± 10% of IBA-1
positive cells, a marker for microglia, and 40 ± 4 % of GFAP, an astrocytic marker, co-localized
with Lmp7 (n = 4). Overall, the biochemical and histological data demonstrate activation of the
immunoproteasome in human diseases characterized by α-synuclein aggregation.
To investigate the potential significance of the immunoproteasome we explored its ability
to degrade α-synuclein fibrils in vitro. For these experiments, we used the 20S
immunoproteasome and the 20S proteasome, which degrade proteins without the need for
ubiquitin tagging or the presence of the 19S regulatory particle (Moscovitz et al., 2015). First, we
secured that the purified immunoproteasome degraded myelin basic protein (MBP), a selective
substrate (Raule et al., 2014). After 22 hours, 96% of MBP was degraded by the
immunoproteasome and 69% by the proteasome (Fig. 3.S8). Next, α-synuclein fibrils generated
from purified human monomeric α-synuclein with typical β-sheet secondary structure were used
as substrate. The immunoproteasome was capable of degrading α-synuclein fibrils in a time
dependent manner achieving more than 50% degradation by 72 hours and nearly complete
degradation after 5 days of incubation (Fig. 3.5a and 3.5b). We further explored the possible
consequences of immunoproteasome-mediated α-synuclein fibril degradation. Since one of the
main functions of the immunoproteasome is to produce peptides for antigen presentation, we
tested if the degradation products exhibit peptide sequences that have been found to elicit MHC I
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and MHC II responses (Sulzer et al., 2017). Mass spectrometry detected 1,111 unique peptide
sequences covering the entire 140 α-synuclein amino acid residues (Data file S5). Further
refinement of the detected peptides indicated that the immunoproteasome produced multiple
peptides within the antigenic regions of α-synuclein (Sulzer et al., 2017), specifically between
residues 31-46 and 116-140 (Fig. 3.5c). Finally, to demonstrate that the immunoproteasome
degrades α-synuclein fibrils in intact cells, we used U-251 cells, a human glioblastoma cell line
that does not express endogenous α-synuclein and minimally detectable basal levels of Lmp7.
The only source of α-synuclein in this cell model is the exogenous α-synuclein PFFs added to the
culture media. In these cells, α-synuclein PFF uptake appears to be dependent on inflammatory
activation as evidence by the lack of uptake of exogenous α-synuclein in PFF only treated cells
(Fig. 3.5d). The link between inflammatory activation and α-synuclein uptake has been previously
documented (Lee et al., 2010). Concurrent treatment with INFγ induces expression of Lmp7 and
intracellular accumulation of exogenous α-synuclein. INFγ only treated cells show the expected
increase in Lmp7, but there is no α-synuclein available to detect in these cells. Intracellular
accumulation of the exogenous α-synuclein PFFs was quantified in the absence or presence of
the Lmp7 specific inhibitor ONX-0914 (Muchamuel et al., 2009). Inhibition of the
immunoproteasome results in greater intracellular accumulation of α-synuclein (Fig. 3.5d and
3.5e) without altering Lmp7 levels. Taken together, the data suggest a possible neuroprotective
role for the induction of the immunoproteasome to maintain proteostatic networks in response to
α-synuclein aggregation.
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Figure 3.5. Degradation of α-Synuclein preformed fibrils by the immunoprotesome.
(a) Representative immunoblot for the SDS-soluble fraction of α-synuclein fibrils in the absence
or presence of purified 20S proteasome or immunoproteasome for the indicated amount of time.
Incubation of pre-formed α-synuclein fibrils with purified 20S proteasome or immunoproteasome
resulted in a time-dependent decrease of oligomeric and monomeric α-synuclein. (b)
Quantification of the ~14kDa α-synuclein band corresponding to monomeric protein in the SDSsoluble fraction. (n = 3). (c) Analysis by mass spectrometry of the α-synuclein peptides
generated after the degradation of α-synuclein fibrils by the purified immunoproteasome. The
relative intensity of the peptides generated within the presumed antigenic regions, residues 3146 and residues 116-140 is shown after 3 and 5 days of incubation. (d) Immunoblot analysis of
α-synuclein and Lmp7 in U-251 cells. Cell were treated with 0.1 μg/mL INFγ for 24 hours prior to
exposure to α-synuclein preformed fibrils. To ascertain the contribution of immunoproteasome
in the degradation of internalized α-synuclein fibrils cells were treated with the Lmp7 specific
inhibitor ONX-0914. (e) Quantification of the normalized intensity α-synuclein in U-251 cells
after induction of Lmp7 and α-synuclein preformed fibril uptake in the absence or presence of
the Lmp7 specific inhibitor ONX-0914, (***p<0.001, n=3, t test).
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3.5 Discussion
Here, we quantified changes in the proteome and phosphorylation signaling in a
validated, non-transgenic mouse model of α-synuclein aggregation. The proteomic approach
achieved quantification of more than 6,000 proteins and 8,000 phosphoproteins, with typical
representation of proteins based on size, localization, and biological function consistent with
similar MS-based proteomic studies using the entire mouse brain (Walther and Mann, 2011) or
specific regions of mouse brain (Jung et al., 2017) indicating a reasonable coverage and
representation of the proteome. The proteomic workflow enabled the quantification of 46 proteins
that have been linked to Parkinson’s disease or associated with Lewy body formation and 220 of
226 proteins that were recently linked to α-synuclein (Chung et al., 2017). Contrary to
expectations, the changes in the proteome and phosphorylation signaling pathways induced by
aggregation of α-synuclein before significant dopaminergic neuron death are minimal and for the
most part proteostasis is preserved. Despite the absence of widespread remodeling of the
proteome, the data provided unique insights for the responses to protein aggregation, revealing
selective changes in protein clusters that participate in dopamine neurotransmission,
maintenance of neuronal and synaptic architecture and immune responses. These selective
changes were absent in PFF-treated Snca-/- mice.
Ontological analysis of the changes in the proteome and phosphoproteome revealed both
expected and novel findings. Notably, and consistent with the anticipated pathology, the data
revealed selective and significant decrease in the relative abundance of proteins that regulate
dopamine biosynthesis (TH, Ddc), transport and storage (VMAT-2) and recycling (DAT). The
decline in the levels of TH, Ddc, VMAT-2 and DAT was greater than the magnitude of neuron loss
supporting previous observations that alteration in synaptic proteins and function precedes
dopaminergic neuron death (Ara et al., 1998; Chung et al., 2009; Garcia-Reitböck et al., 2010;
Jackson-Lewis et al., 1995). This observation is further reinforced by the quantification of
significant changes in proteins that regulate synaptic vesicles and signaling through
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phosphorylation for proteins participating in the organization synaptic architecture and function.
These results support previous reports (Chung et al., 2009; Milber et al., 2012; Rockenstein et al.,
2014) including observations in humans (Milber et al., 2012; Scott et al., 2010) that perturbations
of synaptic protein function and cytoskeletal integrity precede neurodegeneration in α-synuclein
aggregation disorders.
Additional pathways impacted by the aggregation of α-synuclein included changes in
mRNA processing, binding, protein transport and nucleoplasmic function. These changes are
consistent with the alterations in nuclear-cytoplasmic protein and RNA transport observed in
models of mutant huntingtin and TDP-43 neurotoxicity (Woerner et al., 2016). Significant
changes in relative abundance were also quantified for 112 proteins that are annotated as
extracellular and proteins associated with exosomes. Augmentation of extracellular protein
release, including exosomes, in response to α-synuclein has been reported (Danzer et al., 2012;
Emmanouilidou et al., 2010; Minakaki et al., 2018) and may represent neuronal attempt to
remove potential toxic species of α-synuclein, which can be engulfed and degraded by
surrounding glia. Although this hypothesis implies a neuroprotective strategy to accommodate
proteostasis, it may also propagate α-synuclein toxicity and activate inflammatory and immune
glia responses.
The analysis unearthed an increase in the levels of Lmp7, one of the three cardinal
subunits of the immunoproteasome, which may represent a response to protein aggregation and
activation of innate immunity, since the immunoproteasome is primarily induced by inflammatory
stimuli, namely IFNγ (Aki et al., 1994; Heink et al., 2005). Increased Lmp7 levels in the mouse
model of α-synuclein aggregation and, critically, in DLB and PD brains has not been previously
documented. However, induction of the immunoproteasome is not specific for α-synuclein
aggregation. Levels and activity of the immunoproteasome are elevated in postmortem brains of
patients with Huntington’s and Alzheimer’s disease (Aso et al., 2012; Díaz-Hernández et al.,
2003; Mishto et al., 2006; Orre et al., 2013). In Huntington’s disease, Lmp2-positive staining was
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predominantly within neurons and overlapped with approximately 5% of cortical huntingtin protein
aggregates (Díaz-Hernández et al., 2003). In the Alzheimer’s disease brains increased labeling
for the immunoproteasome was associated with reactive glia that surrounded amyloid-β plaques
(Mishto et al., 2006; Orre et al., 2013). Taken in conjunction with our findings that Lmp7 staining
was increased in both neurons and glia in the substantia nigra and co-localized with microglia in
the ventral tegmental area in cases with PD, these data indicate that neurons and glia attempt to
counter protein aggregation by inducing the formation of the immunoproteasome.
The immunoproteasome serves at least two known biological functions. The major
function relates to the generation of peptides presented by MHC class I molecules on the cell
surface for recognition by CD8+ T cells (Driscoll et al., 1993; Gaczynska et al., 1994; Huber et al.,
2012; Kincaid et al., 2011). The immunoproteasome also removes ubiquitin-tagged oxidativelymodified misfolded proteins (Ebstein et al., 2013; Nathan et al., 2013; Seifert et al., 2010; Yun et
al., 2016). Both of these functions may be critical for protein aggregation diseases and
particularly for PD, DLB and related disorders characterized by aggregation of α-synuclein. Our
data indicates that the immunoproteasome degrades α-synuclein PFFs in vitro and in cells,
implicating the induction of the immunoproteasome as a potential pathway for elimination of αsynuclein aggregates. Moreover, the degradation of α-synuclein PFFs resulted in the generation
of potentially antigenic peptides that can induce both MHC I and MHC II responses.
Expression of MHC I in dopaminergic neurons in control (non-disease) and PD
postmortem tissues has been reported (Cebrián et al., 2014; Lindå et al., 1999). Moreover, the
selective expression of MHC I in dopaminergic neurons renders them susceptible to CD8+ T cell
mediated injury and death (Cebrián et al., 2014). A recent study has extended these
observations to show that peptides derived from α-synuclein elicit both MHC I and MHC II
responses to drive cytokine secretion from CD4+ T cells and CD8+ cytotoxic T cells in peripheral
mononuclear cells from patients with PD (Sulzer et al., 2017). Therefore, the induction of the
immunoproteasome in PD may relate to the degradation of α-synuclein and the generation of
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antigenic peptides for T cell presentation. This function may be viewed as detrimental for
dopaminergic neurons as activation of T cells elicits cytotoxic effects in neurons.
However, the immunoproteasome may play an important protective role. Primates and
mice with longer lifespans have elevated levels of the immunoproteasome (Pickering et al.,
2015). This may derive from the role of the immunoproteasome in degrading oxidatively modified,
ubiquitin-tagged, aggregated proteins (Ebstein et al., 2013; Nathan et al., 2013; Seifert et al.,
2010; Yun et al., 2016). The capacity of the immunoproteasome to degrade proteins modified by
oxidants may also be a vital response to neurodegeneration since an association between
oxidized proteins and increased immunoproteasome has been reported (Teoh and Davies, 2004).
Oxidative stress and oxidized proteins have been long considered in the pathological cascade of
neurodegenerative diseases including PD and related α-synuclein aggregation disorders
(Giasson et al., 2000; Ischiropoulos and Beckman, 2003; Souza et al., 2000a). Although several
forms of autophagy and the lysosomal pathway may participate in clearing α-synuclein and
related intermediates such as α-synuclein oligomers (Ebrahimi-Fakhari et al., 2011), the
immunoproteasome may be a viable strategy to influence neuroinflammation as well as clearance
of potentially toxic α-synuclein species. Given these findings, the timely and appropriate
induction of the immunoproteasome by small molecules or other activators may limit the
progression of pathology in neurodegenerative disorders. A recent study provided a proof-ofconcept for this suggestion by identifying small molecules known to inhibit the p38 MAP kinase
arm of MAPK signaling as potent activators of the proteasome (Leestemaker et al., 2017).
Interestingly, the activation of the proteasome by the p38 MAPK inhibitors was shown to increase
removal of overexpressed α-synuclein in cells providing a foundation for future studies that target
the immunoproteasome (Leestemaker et al., 2017).
Data uncovered a significant induction of Lmp7, one of the three principal subunits of the
immunoproteasome. The induction of immunoproteasome has been associated with removal of
misfolded proteins and preservation of proteostasis. Increased Lmp7 levels were also
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documented in postmortem human brain with Parkinson’s disease and increased levels and
proteolytic activity were documented in postmortem brains with DLB disease, which is
characterized by α-synuclein aggregation.
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3.8 Supplemental Figures

Figure 3.S1. Characterization of mouse α-synuclein fibrils. Purified mouse recombinant
wild-type α-synuclein was aggregated by incubating the protein (5 mg/ml) at 37°C under
constant shaking at 1,400 rpm for 8 days. Circular Dichroism (CD) spectra of the aggregated
proteins revealed the presence of is typical of β-sheet rich structures (red). PFFs generated by
sonication of the amyloid-like α-synuclein fibrils retain the β-sheet rich structure (green). The
purified recombinant soluble mouse α-synuclein monomer showed a typical unstructured
spectrum (blue). CD measurements were obtained in 10 mM potassium phosphate.
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Figure 3.S2. Characterization of wild type and Snca-/- mouse models. (a) Representative
staining for Ser-129 phosphorylated α-synuclein in the substantia nigra of injected and noninjected wild type and Snca-/- mice. Insert is higher magnification of neuronal cytoplasmic
inclusions in the injected side; no staining for Ser-129 phosphorylated α-synuclein was found in
the non-injected side. Scale bar = 100 µm. (b) Ser-129 phosphorylated α-synuclein in the
striatum of injected and non-injected wild type and Snca-/- mice. Scale bar = 100 µm. (c)
Staining of midbrain tyrosine hydroxylase (TH) positive neurons in the injected and non-injected
hemispheres of wild type and Snca-/- mice. Scale bar = 500 µm. (d) Immunostaining for TH in
striatum of injected and non-injected hemispheres of wild type and Snca-/- mice. Scale bar =
100 µm. (e) Western blot of total α-synuclein in the injected and non-injected hemispheres of
wild type mice.
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Figure 3.S3. Characterization of [13C6]-lysine-containing tryptic peptide component of
SILAM reference proteome. Log2 [intensity] of individual heavy peptides for each of 4
biological replicate experiments (Ah, Bh, Ch, and Dh) are shown plotted each against the others
below the diagonal. Area proportional Venn diagrams with accompanying peptide counts for
each comparison are shown above the diagonal. Along the diagonal are the corresponding
heavy vs light pairs for each experiment. As expected, histograms of peptide intensities unique
to each experiment in the pairwise comparisons (non-overlap regions of Venn diagrams) were
very heavily weighted toward the lowest quintile of intensities (not shown). Pearson correlation
coefficients for each of the heavy:heavy biological replicate pairwise plots and for the heavy:light
plots are shown along the diagonal. High correlations and tighter spreads of the corresponding
heavy:light peptide pairs (average Pearson correlation = 0.96) than the heavy:heavy peptide
pairs is observed. This is likely due to the coincident sample processing workflow of the SILAM
experiment. In all, approximately 30,000 heavy peptides were quantified across all four
biological replicates which corresponds closely to the number of heavy:light ratios for peptides
determined across the same.
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Figure 3.S4. Number of proteins and phosphopeptides quantified in of Snca-/- mice. Venn
diagrams depict the number of proteins (a) and phosphopeptides (b) quantified in the injected
side (red), non-injected side (blue), and in both sides (green) of the Snca-/- mouse brains (n=3).
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Figure 3.S5. Volcano Plot of proteins and phosphopeptides quantified in Snca-/- mice. (a)
Volcano plot for proteins and (b) for phosphoproteins depicting the proteins (black circles) that
changed significantly (P <0.05) in relative abundance in the inject side as compared to the
contralateral non-injected midbrain. The red dots indicate the proteins with >2-fold increase and
the blue dots the proteins with >2-fold decrease in relative abundance.
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Figure 3.S6. Characterization of the Lmp7 antibody. Western blot image obtained by
scanning the PVDF membrane on an Odyssey LC scanner. U-251 cells were treated with 2 μg
of interferon gamma (INFγ) or PBS for 24 hours and cell homogenates were analyzed on a 12%
Bis-Tris gel, transferred to PVDF membrane, and probed with anti-proteasome 20S LMP7
antibody (ab3329).
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Figure 3.S7. Western blot detection of lmp7 in the mouse brain. Representative western blot
image for Lmp7 obtained by scanning the PVDF membrane on an Odyssey LC scanner. Two
biological replicates of combined midbrain and striatum homogenates from non-injected (N) and
PFF-injected (I) wild type mice were separated on a 12% Bis-Tris gel, transferred to PVDF
membrane and probed with anti-proteasome 20S LMP7 antibody (ab3329). Quantification of
Lmp7 by densitometry confirmed the mass spectrometry-based increase in the injected side
compared to the non-injected side. Lmp7 was not detected in Snca -/- mice by either western
blot or mass spectrometry-based proteomics.
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Figure 3.S8. Degradation of Myelin Basic Protein (MBP) by the 20S constitutive
proteasome and the 20S immunoproteasome. (a) Representative immunoblot for BMP after
incubation with purified 20S constitutive proteasome or 20S immunoproteasome. The 20S
proteasome does not require ubiquitin tagging or the presence of the 19S regulatory particle for
protein degradation. At the indicated time points, aliquots were removed and analyzed by SDSPAGE. (b) Quantification of the monomeric band of MBP indicated that incubation with the
immunoproteasome results in 96% degradation compared to 70% with the constitutive
proteasome after 22 hours of incubation; n=3.
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4.1 Abstract
Parkinson’s disease (PD) is a neurodegenerative disorder characterized by loss of dopaminergic
neurons and the presence of Lewy bodies, proteinaceous inclusions containing aggregated αsynuclein. A growing body of evidence suggests α-synuclein aggregation is a key driver of
neurodegeneration in PD. Several classes of small molecules, many containing phenolic ring
structures, have shown promise in altering aggregation of α-synuclein. Herein, novel analogs of
nordihydroguaiaretic acid (NDGA), a phenolic dibenzenediol lignin, were shown to induce
modest, progressive compaction of monomeric α-synuclein without preventing the dynamic
adoption of α-helical conformations. The structural alteration of monomeric α-synuclein prevented
the primary and secondary nucleation-dependent formation of amyloid-like fibrils. The NDGA
analog-mediated inhibition of fibril formation persisted for 14 days and NDGA analog-pretreated
α-synuclein did not aggregate even in the absence of molecules in the aggregation mixture.
Strikingly, NDGA-preatreated α-synuclein suppressed aggregation of naïve untreated monomeric
α-synuclein. Further, cyclized NDGA reduced α-synuclein-driven neurodegeneration in
Caenorhabditis elegans. NDGA analogs that stabilize aggregation-resistant α-synuclein
monomers, without interfering with their ability to adopt functional conformations, might yield
therapies to prevent or slow neurodegeneration in PD.

80

4.2 Introduction
Parkinson’s disease (PD) is an age-related neurodegenerative disorder characterized by
a progressive motor phenotype including tremors, rigidity, and bradykinesia. These symptoms are
driven primarily by loss of dopamine-producing neurons in the substantia nigra pars compacta.
Lewy bodies, intracellular proteinaceous inclusions, are the histopathological hallmark of PD.
Immunohistochemical analysis of Lewy bodies revealed aggregated forms of α-synuclein, a 140
amino acid neuronally-expressed protein, as a major component (Baba et al., 1998; Spillantini et
al., 1997). Mutations, duplications, and triplications of the gene encoding α-synuclein cause
dominantly-inherited familial forms of PD (Chartier-Harlin et al., 2004; Krüger et al., 1998;
Polymeropoulos et al., 1997; Singleton et al., 2003). The pathological and genetic evidence
implicating α-synuclein in PD has sparked numerous studies of the normal function of α-synuclein
and its role in PD pathogenesis. α-Synuclein has been implicated in synaptic function (Abeliovich
et al., 2000). It preferentially binds lipid membranes with high curvature (Middleton and Rhoades,
2010) and may modulate neurotransmitter release and synaptic function by affecting vesicular
fusion (Greten-Harrison et al., 2010; Larsen et al., 2006; Murphy et al., 2000; Nemani et al.,
2010).
Repeated studies across various animal models have shown that expression of mutant αsynuclein with altered aggregation kinetics causes neurodegeneration (Giasson et al., 2002;
Yang et al., 2015). Likewise, induction of α-synuclein aggregation in wildtype animals by seeding
with α-synuclein aggregates—isolated from PD Lewy bodies (Recasens et al., 2014) or
generated in vitro (Luk et al., 2012a; Sacino et al., 2014a; Shimozawa et al., 2017)—produces
progressive neurodegeneration. α-Synuclein aggregation also occurs in animal models of
dopamine neuron degeneration induced by oxidative chemical insult (Betarbet et al., 2000; Kowall
et al., 2000).
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The implication of α-synuclein in PD pathogenesis stimulated several screens for small
molecules that alter its aggregation. Dopamine and related catecholamines were among the first
molecules found to prevent α-synuclein fibril formation (Conway et al., 2001). Oxidation of vicinal
hydroxyls in dopamine, and related phenols, induces formation of soluble α-synuclein oligomers
that do not incorporate into fibrils (Mazzulli et al., 2006; Meng et al., 2009; Norris et al., 2005).
Recently, dopamine-induced α-synuclein oligomers were shown to contribute to
neurodegeneration in mice (Mor et al., 2017), but the precise mechanism of oligomer toxicity
remains a subject of debate (Danzer et al., 2007).
Ongoing research has identified many other inhibitors of α-synuclein aggregation. Many
of these inhibitors stabilize multimers or oligomers through direct interaction with α-synuclein (e.g.
various phenols, catechols, and flavonoids (Ehrnhoefer et al., 2008; Fernandes et al., 2017; Di
Giovanni et al., 2010; Lorenzen et al., 2014; Masuda et al., 2006; Meng et al., 2009, 2010; Ono
and Yamada, 2006), Anle138b (Deeg et al., 2015; Wagner et al., 2013), rifampicin (Li et al.,
2004)). One well studied member of this groups is epigallocatechin gallate (EGCG), a polyphenol
sharing the vicinal hydroxyls implicated in dopamine’s interaction with α-synuclein. Despite their
chemical similarities, dopamine and EGCG have divergent effects on the structure of α-synuclein
(Konijnenberg et al., 2016). In fact, while dopamine may induce toxic oligomers, adding EGCG
during cell-free α-synuclein aggregation produces species less toxic to cells (Ehrnhoefer et al.,
2008). Other aggregation inhibitors alter α-synuclein-protein or -lipid interactions to prevent
aggregation (e.g. NPT100-18A (Wrasidlo et al., 2016), squalamine (Perni et al., 2017), PcTS
(Fonseca-Ornelas et al., 2014; Lee et al., 2004), Hsp70 (Danzer et al., 2011)). Recent studies
have examined small molecules that directly stabilize α-synuclein monomers (e.g. BIOD303
(Moree et al., 2015), nortriptyline (Collier et al., 2017), CLR01 (Acharya et al., 2014; Prabhudesai
et al., 2012)). However, it remains unknown whether these small molecules perturb α-synuclein’s
lipid interactions, which are directly implicated in its role in neurotransmitter release (Burré et al.,
2014; Dettmer et al., 2017; Lou et al., 2017).
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In this study we employed nordihydroguaiaretic acid (NDGA), a phenolic dibenzenediol
lignan that inhibits α-synuclein aggregation (Caruana et al., 2011; Ono and Yamada, 2006).
Recent work has exhaustively characterized the products and kinetics of the oxidation of NDGA
and several novel analogs (Asiamah et al., 2015). We provide evidence that cyclized NDGA,
formed during oxidation, interacts with α-synuclein to produce modified monomers. We
demonstrate that these aggregation-resistant monomers retain their capacity to interact with
phospholipid membranes and that they inhibit aggregation of untreated α-synuclein. Further, we
demonstrate for the first time that cyclized NDGA reduces α-synuclein-driven neurodegeneration
in a relevant animal model. Generating α-synuclein species that undergo native structural
dynamics while exerting a dominant-negative effect of α-synuclein aggregation and neurotoxicity
represents a new paradigm for intervening in PD and related disorders.

83

4.3 Results
NDGA inhibits both primary and secondary nucleation-mediated α-synuclein aggregation
Two established assays, measurement of insoluble protein and Thioflavin-T binding,
quantified the effect of NDGA on the aggregation of monomeric α-synuclein. NDGA caused
concentration-dependent inhibition of insoluble α-synuclein accumulation and amyloid-like
aggregate formation (Fig. 4.1a and b). Maximal inhibition was achieved at stoichiometric,
equimolar concentrations of NDGA to monomeric α-synuclein. To confirm the Thioflavin-T
findings, the secondary structure of aggregates was quantified by circular dichroism (CD). NDGA
caused a dose-dependent decrease in the β-sheet content of the α-synuclein aggregates, as
indicated by molar ellipticity decreases at 200nm and increases at 220nm (Fig. 4.1c). Finally,
transmission electron microscopy was used to image the α-synuclein aggregates produced in the
presence or absence of NDGA. Typical α-synuclein fibrils were observed in the absence of
NDGA, but not after aggregation with equimolar NDGA (Fig. 4.1d). These data demonstrate that
stoichiometric concentrations of NDGA inhibit the formation of amyloid-like α-synuclein fibrils.
The preceding experiments examined the effect of NDGA on a typical α-synuclein
aggregation assay, in which primary nucleation is the rate-limiting step for the formation of fibrils.
Aggregation of α-synuclein can also proceed by a secondary nucleation surface-catalyzed
formation of fibrils. To test the effect of NDGA on secondary nucleation-dependent aggregation,
α-synuclein fibrils (representing 5% of total α-synuclein) were added with monomeric α-synuclein.
Equimolar NDGA (molecule to monomeric α-synuclein) inhibited the formation of insoluble αsynuclein aggregates in the presence of fibril seeds (Fig. 4.1e). Together, these findings
demonstrate that stoichiometric NDGA prevents both primary and secondary nucleation
dependent aggregation of α-synuclein.
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Figure 4.1: NDGA inhibits recombinant human α-synuclein aggregation. (a) Insoluble αsynuclein present after 7 days aggregation was reduced by NDGA and EGCG in a dosedependent fashion as compared to solvent control. Recombinant human wildtype α-synuclein
(138 µM) was aggregated for 7 days in the presence of EGCG or NDGA at the indicated molar
ratios. After aggregation, PBS-insoluble α-synuclein was separated by centrifugation (21k g for
10 min). Soluble and insoluble fractions were boiled in SDS, run by SDS-PAGE, and colloidal
stained. α-Synuclein in each fraction was quantified by in-gel densitometry. (n = 3-5). (b)
Formation of amyloid α-synuclein fibrils quantified by ThioT was reduced by NDGA and EGCG
in a dose-dependent fashion as compared to control after 7 days aggregation. (n = 3-5). (c) αSynuclein beta-sheet secondary structure was reduced by EGCG and NDGA in a dose
dependent fashion. Recombinant human wildtype α-synuclein (138 µM) was aggregated for 7
days in the presence of EGCG or NDGA at the indicated molar ratios. Secondary structure was
quantified by circular dichroism. (d) Transmission electron microscopy images of α-synuclein
aggregates after 3 days aggregation with small molecules at 1:1 molar ratio. (e) Insoluble αsynuclein present after 7 days aggregation in the presence of a 5% fibril seed was reduced by
EGCG and NDGA. EGCG or NDGA were present at a 1:1 molar ratio. After aggregation, PBSinsoluble α-synuclein was separated by centrifugation (21k g for 10 min). Soluble and insoluble
fractions were boiled in SDS, run by SDS-PAGE, and colloidal stained. α-Synuclein in each
fraction was quantified by in-gel densitometry. (n = 3).
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Interaction with α-synuclein requires oxidation and cyclization of NDGA
We used N-acetylcysteine (NAC), an electron donor, to inhibit NDGA oxidation in the
presence of α-synuclein. NAC was included in a typical α-synuclein aggregation mixture at 20:1
molar excess to NDGA. After aggregation for 3 days, levels of α-synuclein aggregation were
measured by the established solubility assay. mNDGA, a NDGA analog incapable of oxidation
and cyclization was included as a negative control (Supplemental Fig. 4.S1). The addition of NAC
allowed α-synuclein to aggregate in the presence of NDGA, suggesting that oxidation is
necessary (Fig. 4.2a and b). The inclusion of NAC also reduced levels of quinone-containing
NDGA oxidation products detected by near-infrared fluorescence (nIRF), a technique developed
to study the oxidation-dependent interaction between α-synuclein and dopamine (Mazzulli et al.,
2016) (Fig. 4.2c). The correlation of increased aggregation and decreased quinone nIRF
suggests a relationship between NDGA oxidation and inhibition of α-synuclein aggregation.
Separately, catalase, which rapidly converts H2O2 to water and hydrogen gas, was included in the
aggregation assay to determine whether H2O2 that might be produced during NDGA oxidation
mediated the effects on aggregation. Inclusion of catalase had no effect on α-synuclein
aggregation in the presence of NDGA nor on quinone nIRF, indicating that the effect is not H2O2dependent (Fig. 4.2a, Supplemental Fig. 4.S2). These data indicate that NDGA interaction with αsynuclein is oxidation-dependent but not mediated by peroxide chemistry.
Previous work has identified the majority product of NDGA oxidation as a cyclized form
(Asiamah et al., 2015). During that study, novel NDGA analogs with defined oxidation pathways
were generated. Here, these analogs were used to examine of the role of cyclization in NDGA’s
oxidation-dependent inhibition of α-synuclein aggregation. We employed NDGA and two such
analogs: NDGA-1, which oxidizes with comparable kinetics but does not cyclize due to unilateral
hydroxyl substitution, and NDGA-5, which cyclizes more readily than NDGA due to reduced steric
hindrance in the crosslinking region (Supplemental Fig. 4.S1). α-Synuclein was aggregated for 3
days in the presence of equimolar NDGA analogs, and aggregation was quantified by the
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solubility assay. Both cyclizing analogs, NDGA and NDGA-5, inhibited α-synuclein aggregation,
while non-cyclizing NDGA-1 did not (Fig. 4.2d). The products of the above experiment where also
analyzed by nIRF. NDGA and NDGA-5-treated α-synuclein exhibited quinone nIRF signals, while
NDGA-1-treated α-synuclein did not (Supplemental Fig. 4.S3). These results indicate that
cyclized forms of NDGA, or the process of cyclization, are required for interaction with αsynuclein and inhibition of aggregation. To address this uncertainty, α-synuclein was aggregated
in the presence of cNDGA and cNDGA-5, the purified cyclized forms of NDGA and NDGA-5,
respectively (Supplemental Fig. 4.S1). Using the solubility assay, both cNDGA and cNDGA-5
inhibited α-synuclein aggregation as potently as NDGA (Fig. 4.2e, Supplemental Fig. 4.S4). This
indicates that NDGA’s inhibition of α-synuclein aggregation is mediated by cyclized oxidation
products.
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Figure 4.2: Interaction between NDGA and α-synuclein requires NDGA oxidation and
cyclization. (a) NDGA treatment did not affect α-synuclein aggregation in the presence of Nacetylcysteine. α-Synuclein was aggregated for 3 days in the presence of 1:1 small molecules.
After aggregation, PBS-insoluble α-synuclein was separated by centrifugation (21k g for 10 min).
Soluble and insoluble fractions were boiled in SDS, run by SDS-PAGE, and colloidal stained. αSynuclein in each fraction was quantified by in-gel densitometry. NAC was added at 20x molar
excess to small molecule and catalase was added equal to 5% of protein, providing excess
hydrogen peroxide decomposition capacity. (b) Colloidal staining of representative gels showed
the formation of insoluble α-synuclein aggregates in the presence of NDGA and NAC. (c) Nearinfrared fluorescent imaging of the same gels before colloidal staining showed a reduction of
quinone-dependent fluorescence in the presence of NAC. (d) α-Synuclein did not aggregate in
the presence of cyclizable analogs, NDGA and NDGA-5, but did with non-cyclizable NDGA-1. (n
= 3). (e) α-synuclein did not aggregate in the presence of cyclized cNDGA and cNDGA-5. (n =
3). α-Synuclein was aggregated for 3 days in the presence of 1:1 small molecules. After
aggregation, PBS-insoluble α-synuclein was separated by centrifugation (21k g for 10 min).
Soluble and insoluble fractions were boiled in SDS, run by SDS-PAGE, and colloidal stained. αSynuclein in each fraction was quantified by in-gel densitometry.
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NDGA induces modest, progressive α-synuclein compaction without preventing dynamic
adoption of α-helical conformation
During analysis of the interaction between NDGA and α-synuclein, equimolar incubation
consistently produced nIRF-positive quinone-modified α-synuclein (Supplemental Fig. 4.S5).
Based on this observation, NDGA-treated α-synuclein was further analyzed to determine any
structural effects of the interaction. Native nano-ESI mass spectra (ESI-MS), collected following
10 minute incubations of the protein-ligand mixtures, detected α-synuclein-NDGA complexes with
masses matching the theoretical values of the unmodified protein and ligand (Natalello et al.,
2017). Masses indicative of α-synuclein modifications such as oxidation or nitrosylation were not
detected. Complexes were observed with higher relative intensities at low protein charge states,
suggesting a preferential binding to the more compact α-synuclein conformations as previously
observed with EGCG. However, levels of α-synuclein binding were much lower for NDGA than
previously observed with EGCG (Konijnenberg et al., 2016) (Supplemental Fig. 4.S6).
Ion-mobility mass spectrometry (IM-MS) allows for highly sensitive detection of changes
in ion compactness, mass, and charge. Of note, this allows ions of identical mass and charge to
be distinguished by compactness. This attribute of IM-MS has previously been employed to show
the differential effects of EGCG and dopamine on α-synuclein compaction (Konijnenberg et al.,
2016). IM-MS revealed that incubation with NDGA, but not mNDGA, resulted in α-synuclein
assuming slightly more compact conformations (Fig. 4.3a). This compaction was more
pronounced in lower charge states (+5 through +7) in which distinct populations of conformers
with differing compaction can be observed. These data indirectly indicate complex formation with
conformational memory, although the complexes are likely lost under these experimental
conditions. The previous IM-MS study of EGCG-treated α-synuclein found increased pool of
compact conformations, as well as mass-shifts consistent with EGCG binding (Konijnenberg et
al., 2016). As with ESI-MS, IM-MS did not detect substantial amounts of α-synuclein with mass-
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shifts indicative of covalent adduction by NDGA. Mass spectrometry indicates that NDGA causes
subtle structural remodeling of α-synuclein, without forming covalent adducts.
NMR allowed for localization of NDGA’s structural effects within the sequence of αsynuclein. After 24 hours incubation with 1:1 NDGA small variations in peak positions were
observed in the N-terminus – Val 3, Met 4, Phe 5 – as well as His 50 (Fig. 4.3b). cNGDA and
NDGA-1-treatment caused similar changes in the spectra. Incubation with 3:1 NDGA resulted in
more pronounced shifts in the same set of peaks.
These samples were followed for several days through NMR revealing a progressive
variation of the peak shifts. After several days, additional changes occurred in the signals of
several peaks. These peaks showed a second set of signals, indicative of a subset of the αsynuclein population with altered conformation at these residues (Supplemental Fig. 4.S7).
Förster resonance energy transfer (FRET) analysis of α-synuclein provided further insight
into the regions altered by NDGA treatment. This examination employed several synthetic αsynuclein proteins with varying fluorescent label pairs spread throughout the amino acid
sequence. Based on this methodology, FRET signal from an individual label pair can be
converted to an intramolecular distance within α-synuclein and, when taken together, the multiple
label pairs provided eight partially overlapped measurements covering the amino acid sequence
from residue 9 to 136 (Ferrie et al., 2018). FRET revealed progressive changes in α-synuclein
conformation when treated with EGCG, while NDGA, cNDGA, and mNDGA did not induce
changes, even after 24 hours (Fig. 4.3c and d). As with IM-MS and NMR, NDGA-treatment was
found to induce minimal changes in α-synuclein conformation, while EGCG showed more marked
effects.
NDGA-treated α-synuclein secondary structure was examined using circular dichroism
(CD). CD failed to detect any changes in the secondary structure of pretreated, dialyzed αsynuclein, further confirming the IM-MS and NMR analyses (Fig. 4.3e). Despite observing limited
effects of NDGA on α-synuclein structure in aqueous solution, we also examined whether NDGA91

treatment alters the capacity of α-synuclein to interact with hydrophobic membranes. Membrane
interaction induces the N-terminus of α-synuclein to assume an α-helical secondary structure
(Davidson et al., 1998; George et al., 1995; Ulmer and Bax, 2005). Capacity for membrane
interaction is necessary for α-synuclein’s putative biological functions in the synapse (Abeliovich
et al., 2000; Murphy et al., 2000; Nemani et al., 2010). Neither NDGA nor mNDGA treatment
prevented α-synuclein from assuming α-helical conformations in the presence of SDS, just as
occurred under control conditions (Fig. 4.3f). This indicates that the structural changes induced by
NDGA do not restrict α-synuclein’s dynamic flexibility.
The ability of NDGA-treated α-synuclein to interact with membranes was further
examined by fluorescence correlation spectroscopy (FCS), which has been used extensively to
study the interaction of α-synuclein with lipid vesicles (Middleton and Rhoades, 2010; Rhoades et
al., 2006). The binding of fluorescently labelled recombinant human α-synuclein to various
concentrations of phospholipid vesicles (1:1, POPS:POPC) was compared following α-synuclein
incubation for 24 hours with equimolar NDGA analogs or solvent alone. NDGA, cNDGA, and
mNDGA did not alter phospholipid affinity as indicated by similar protein binding affinity at each
vesicle concentration, regardless of treatment condition (Fig. 4.3g). FCS was also used to
determine whether the addition of NDGA would displace α-synuclein already bound to
phospholipid vesicles. The fraction of α-synuclein bound to vesicles was not altered by the
addition of NDGA as compared to the addition of solvent alone (Fig. 4.3h). These data further
indicate that NDGA treatment does not perturb α-synuclein interaction with hydrophobic
membranes. Collectively, these results show that NDGA causes α-synuclein compaction across
the sequence, without altering secondary structure or preventing structural remodeling involved in
physiological function.

92

93

Figure 4.3: NDGA induces compaction of α-synuclein without preventing structural
remodeling. (a) NDGA treatment induced compaction of monomeric α-synuclein relative to
mNDGA treatment. Ion-mobility mass spectrometry detected increased abundance of αsynuclein species with lower collisional cross section after α-synuclein was incubated with
NDGA at 5:1 excess for 10 minutes. (b) NDGA treatment of α-synuclein did not induce extensive
shifts in 2D NMR spectra. α-Synuclein was incubated 1:1 with NDGA for 24 hours before spectra
were collected. NDGA-treated α-synuclein spectra (blue) was overlaid on solvent-treated αsynuclein (red). FRET measurement of (c) 0 hour and (d) 24 hour small molecule treatments
showed progressive alteration of α-synuclein intramolecular distances by EGCG, but not NDGA,
cNDGA, or mNDGA. The dashed line depicts 1 µM α-synuclein treated with buffer (1x PBS).
Treatments were 5 µM NDGA (green square), EGCG (red triangle), cNDGA (purple inverted
triangle), and mNDGA (blue diamond). (n = 3). (e) α-Synuclein secondary structure was not
altered by pretreatment with NDGA. (f) NDGA pretreatment did not prevent α-synuclein
assuming α-helical secondary structure in the presence of SDS micelles. α-Synuclein was
incubated 1:1 with NDGA, mNDGA, or solvent alone for 24 hours and then dialyzed against PBS
for 24 hours. 40 mM SDS micelles were added 5 minutes before analysis. Secondary structure
was quantified by circular dichroism. (g) NDGA treatment did not alter α-synuclein phospholipid
binding. α-Synuclein was incubated 1:1 with NDGA analogs or solvent alone for 24 hours before
fluorescence correlation spectroscopy in the presence of POPS:POPC vesicles at the indicated
concentrations. (n = 3). (h) Addition of NDGA did not displace fluorescently labeled α-synuclein
from POPS:POPC vesicles. (n = 3).
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NGDA pretreated α-synuclein stably resists seeded aggregation
Based on the progressive remodeling of α-synuclein treated with NDGA, we analyzed the
capacity of NDGA-pretreated α-synuclein to aggregate into fibrils. α-Synuclein was incubated with
equimolar NDGA (as well as mNDGA and EGCG controls) for 24 hours before dialysis against
excess PBS for 24 hours. This pretreated, dialyzed α-synuclein was then aggregated for 3 days
before undergoing the solubility assay (as depicted in Supplemental Fig. 4.S8). NDGA, but not
mNDGA, pretreatment prevented α-synuclein aggregation (Fig. 4.4a). Further, pretreated,
dialyzed α-synuclein was aggregated for 14 days to test the duration of the effect. Again, NDGA
but not mNDGA pretreatment prevented α-synuclein aggregation (Supplemental Fig. 4.S9).
Consistent with previous data, we found that pretreatment with cyclizing (NDGA and NDGA-5)
and cyclized (cNDGA and cNDGA-5) analogs prevented α-synuclein aggregation, while noncyclizing analogs (NDGA-1 and SECO-1) did not (Supplemental Fig. 4.S10 and 4.S11). We also
examined the soluble species that remained following aggregation of pretreated, dialyzed αsynuclein using native state SEC and found that monomeric species are the majority product
(Supplemental Fig. 4.S12). Collectively, these findings demonstrate the NDGA pretreatment
renders α-synuclein monomers resistant to aggregation. This effect was not observed with nonoxidizable and non-cyclizing analogs of NDGA.
Native-state SEC fractionation found that pretreatment with either NDGA or EGCG
produces both monomeric and oligomeric α-synuclein species (Supplemental Fig. 4.S5). We
compared the aggregation of these two pools of α-synuclein species. α-Synuclein was incubated
with equimolar small molecules for 24 hours before oligomeric (≥51Å) and monomeric (<51Å)
species were separated using native state SEC. The resulting fractions were then aggregated for
3 days before analysis by the solubility assay. Both monomers and oligomers produced upon
NDGA and EGCG pretreatment resisted aggregation, while the majority of mNDGA treatment
products formed insoluble aggregates (Fig. 4.4b). This indicates that while aggregation-resistant
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α-synuclein oligomers do form after NDGA treatment, resulting monomers are also aggregationresistant, even in the absence of oligomers.
Next, we explored whether NDGA can prevent surface-catalyzed, secondary nucleationdependent, aggregation of α-synuclein. Pretreated, dialyzed α-synuclein was aggregated for 3
days in the presence of α-synuclein fibril seeds (equal to 5% of total α-synuclein in solution)
before aggregation was quantified by the solubility assay. Again, NDGA but not mNDGA
pretreatment reduced α-synuclein aggregation (Fig. 4.4c). This demonstrates that NDGApretreated, dialyzed α-synuclein does not readily undergo secondary nucleation to form species
capable of incorporating into existing fibrils.
Based on the observation that NDGA treatment prevents α-synuclein aggregation, we
conducted a novel analysis to determine whether aggregation of untreated α-synuclein is altered
by the presence of NDGA-pretreated α-synuclein. Pretreated, dialyzed α-synuclein was
generated as before, then mixed with untreated α-synuclein at varying ratios and the resulting
mixtures were aggregated for 3 days before undergoing the solubility assay (as depicted in
Supplemental Fig. 4.S12). The addition of pretreated, dialyzed α-synuclein caused a superstoichiometric reduction in insoluble α-synuclein, demonstrating that aggregation of untreated αsynuclein was reduced (Fig. 4.4d). This effect is demonstrated in the 20% condition wherein
NDGA pretreated, dialyzed α-synuclein represents only 20% of total α-synuclein, but insoluble αsynuclein is reduced from 88% in control conditions to 37%. These data, taken in totality, indicate
that pretreatment with NDGA produces α-synuclein monomers that are not only resistant to
aggregation, but reduce aggregation of α-synuclein never exposed to NDGA.
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Figure 4.4: NDGA pretreatment prevents α-synuclein aggregation. (a) α-Synuclein did not
aggregate after pretreatment with NDGA. α-Synuclein was incubated 1:1 with small molecules
for 24 hours then dialyzed against PBS for 24 hours. After aggregation for 3 days, PBS-insoluble
α-synuclein was separated by centrifugation (21k g for 10 min). Soluble and insoluble fractions
were boiled in SDS, run by SDS-PAGE, and colloidal stained. α-Synuclein in each fraction was
quantified by in-gel densitometry. (n = 3). (b) Both oligomeric and monomeric α-synuclein
species induced by NDGA treatment resist aggregation. α-Synuclein was incubated 1:1 with
small molecules for 24 hours then subjected to native state size exclusion chromatography.
Oligomeric (≥51Å) and Monomeric (<51Å) α-synuclein fractions were collected and aggregated
separately for 3 days. Soluble and insoluble species were separated and quantified as above. (n
= 3). (c) NDGA-treated α-synuclein resisted fibrillization in the presence of 5% fibril seed. αSynuclein was incubated 1:1 with small molecules for 24 hours then dialyzed against excess
PBS for 24 hours. Untreated α-synuclein fibrils equal to 5% total protein was added immediately
before mixtures were aggregated for 3 days. Soluble and insoluble species were separated and
quantified as above. (n = 3). (d) NDGA pretreated, dialyzed α-synuclein inhibited aggregation of
untreated α-synuclein. α-Synuclein was incubated 1:1 with small molecules for 24 hours then
dialyzed against excess PBS for 24 hours. Pretreated, dialyzed α-synuclein was then mixed with
untreated monomeric α-synuclein at the indicated ratios. Mixtures were aggregated for 3 days.
Soluble and insoluble species were separated and quantified as above. (n = 3).
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cNDGA reduces α-synuclein-driven dopamine neurodegeneration in animals
We examined the effect of NDGA and cNDGA treatment on α-synuclein-driven
neurodegeneration. We employed a widely used C. elegans model in which expression of human
wildtype α-synuclein in dopaminergic neurons leads to progressive neurodegeneration. Animals
were treated with varying doses of NDGA or cNDGA from hatching until the day before scoring on
either day 6 or day 8. NDGA did not have a statistically significant effect on the number of
animals undergoing neurodegeneration. However, cNGDA caused a significant reduction in the
number of animals with degenerating dopamine neurons across all doses at day 8 (Fig. 4.5a).
Representative images of animals scored during this experiment show the loss of fluorescent
dopamine neuron processes and bodies in solvent and NDGA-treated animals (Fig. 4.5b). This
demonstrates, for the first time, that cNDGA can reduce neurodegeneration caused by αsynuclein.
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Figure 4.5: cNDGA reduces α-synuclein-driven neurodegeneration. (a) cNDGA, but not
NDGA reduces dopaminergic neurodegeneration in C. elegans expressing wildtype α-synuclein.
Animals were exposed to each concentration of the drugs on days 0-3, 5, and 7 post-hatching.
Animals were scored on days 6 and 8 post-hatching for dopaminergic neurodegeneration. The
data are represented as mean ± SEM; one-way ANOVA with Tukey’s post hoc test for multiple
comparisons. (n = 3; 30 animals per replicate; * p < 0.05; ns, not significant). (b) Representative
images from day 8 post-hatching. Arrowheads indicate intact neurons while arrows indicate
degenerating or missing neurons. Scale bar represents 10 µm.
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4.4 Discussion
α-Synuclein aggregation remains a promising target for therapeutic development. Using
NDGA and novel analogs, we uncovered that NDGA oxidation and cyclization was required for
interaction with monomeric α-synuclein. This interaction caused slight compaction throughout the
α-synuclein sequence and prevented α-synuclein aggregation into fibrils. Indeed, NDGA-treated
monomers not only resisted aggregation, but prevented aggregation of naïve untreated αsynuclein. Treatment with cNDGA reduced neurodegeneration in an animal model of α-synuclein
neurotoxicity. Taken together, these findings suggest that NDGA and related molecules that
prevent α-synuclein aggregation without perturbing native structure and associations may be
promising targets for PD and related disorders characterized by α-synuclein aggregation.
Attempts to develop therapeutic strategies targeting α-synuclein have included
decreasing levels by altering expression (Zharikov et al., 2015b) and clearance (Dehay et al.,
2010; Lee, 2004), immunological targeting (Masliah et al., 2005, 2011), and altering aggregation.
Many aggregation inhibitors were identified through chemical library screens before being
subjected to mechanistic analysis (Conway et al., 2001; Masuda et al., 2006; Ono and Yamada,
2006). The neurotransmitter dopamine, and molecules that share structural and chemical
similarities, were the first inhibitors identified and are among the most potent inhibitors of αsynuclein aggregation (Conway et al., 2001).
Identification of dopamine and related phenols as inhibitors of α-synuclein aggregation
has led to many studies of phenolic compounds as potentially neuroprotective inhibitors. The
most studied of these is EGCG, which is currently undergoing clinical trials in multiple system
atrophy, a synucleinopathy characterized by microglial inclusions (Levin et al., 2016). EGCG was
found to be neuroprotective in animals treated with MPTP, which induces α-synuclein-dependent
dopaminergic neurodegeneration (Chen et al., 2015; Reznichenko et al., 2010). Adding EGCG
during in vitro α-synuclein aggregation results in less toxic products (Ehrnhoefer et al., 2008).
Given the structural differences between EGCG and NDGA, as well as the existing knowledge
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about NDGA oxidation and the availability of analogs, we hope that studying NDGA as an αsynuclein aggregation inhibitor will provide new insight into the neuroprotective potential of
inhibiting α-synuclein aggregation.
Our analysis revealed some substantial departures between the effects of NDGA and
EGCG on α-synuclein. Konijnenberg et al. found, using IM-MS, that EGCG induces α-synuclein
compaction (Konijnenberg et al., 2016), while analysis conducted by the same group for this
study showed that NDGA and cNDGA cause a more subtle effect (Fig. 4.3a). Likewise, FRET
found that EGCG causes substantial α-synuclein remodeling, while NDGA and cNDGA have no
measurable effect on intramolecular distances (Fig. 4.3b). We also observed consistent
differences in the patterns of SDS-stable multimers present after α-synuclein was treated with
EGCG and NDGA (Fig. 4.2b and Supplemental Fig. 4.S2, 4.S5, and 4.S12). This trend of subtle,
but measurable, differences between the effect of the two molecules leaves open the possibility
of different mechanisms of interaction with α-synuclein and differing biophysical properties of the
resulting species.
Previous studies of EGCG have focused on the oligomers formed when α-synuclein is
aggregated in the presence of EGCG (Bieschke et al., 2010; Ehrnhoefer et al., 2008; Yang et al.,
2017). In this study, we found that α-synuclein aggregation in the presence of EGCG and NDGA
does produce oligomers, but that monomers are the predominant product, representing more
than 75% of soluble protein (Supplemental Fig. 4.S12). Further, we found that α-synuclein
monomers and oligomers induced by pretreatment with EGCG and NDGA both resisted
aggregation (Fig. 4.4b). This aggregation was conducted after separation by size-exclusion
chromatography, which removed from solution any EGCG or NDGA not interacting with αsynuclein, suggesting a stable interaction or modification of α-synuclein itself. Most strikingly,
pretreated species inhibited aggregation of untreated α-synuclein, suggesting a dominantnegative effect on aggregation. This effect, not previously described for EGCG or any other
exogenous phenolic inhibitors, may contribute to their neuroprotective effects. The combination of
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a durable modification of α-synuclein and a dominant negative effect on aggregation are very
desirable given concerns over polyphenol bioavailability in the brain (Pogačnik et al., 2016) and
the hepatotoxic side effects seen with EGCG (Lambert et al., 2010; Levin et al., 2016).
Lipid-bound α-synuclein is resistant to aggregation (Zhu and Fink, 2003), and appropriate
membrane interactions are implicated in its physiological function (Burré et al., 2014; Dettmer et
al., 2017). As such, an ideal therapeutic targeting α-synuclein aggregation would allow normal
lipid interaction. Interestingly, both CD and FCS showed that the membrane interactions of αsynuclein were not perturbed by NDGA-treatment (Fig. 4.3f, g, and h). Preservation of αsynuclein membrane interaction may help explain the divergent effects of NDGA and dopamine
on neuron viability. Indeed, α-synuclein oligomers induce membrane destabilization and
dopamine-induced oligomers may contribute to neurodegeneration in synucleinopathies (Danzer
et al., 2007; Mor et al., 2017). Future studies aimed at identifying neuroprotective α-synuclein
aggregation inhibitors would be well served by incorporating methods to determine whether
membrane interactions are maintained, as is the case with NDGA.
NDGA pretreatment induced an NMR peak shift at His 50 (Fig. 4.3b). His 50 falls within
the second α-helical region during α-synuclein interaction with curved lipid membranes, falling in
sequence just after the fourth lysine-rich repeat (George et al., 1995; Ulmer and Bax, 2005). His
50 also mediates oligomer-stabilizing interaction between α-synuclein and divalent metal ions,
particularly Cu(II) (Binolfi et al., 2006; Rasia et al., 2005). Additionally, His 50 to Gln mutation
causes autosomal dominant familial PD and accelerates α-synuclein aggregation in vitro (AppelCresswell et al., 2013; Ghosh et al., 2013; Proukakis et al., 2013). This suggests that interaction
with His 50 could alter α-synuclein aggregation kinetics. Further investigation of the interaction
between NDGA and His 50 might provide insight into NDGA’s inhibition of α-synuclein
aggregation.
The chemistry underpinning dopamine and related small molecule modulators of αsynuclein aggregation includes the capacity for auto-oxidation and the presence of vicinal
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hydroxyl (catechol) moieties (Meng et al., 2009; Norris et al., 2005). In this study, we have
expanded the previous observations and documented many new mechanistic insights for the
biochemistry of catechol structures to inhibit the aggregation of α-synuclein. We found that
NDGA-analogs require two pairs of vicinal hydroxyls to interact with α-synuclein. NDGA-1, which
contains only one pair of vicinal hydroxyl groups, did not modify α-synuclein or inhibit
aggregation. This indicates that NDGA cyclization, which is enabled by its two pairs of vicinal
hydroxyls, is required for inhibition of α-synuclein aggregation (Asiamah et al., 2015). Indeed,
cNDGA and cNDGA-5, two cyclized analogs of NDGA, were found to inhibit α-synuclein
aggregation. The finding that NDGA’s cyclized oxidation products are responsible for its effects
on α-synuclein aggregation presents the dual opportunities to study NDGA as a prodrug,
converted by oxidation-dependent cyclization to active cNDGA, and to examine novel molecules
based on the cNDGA structure in hopes of identifying inhibitors of α-synuclein aggregation.
The importance of NDGA cyclization is reinforced by the finding that cNDGA, but not
NDGA, treatment reduces neurodegeneration caused by expression of human α-synuclein in
dopamine neurons in C. elegans (Fig. 4.5). There are many potential explanations for the
divergent effects of the two molecules, including differences in stability, uptake, metabolism, and
excretion. One possibility is that NDGA does not form cNDGA under these conditions. Oxidation
of NDGA likely occurs less frequently in the reducing environment of the cell (Back et al., 2012),
and yield of cNDGA may be lower than previously observed. While the cyclization of NDGA has
been precisely described under controlled conditions in buffer (Asiamah et al., 2015), it has never
been examined in a complex milieu or within a living cell, where other chemistry may occur.
Collectively, these findings change our understanding of the mechanisms of phenolic αsynuclein aggregation inhibitors. We demonstrate, for the first time, that NDGA’s interaction with
α-synuclein requires oxidation-dependent cyclization, reframing NDGA as a prodrug. Additionally,
we show that both NDGA and EGCG stably modify α-synuclein monomers, rendering them
aggregation incompetent. In the case of NDGA, this is achieved without altering the structure of
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α-synuclein in solution, nor perturbing membrane interactions. This combination of attributes has
not been previously observed in other inhibitors of α-synuclein aggregation. Further examination
is certainly warranted to determine whether NDGA analogs might provide the basis for novel
neuroprotective therapies for PD and related synucleinopathies.
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4.5 Methods
In vitro α-synuclein aggregation analyses
Recombinant human wildtype α-synuclein was expressed and purified from E. coli as previously
described (Winner et al., 2011). Purified α-synuclein was used at at 2 mg/ml (138 µM) with or
without small molecules at various molar ratios in PBS with 1% DMSO. Mixtures were aggregated
for 3 or 7 days at 37°C shaking at 1400 rpm. Alternatively, purified α-synuclein was incubated for
24 hours with or with equimolar small molecules in PBS with 1% DMSO. Resulting mixtures were
then dialyzed against excess PBS for 24 hours at 4°C (using mini-dialysis tubes, Thermo Fisher
69572). Mixtures were aggregated for 3 or 14 days shaking at 1400 rpm.
α-Synuclein solubility analysis and densitometric quantification
Sedimentation was performed by centrifugation at 21,000 g for 15 minutes. Supernatants were
removed, and pellets were resuspended in an equal volume. Pellets and supernatants were
boiled in SDS sample buffer for 3 minutes at 95°C. α-Synuclein species were resolved by SDSPAGE in 12% Bis/Tris gels and stained in-gel with colloidal blue (Invitrogen LC6025). Stained
gels were imaged at 700 nm using LI-COR Odyssey Infrared Imaging System and densitometric
quantification was conducted using LI-COR Odyssey software suite 3.0.
Near infrared fluorescence
SDS-PAGE gels were imaged as previously described (Mazzulli et al., 2016). Briefly, gels were
imaged immediately after electrophoresis at 700 nm with intensity 10 on LI-COR Odyssey
Infrared Imaging System.
Size-exclusion chromatography
For size exclusion chromatography 200µL recombinant α-synuclein (2mg/ml) was injected onto a
Superdex 200 10/300 GL (GE Healthcare) connected to an Agilent 1100 series HPLC system and
fraction collector controlled by ChemStation software version 1.04 (Agilent). Mobile phase
consisted of 25mM HEPES and 150 mM NaCl, pH 7.25 with a 0.3 ml/min flow rate. Fractions
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corresponding to 140-100, 100-85, 85-75, 75-68, 68-61.5, 61.5-56, 56-51, 51-47, 47-43, 43-39,
39, 39-36, 36-32, 32-29, 29-26 Å were combined and concentrated using 3kDa NMWL ultracel
microcon filters (Millipore UFC5003). SEC column elution time was calibrated to Å size using
globular protein standards (GE Healthcare).
Circular dichroism
Circular dichroism spectra were obtained on a Jasco-810 spectropolarimeter maintained in the
Children's Hospital of Philadelphia Protein Core facility. Protein in PBS was diluted to 20 μM in
0.05 M KH2PO4 pH 7.8. Spectra were corrected for baseline measurement of an equivalent
volume of PBS diluted in KH2PO4 buffer. Spectra were collected with a scanning width of 1 nm, at
5 nm/min with 2 accumulations per run.
Transmission electron microscopy
Transmission electron microscopy was conducted on a JEOL1010 maintained in the University of
Pennsylvania Electron Microscopy Resource Laboratory. Protein solutions were diluted to 0.5
mg/ml (34.5 µM) before mounting to carbon-coated 300 grids and negative staining with 2%
uranium acetate. Images were collected with at HV = 80.0 kV, Magnification 50,000x. Contrast
was automatically adjusted during capture for each image, and not altered after capture. 1 µm
scale bars were included for each image presented.
Nuclear magnetic resonance spectroscopy
To provide atomic resolution information on α-synuclein, 2D 1H-15N NMR spectra were acquired
through a series of BEST-TROSY HSQC (Favier and Brutscher, 2011), a fast and common
experiment used to evaluate if there is an effect of the different molecules on some amino acids,
each of them represented by a HN-N correlation (a cross-peak in the 2D spectrum).
All the NMR experiments were recorded on a Bruker Avance III spectrometer operating at 900
MHz 1H frequency (21.14 T) equipped with a cryogenically cooled probehead for triple resonance
experiments (TCI). The pulses involved in this pulse sequence were the standard ones used to
investigate bio-molecules(Brutscher et al., 2015). The 15N hard pulses were applied at the center
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of the region (117.02 ppm) and the 1H band selective pulses were applied at the center of the
amide proton region at 8.70 ppm. A spectral width of 10822.511 Hz in the direct 1H dimension
and 3647.991 Hz in the indirect 15N dimension was used. All the spectra were recorded with 8
scans per increment, 4096 and 2048 points in the direct dimension and in the indirect dimension
respectively and a recycle delay of 500 ms.
The experiments were recorded at 288.0 K on a 165 μM uniformly 15N labeled α-synuclein
sample, prepared as previously described (Huang et al., 2005), in buffer (10 mM KPi, 140 mM
NaCl, 0.25 mM EDTA + Roche protease inhibitors, pH 7.5). 5% D2O was added for the lock
signal. The different drugs (described above) were added as DMSO solutions at 1:1
stoichiometric ratio and left at room temperature 24 hours to incubate before NMR
measurements. The same experiments were acquired on a sample containing 3 equivalents of
NDGA. Care was taken to minimize the volume of the DMSO solution added and to keep it
constant for all the samples investigated. All the samples were analyzed again in the following
days (outlined in Supplementary Table 1) to evaluate thermodynamic and kinetic effects.
Native nano-electrospray ionization mass spectrometry
ESI-MS experiments were conducted as previously described (Konijnenberg et al., 2016). The
only methodological departure was the inclusion of DMSO to solubilize the ligands. Briefly, MS
spectra were collected after 10 minute incubation of protein-ligand mixtures in 7.4 pH 10 mM
ammonium acetate. Spectra were collected using a hybrid quadrupole-time-of-flight mass
spectrometer (QSTAR-Elite, Biosystems, Foster City, CA) equipped with a nano-ESI sample
source.
Ion mobility mass spectrometry
IM-MS experiments were conducted as previously described (Konijnenberg et al., 2016). The only
methodological departure was the inclusion of DMSO to solubilize the ligands. Briefly, MS spectra
were collected after 10 minute incubation of protein-ligand mixtures in 7.4 pH 10 mM ammonium
acetate. α-Synuclein was present in the mixtures at 20 µM, ligand at 100 µM. Ion mobility-mass
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spectrometry (IM-MS) was performed on a Synapt G2 HDMS (Waters, Manchester, U.K.) using
nano-ESI with homemade gold-coated borosilicate capillaries.
Fluorescence correlation spectroscopy
Expression of fluorescently-labeled α-synuclein
α-Synuclein protein labeled at residue S9C with Alexa Fluor 488 was produced via recombinant
protein production. Plasmid containing α-synuclein S9C fused to a polyhistidine-tagged GyrA
intein from Mycobacterium xenopi (Mxe) was transformed into BL21 DE3 competent cells by heat
shocking at 42°C. Single colonies grown on Ampicillin (Amp) plates were picked to inoculate
primary cultures in LB supplemented with 1μg/mL Amp. Primary cultures were combined into
secondary cultures, which were grown at 37°C in a shaker-incubator until optical density (OD)
reached ~0.6. Expression of the gene of interest was induced with Isopropyl β-D-1thiogalactopyranoside (IPTG). Cells were then grown in the shaker-incubator at 18°C overnight.
After centrifugation (5000 rpm, 20 min, 4°C), cell pellets were re-suspended in re-suspension
buffer (20 mM Tris, 1 mM PMSF, 1 Roche protease inhibitor tablet, pH 8.3) and sonicated in a
cup in an ice bath (5 min, 1 s ON, 1 s OFF). The resulting lysate was centrifuged (14,000 rpm, 25
min, 4°C), and supernatant containing the protein of interest (POI) was purified over Ni-NTA
affinity column. Intein cleavage was carried out by incubation with 200 mM β-mercaptoethanol
(βME) on a rotisserie over night at room temperature. Cleaved POI was dialyzed into 20 mM Tris
pH 8 before purification over a second Ni-NTA column to remove the free intein from the sample.
Flow-through containing the POI was kept, dialyzed into 20 mM Tris pH 8, and spin concentrated.
Labeling with Alexa Fluor 488 (AF488) maleimide was done by adding 4 equivalents (eq.) of
fluorophore dissolved in DMSO. The reaction tube was wrapped in aluminum foil and incubated
at 37°C for ~6 hrs. Formation of the product α-synuclein C9-AF488 was checked by matrixassisted laser desorption ionization mass spectrometry (MALDI-MS) and polyacrylamide gel
electrophoresis (SDS-PAGE). Labeled protein was purified by fast-protein liquid chromatography
(FPLC) using a Hi-Trap Q 5 mL column and by reverse-phase high-performance liquid
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chromatography (RP-HPLC) using a C18 preparatory column. Purified protein was spin
concentrated into buffer (20 mM Tris, 100 mM NaCl), and aliquots were stored at -80°C.
Treating α-synuclein with drug molecules
The concentration of α-synuclein aliquots was determined by UV-Vis at 488 nm. The drug
molecules NDGA, mNDGA, and cNDGA were dissolved in DMSO and diluted 10-fold into buffer
(20 mM Tris, 100 mM NaCl). A control of 10% DMSO in buffer was also made. Each aliquot of αsynuclein was respectively treated with 1eq. of NDGA, mNDGA, and cNDGA, and DMSO-buffer.
Treatment samples were incubated at room temperature for 8 hours, then dialyzed against 10
mM Tris, 100 mM NaCl overnight.
Preparation of lipid vesicles
Synthetic lipid vesicles were prepared for use in binding experiments. A mixture in 50:50 molar
ratio of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoserine (POPS) and 1-palmitoyl-2-oleoyl-snglycero-3-phosphocholine (POPC) were drawn from chloroform stock and dried under nitrogen
gas to form a film inside a glass vial. Films were desiccated under vacuum and re-hydrated in 3(N-morpholino)propanesulfonic acid (MOPS) buffer. 10 Freeze-thaw cycles consisting of cooling
in liquid nitrogen for 40 s and warming in a 60°C water bath for 2 min were performed to aid the
formation of uniformly sized vesicles. Using syringes fitted onto an extruder, vesicles were
pushed 31 times through 50 nm pore membranes. Vesicles were determined by Dynamic Light
Scattering (DLS) to be monodisperse and distributed uniformly around 80 nm in diameter,
consistent across different concentrations of all samples. All lipid vesicles were prepared fresh
and used within 48 hours of extrusion.
Fluorescence correlation spectroscopy
Eight-well chambered coverglasses (Nunc, Rochester, NY) were prepared by plasma cleaning
followed by incubation over night with polylysine-conjugated polyethylene glycol (PEG-PLL),
prepared using a modified Pierce PEGylation protocol (Pierce, Rockford, IL). PEG-PLL coated
Chambers were rinsed with and stored in Milli-Q water until use. FCS measurements were done
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on a lab-built instrument based on an Olympus IX71 microscope with a continuous emission 488
nm DPSS 50 mW laser (Spectra-Physics, Santa Clara, CA). All measurements were done at
20°C. The laser power entering the microscope was adjusted to 4.5 μW. Fluorescence emission
collected through the objective was separated from the excitation signal through a Z488rdc long
pass dichroic and an HQ600/200m bandpass filter (Chroma, Bellows Falls, VT). Emission signal
was focused through a 50 μm optical fiber. Signal was amplified by an avalanche photodiode
(Perkin Elmer, Waltham, MA) coupled to the fiber. A digital autocorrelator (Flex03Q-12,
correlator.com, Bridgewater, NJ) was used to collect 30 autocorrelation curves of 30 seconds for
each measurement. Fitting was done using MATLAB (The MathWorks, Natick, MA).
Binding assay of drug-treated α-synuclein to lipid vesicles
FCS was used to examine the binding affinity of drug-treated α-synuclein to lipid vesicles. Each
drug-treated α-synuclein labeled with AF488 was examined in the presence of varying
concentrations of lipid vesicles, and each autocorrelation curve was fit to a 2-component equation
to extract the fraction of bound α-syn at each concentration. From these data, a binding curve
was generated and fit to an exponential to determine the dissociation constant Kd, i.e. the
concentration at which half of the protein is bound. In fitting the autocorrelation curves for α-syn in
the presence of lipid vesicles, the diffusion time (τ) of bound and unbound α-syn were
respectively fixed to experimentally determined values. The diffusion time of unbound protein,
ταS, was determined by measurements of the protein in buffer without lipids. Since bound protein
diffuses with the vesicles to which they are bound, the diffusion time of the vesicles, τvesicle, was
determined by measurements of BODIPY-labeled 50:50 POPS/POPC. The diffusion time of our
unlabeled vesicles were also deduced from a calibration curve generated from the diffusion times
of commercial fluorescent bead standards of 50 nm and 100 nm in diameter.
To generate a vesicle-binding curve, FCS was performed on α-syn C9-AF488 in the presence of
varying concentrations (0.005 mM to 1 mM lipid) of 50:50 POPS/POPC. The accessible surface
lipid concentration was calculated based on the characteristic bilayer thickness of POPS and
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POPC. The fraction of bound protein was extracted from the fit to each autocorrelation curve by
fixing ταS and globally fitting τvesicle to the same value across all concentrations.

The fraction bound was plotted against accessible lipid concentration and fit to an exponential,
from which the Kd was determined.

Assay for effect of NDGA on lipid-bound α-synuclein
Untreated α-synuclein C9-AF488 (final concentration 20 μM) was added to 250 μL of 0.05 mM
POPS/PC in a microscope chamber well. The sample was incubated for 15 minutes to ensure
maximum binding interactions. NDGA stock was made by dissolving the drug in ethanol and
diluting 10-fold into buffer (20 mM Tris, 100 mM NaCl). NDGA was added at 20 μM final
concentration to the vesicle-bound α-synuclein sample, and fraction of protein bound was
determined using the fitting described above. A control treatment was made of 10% ethanol in
buffer, and fraction of protein bound was determined in the same manner.
Förster resonance energy transfer anaylsis
Small molecule stock solutions containing either NDGA, EGCG, cNDGA or mNDGA were
prepared in DMSO. Labeled proteins constructs, including new constructs not previously
described, were prepared using methods previously described (Ferrie et al., 2018). Labeled
positions not previously reported were confirmed by mass spectrometry of both the full-length
protein and fragments from trypsin digestion using MALDI. The concentration of each protein
stock was assessed by UV-Vis absorbance of the attached fluorescein-maleimide [Fam] (ε494 =
68,000 M-1cm-1) and/or tetramethylrhodamide azide [Raz] (ε555 = 87,000 M-1cm-1) dyes.
Fluorescence assays were performed in a black, clear bottom half-diameter Greiner 96-well plate
and measurements were taken on a Tecan M1000 plate reader. Each well of the plate contained
111

a single protein sample, containing either one or both fluorescent labels, and one of the small
molecules of interest. Protein samples were also measured in the absence of small molecules as
a control. Each sample was prepared in 1X PBS with a final concentration of 1 μM protein.
Samples containing NDGA, EGCG, cNDGA and mNDGA were prepared with a 5-fold excess of
small molecules relative to the protein concentration. Small molecule stocks were prepared just
prior to performing the assay. Each assay was performed by diluting the protein in buffer in each
well and adding the small molecule solution, using a multichannel pipette, just prior to measuring
the fluorescence. Each sample was excited at 494 nm and the emission spectrum was measured
from 502 - 700 nm with a 1 nm step size. Each step consisted of 50 flashes at a frequency of 400
Hz with a 20 μs integration time and the gain was set to 135. The Z-position of the plate was
optimized prior to the first measurement and was maintained at 21728 μm for all measurements.
All measurements were performed at room temperature. After measuring the emission spectrum
from each well immediately after the introduction of small molecule, the plates were sealed with
parafilm and covered in aluminum foil and left at room temperature for 24 hrs. After 24 hrs the
fluorescence of each sample was measured again as detailed above. The FRET between Fam
and Raz probes attached to a single protein was assessed by computing the fluorescence
quenching of the donor Fam fluorophore induced by the presence of the Raz acceptor as
previously described (Ferrie et al., 2018). FRET efficiencies were converted to average
interresidue distances using the Förster equation and a gaussian chain polymer model.
Analysis of dopaminergic neurodegeneration in C. elegans
Generation of transgenic nematodes
Transgenic C. elegans lines were generated by microinjection using previously described
methods (Berkowitz et al., 2008). The strain UA294 (baEx175 a,b,c [Pdat-1::WT a-syn, Punc54::tdTomato];

vtIs7[Pdat-1::GFP]) was generated by injecting with a solution of 50 ng/μl plasmid

with either Pdat-1::WT a-syn with a phenotypic marker (Punc-54::tdTomato, 50 ng/μl, for body wall
muscle expression). Three distinct stable lines (a, b, c) were generated.
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Analysis of dopaminergic neurodegeneration and NDGA analog treatments in C.
elegans
NDGA and cNDGA were used at final concentrations of 10µM, 50µM, or 100µM in ethyl acetate
(EtAc). Three resulting independent transgenic lines (a, b, c) were synchronized, and exposed to
corresponding concentration of NDGA, cNDGA, or solvent (EtAc) from hatching to day 3, then
were transferred and maintained on NGM plates until the day of analysis. Animals on NGM plates
were treated with additional NDGA, cNDGA, or solvent on days 5 and 7. For dopaminergic
neurodegeneration analyses, the transgenic animals were scored as described previously
(Hamamichi et al., 2008). Briefly, on the day of analysis, the six anterior dopaminergic neurons
(four CEP (cephalic) and two ADE (anterior deirid)) were examined in 30 randomly selected
nematodes with the marker transgene (tdTomato) in the body wall muscle cells. Worms were
considered normal when all six anterior neurons were present without any signs of degeneration,
such as broken dendritic process, cell body loss, dendritic blebbing, or a missing neuron. In total,
at least 90 adult worms were analyzed for each treatment condition, at least 30 for each
independent transgenic line. An average of total percentage of worms with normal neurons was
reported in the study.
Reagents
Nordihydroguaiaretic acid, NDGA 74540 Aldrich; (−)- Epigallocatechin gallate, EGCG E4143
Sigma; Terameprocol/mNDGA, T3455 Sigma; Catalase, C9322 Sigma; NDGA analogs NDGA-1,
SECO-1, NDGA-5, cNDGA, and cNDGA-5 were generated, purified, and validated by Krol et al.
at the University of Saskatchewan as previously described (Asiamah et al., 2015).
Statistical analysis
Statistical analysis was conducted using Prism 5 software (GraphPad). Unpaired students t test
was used for comparisons between two groups. Comparisons between multiple independent
groups used one-way ANOVA with Tukey’s post hoc test for multiple comparisons. Comparisons
involving multiple groups, such as molecule and dose comparisons, used two-way ANOVA with
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Tukey’s post hoc test for multiple comparisons. In all cases p < 0.05 was considered statically
significant.
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4.6 Supplemental Figures

Figure 4.S1. Structures of EGCG, NDGA, and NDGA analogs employed in this study.
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Figure 4.S2: Colloidal and nIRF images of α-synuclein aggregation in the presence of 5%
catalase. (a) Colloidal stained gel (b) nIRF image of the same gel before colloidal staining
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Figure 4.S3: Colloidal and nIRF images of α-synuclein aggregation in the presence of
NDGA analogs. (a) Colloidal images of gels after separation by centrifugation. (b) Near-infrared
images of the same gels before colloidal staining.
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Colloidal

nIRF

Figure 4.S4: Colloidal and nIRF images of α-synuclein aggregation in the presence of
cyclized NDGA analogs. (a) Colloidal images of gels after separation by centrifugation. (b)
Near-infrared images of the same gels before colloidal staining.
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Figure 4.S5: NDGA pretreatment produces nIRF positive α-synuclein monomers. (a)
Workflow for CD analysis and aggregation. (b) Near-infrared fluorescence images of NDGA and
EGCG pretreated, dialyzed α-synuclein separated by native-state size-exclusion
chromatography. (c) Colloidal staining of the same gels shown in panel b.
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Figure 4.S6: Electrospray mass spectrometry characterization of α-synuclein-NDGA
interaction. (a) Nano-ESI-MS spectra in positive-ion mode of 30 μM α-synuclein in the absence
and presence of NDGA at 90 μM and 140 μM. (b) Magnification of the spectra in the Upper
panel. The number of NDGA molecules bound to α-synuclein monomers is indicated by red
numbers. Dimer-specific peaks of α-synuclein are labeled as “D”. Charge states are indicated by
black numbers.
Nano-ESI-MS spectra were collected as described in Konijnenberg et al., 2016.
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Figure 4.S7: 2D NMR spectra comparing α-synuclein treated with 1:1 NDGA for 24 hours
(red), with (a) α-synuclein treated with 3:1 NDGA for 24 hours (blue), and (b) α-synuclein treated
with 1:1 NDGA for 10 days (blue).
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Figure 4.S8: Workflow for analysis of pretreated, dialyzed α-synuclein
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Figure 4.S9: NDGA pretreatment inhibits α-synuclein aggregation despite 14 days under
aggregation conditions.
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Figure 4.S10: Colloidal and nIRF images of NDGA analog pretreated, dialyzed α-synuclein
aggregation (a) Colloidal images of gels after separation by centrifugation. (b) Near-infrared
images of the same gels before colloidal staining.
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Figure 4.S11: Colloidal and nIRF images of cyclized NDGA analog pretreated, dialyzed αsynuclein aggregation (a) Colloidal images of gels after separation by centrifugation. (b) Nearinfrared images of the same gels before colloidal staining.
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Figure 4.S12: nIRF positive monomers are the predominant product of α-synuclein
aggregation in the presence of EGCG and NDGA. (a) Workflow (b) Colloidal (c) Densitometry
(d) nIRF
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CHAPTER 5: SUMMARY AND CONCLUSION
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Lewy bodies serve as the histopathological hallmark of sporadic PD. Their presence
correlates with disease progression and, more roughly, with dysfunction in the regions containing
pathology (Braak et al., 2003; Emre, 2003). However, this correlation is imperfect, as highlighted
by the presence of Lewy bodies in some non-parkinsonian patients and the lack of Lewy
pathology in certain forms of PD (Ding et al., 2006; Gaig et al., 2007). Despite the uncertainty
surrounding the relationship between Lewy pathology and neurodegeneration in sporadic PD,
results from familial forms of PD and animal models strongly imply that α-synuclein aggregation
drives neuron dysfunction and eventual death. All of the SNCA gene mutations that drive familial
forms of PD cause alterations in α-synuclein aggregation kinetics (Appel-Cresswell et al., 2013;
Krüger et al., 1998; Lesage et al., 2013; Pasanen et al., 2014; Polymeropoulos et al., 1997;
Proukakis et al., 2013; Zarranz et al., 2004). Likewise, transgenic animals expressing these
mutants show both pathology and neurodegeneration, though none perfectly recapitulates human
disease caused by the same mutation (Emmer et al., 2011; Giasson et al., 2002; Gomez-Isla et
al., 2003; Lee et al., 2002; van der Putten et al., 2000).
Compelling evidence for the neurotoxicity of α-synuclein aggregation can been found in
animal models driven by PFF injection. In these models, injection of α-synuclein aggregates into
wildtype mice gives rise to progressive α-synuclein aggregation and concomitant
neurodegeneration (Luk et al., 2012b, 2012a). Notably, this phenotype is dependent on the
aggregation of endogenous α-synuclein and does not occur in SNCA knockout mice. α-Synuclein
aggregate injection has been shown to induce pathology and neurodegeneration in several
mammals (Manfredsson et al., 2018; Shimozawa et al., 2017) and similar results are induced by
injection of Lewy body extracts from PD patients (Holmqvist et al., 2014; Recasens et al., 2014).
Considered alongside the evidence from sporadic and familial PD, these data further strengthen
the arguments that some unknown form or forms (Peng et al., 2018) of aggregated α-synuclein
act as pathogenic seeds, leading to the propagation of pathology throughout the brain (a feature
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that may be shared by other neurodegenerative diseases (Guo and Lee, 2014)), and that the
aggregation of α-synuclein drives neurodegeneration.
The later conclusion begs the question of which processes during α-synuclein
aggregation, or products thereof, cause neurotoxicity. This study aimed to provide tools and
understanding to address this deficit. We reviewed how the dynamic structure of α-synuclein
affects its physiological functions and roles in pathology. We endeavored to untangle the cellular
processes involved by examining the changes in the mouse brain proteome and
phosphoproteome during α-synuclein aggregation. We deepened understanding of the products
of aggregation by evaluating the chemistry and products of the interaction between α-synuclein
and NDGA, a putatively neuroprotective α-synuclein aggregation inhibitor.
Chapter 2 underscores how much of α-synuclein function and pathology can be traced to
its remarkable structural dynamism. α-Synuclein’s role in the synapse is made possible by
interactions with lipids, other α-synuclein monomers, and lipid-bound V-SNAREs (Burré et al.,
2010, 2014; Davidson et al., 1998; Wang et al., 2014; Zhu et al., 2003b). Identifying the native
state of α-synuclein remains difficult, and it seems increasingly unlikely that there is one single
cytosolic conformation of α-synuclein. Native states may include lipid-containing conformations,
multimers, and monomeric conformers (Bartels et al., 2011; Gould et al., 2014; Wang et al.,
2011). Despite this complexity, many studies have found that disturbance of native α-synuclein
structure increases its propensity to aggregate. In fact, all SNCA mutations linked to early onset
PD fall in the α-synuclein N-terminal domain involved in lipid and protein interaction. Indeed,
these mutations perturb native multimers/conformers (Dettmer et al., 2015a). Further, mutations
designed to interrupt native structure also alter vesicular trafficking (Dettmer et al., 2017). Taken
together, existing research shows that complex dynamics link α-synuclein’s native state, its
interactions with vesicular function, and its propensity for pathological aggregation. When
considered through the lens of therapeutic development, this demonstrates the importance of
examining the effect of any intervention on the native structure of α-synuclein.
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The findings presented in Chapter 3 represent the first proteomic analysis of the mouse
brain undergoing neurodegeneration due to endogenous α-synuclein aggregation. Our analysis
was able to quantify relative abundance (between healthy and diseased hemispheres) of more
than 6,000 proteins and 8,000 phosphopeptides. Among these, only 6% of proteins and 1.6% of
phosphopeptides changed in relative abundance during α-synuclein aggregation. This
demonstrates that proteomic changes were limited to a small subset of proteins. This result does
not support the hypothesis that widespread proteostatic disruption mediates α-synuclein
neurotoxicity (Balch et al., 2008; Douglas and Dillin, 2010). Significant changes were observed in
the relative abundance of several proteins involved in dopamine biosynthesis and
neurotransmission, consistent with localized dysfunction of dopamine neuron synapses.
Ontological analysis of proteins with significant changes in relative abundance showed marked
changes in the areas of mRNA processing, mRNA binding, protein translation, and protein
folding, suggesting adaptive proteostatic responses to α-synuclein aggregation and
neurodegeneration.
Of particular interest, Lmp7―a component of the immunoproteasome―increased in
hemispheres undergoing α-synuclein aggregation. Strikingly, this result was observed in each of
the varying statistical workflows evaluated during the preparation of the manuscript. The
immunoproteasome is induced in other neurodegenerative diseases, but had never been studied
in synucleinopathies (Aso et al., 2012; Díaz-Hernández et al., 2003; Mishto et al., 2006; Orre et
al., 2013). We found increases in Lmp7 levels and immunoproteasome function in brain tissue
from patients with PD and DLB. In vitro, the immunoproteasome degraded α-synuclein
aggregates, producing potentially antigenic peptide fragments (Sulzer et al., 2017). In totality,
these data demonstrate that the immunoproteasome is induced in response to α-synuclein
aggregation and directly digests α-synuclein fibrils. The data further suggest that Lmp7 may
modulate inclusion formation, propagation, and neuroinflammation.
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Functional immunoproteasome knockout mice exist (Kincaid et al., 2011) and PFF
injection of these mice could provide an excellent model in which to test whether induction of the
immunoproteasome during α-synuclein aggregation is protective or deleterious. Activity of the
immunoproteasome can also be manipulated pharmacologically (Muchamuel et al., 2009), raising
the possibility of the immunoproteasome as a druggable target in human disease. However, it is
difficult to predict the downstream effects of genetic or pharmacological reduction of
immunoproteasome activity during α-synuclein aggregation. If immunoproteasome induction in
the brain produces α-synuclein peptide fragments that cause T-cell activation, the induction may
contribute to the neuroinflammation that occurs prior to neurodegeneration driven by α-synuclein
aggregation (Duffy et al., 2018; Sulzer et al., 2017). Indeed, dopaminergic neurons in the SNpc
express MHC-I and MHC-I-induced T-cell activation leads to neuron death (Cebrián et al., 2014).
Additionally, partial degradation of α-synuclein fibrils might increase the number of seedingcompetent α-synuclein species in the brain, accelerating the spread of pathology (Luk et al.,
2012b; Tran et al., 2014). This uncertainty underscores the value of investigating the effect of
Lmp7 induction on α-synuclein aggregation pathology and neurodegeneration.
The study of NGDA, presented in Chapter 4, first sought to elucidate the chemistry of the
interaction between NDGA and α-synuclein. NDGA shares the vicinal hydroxyl substitution
responsible for the interaction between α-synuclein and dopamine (Conway et al., 2001). As with
dopamine, and related catecholamines (Mazzulli et al., 2007; Norris et al., 2005), NDGA must
undergo oxidation to interact with α-synuclein. NDGA analogs allowed for further insight into the
interaction between NDGA and α-synuclein. Oxidation-dependent cyclization of NDGA was
required for interaction with α-synuclein and inhibition of aggregation. As mentioned in Section
4.4, this recasts NDGA as a prodrug that can be oxidized to form α-synuclein-interaction
competent cNDGA. As such, if future studies employ NDGA and related analogs, careful
consideration should be given how rates of oxidation and cyclization might impact bioavailability
and side-effects. Particular attention should be given to hepatotoxic side-effects which are
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common in studies evaluating aggregation-inhibiting polyphenols, such as EGCG and exifone
(Lambert et al., 2010; Levin et al., 2016; Ouzan et al., 1990). Promisingly, rates of NDGA
cyclization have already been manipulated though rational chemical modification of the
crosslinker connecting the two aromatic rings. Reducing steric hindrance in the region increases
kinetics and yield of NDGA cyclization (Asiamah et al., 2015).
Given the importance of α-synuclein conformation―reviewed in Chapter 2―we also
analyzed the conformational effects of NDGA. Independent analysis by IM-MS, NMR, and FRET
found that NDGA and cNDGA induced only subtle conformational changes. Both compounds
caused slight compaction of monomeric α-synuclein, which progressed with incubation time.
These effects were much less profound than those caused by EGCG in previous studies
employing IM-MS and NMR (Ehrnhoefer et al., 2008; Konijnenberg et al., 2016). Likewise, FRET
analysis showed that EGCG induced significant changes in α-synuclein conformation after 24
hours, while NDGA was indistinguishable from negative controls. As α-synuclein physiological
function requires membrane interaction (Burré et al., 2010; Lou et al., 2017), we also measured
the effect of NDGA treatment on phospholipid binding affinity using FCS. FCS found that
treatment with NDGA and cNDGA did not alter phospholipid binding affinity, nor did NDGA
displace lipid-bound α-synuclein. This result demonstrates that while interaction with cNDGA
prevents α-synuclein aggregation, it does not alter native α-synuclein conformational dynamics
essential for physiological function.
Maintaining the dynamic structure of monomeric α-synuclein suggests two potential
advantages when considering NDGA analogs as potential neuroprotective anti-aggregation
therapies. First, this attribute might preserve α-synuclein’s function in the presynapse.
Membrane-bound α-synuclein mediates SNARE function and vesicular fusion (Burré et al., 2010;
Lou et al., 2017). α-Synuclein multimerization has also been implicated during this process (Burré
et al., 2014; Wang et al., 2014), highlighting the importance of complex interactions. Disruption of
α-synuclein function in the synapse does not cause profound neurological dysfunction (Abeliovich
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et al., 2000; Dettmer et al., 2017; Vargas et al., 2014), but prolonging typical neurotransmission
should be paramount during neurodegeneration. Second, membrane binding may enhance
aggregation resistance of NDGA-treated α-synuclein. During in vitro aggregation of α-synuclein,
levels of lipid binding directly correlate with lag time to fibril formation (Zhu and Fink, 2003).
Likewise, native multimers/conformers are more resistant to aggregation (Bartels et al., 2011) and
mutation of the lysine-rich repeats implicated in lipid binding and multimerization leads to
inclusion formation (Dettmer et al., 2015b). Indeed, using small molecules to stabilize αsynuclein-lipid interactions both reduces inclusion formation and cytotoxicity (Fonseca-Ornelas et
al., 2014).
It is important to note that there is some controversy around the role of lipids in αsynuclein aggregation. Lipids may enhance fibril nucleation (Galvagnion et al., 2015) and one
small molecule has been shown to displace α-synuclein from lipids while reducing aggregation
(Perni et al., 2017). However, given the physiological role of lipid-bound α-synuclein and the
importance of native multimerization in reducing aggregation, the preponderance of evidence
supports the conclusion that disrupting native conformations increases the likelihood that αsynuclein will form pathological aggregates.
Ultimately, our study of NDGA was motivated by its potential to reduce α-synuclein
aggregation. As expected, its presence during aggregation prevented α-synuclein fibril formation
(Ono and Yamada, 2006). Remarkably, however, pretreatment with either NDGA or EGCG
rendered α-synuclein resistant to aggregation, even after dialysis or native-state SEC was used
to remove unbound NDGA or EGCG from the aggregation mixture. This effect persisted during a
two week aggregation of pretreated α-synuclein, suggesting the modification is highly stable.
Adding fibril seeds to the aggregation mixture did not induce aggregation of pretreated αsynuclein, demonstrating that the effect does not simply prevent fibril nucleation, but that
pretreated α-synuclein is resistant to incorporation into existing fibrils. One potential explanation
of these effects is that the slight conformational changes induced by NDGA treatment might
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prevent α-synuclein aggregation. Another is that the SDS-stable, dialysis-resistant interaction that
occurs between NDGA oxidation products and α-synuclein (observed by near-infrared
fluorescence) results in a chemical change, or direct steric hindrance, that prevents incorporation
into α-synuclein fibrils.
Most strikingly, the presence of pretreated α-synuclein inhibited aggregation of naïve,
untreated α-synuclein. To the best of our knowledge, this dominant-negative effect has not
previously been documented with EGCG nor any other neuroprotective inhibitor of α-synuclein
aggregation. Our study does not explore the mechanism by which this effect occurs. It is possible
that pretreated α-synuclein interacts with and transforms untreated α-synuclein monomers, or
recruits untreated α-synuclein into aggregation-resistant multimers. This seems unlikely given the
random coil structure exhibited by pretreated recombinant α-synuclein in solution, which is
inconsistent with the α-helical structure exhibited by aggregation-resistant α-synuclein multimers
extracted from cells (Bartels et al., 2011; Wang et al., 2011). Likewise, given the slight
conformational changes observed, there is no ready explanation for why untreated α-synuclein
would adopt the same conformation in solution. Instead, it seems more likely that incorporation of
pretreated α-synuclein into fibrils or oligomers composed of untreated α-synuclein renders them
aggregation incompetent. This hypothesis provides an explanation for the dominant-negative
effect without having to propose that structural changes propagate between pretreated and
untreated monomers. It is also consistent with our observation of α-synuclein oligomers after αsynuclein aggregation in the presence of both EGCG and NDGA (Fig 4.S12), as well as previous
reports of EGCG-stabilized oligomers (Ehrnhoefer et al., 2008).
Results from C. elegans reinforced the potential for neuroprotective therapies based on
NDGA analogs and the importance of cyclization in NDGA’s interaction with α-synuclein.
Expression of α-synuclein in C. elegans dopamine neurons leads to age-related progressive
degeneration that can be altered by direct interaction between α-synuclein and small molecules
(Mor et al., 2017). NDGA treatment of these animals failed to alter the neurodegenerative
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phenotype. However, treatment with cNDGA reduced the number of animals experiencing
neurodegeneration. This divergence is striking given the similarity of the effects of NDGA and
cNDGA on α-synuclein conformation and aggregation in vitro. Potential explanations for this
difference are discussed in Section 4.4, though no conclusion can be reached based on the
current study. Regardless, the finding that cNDGA, but not NDGA, affords protection against αsynuclein-driven neurodegeneration powerfully underscores the importance of considering NDGA
cyclization in subsequent studies of its interaction with α-synuclein. Pending further study, our
findings suggest that cNDGA should be considered the active form of NDGA with regard to
inhibiting α-synuclein aggregation and reducing neurotoxicity caused by α-synuclein.
Overall, this thesis provides three novel findings. First, inhibition of α-synuclein
aggregation by NDGA requires oxidation-dependent cyclization. Second, phenolic molecules
inhibit α-synuclein aggregation by remodeling α-synuclein monomers, rendering them stably
resistant to aggregation. Third, modified α-synuclein monomers exhibit a dominant-negative
effect on α-synuclein aggregation. Consequently, small molecule induction of dominant-negative,
aggregation-preventing α-synuclein monomers may represent a new paradigm for therapeutic
development in PD and related synucleinopathies.
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